ZA200504523B - Disease treatment via antimicrobial peptide inhibitors. - Google Patents
Disease treatment via antimicrobial peptide inhibitors. Download PDFInfo
- Publication number
- ZA200504523B ZA200504523B ZA200504523A ZA200504523A ZA200504523B ZA 200504523 B ZA200504523 B ZA 200504523B ZA 200504523 A ZA200504523 A ZA 200504523A ZA 200504523 A ZA200504523 A ZA 200504523A ZA 200504523 B ZA200504523 B ZA 200504523B
- Authority
- ZA
- South Africa
- Prior art keywords
- molecule
- cell
- tissue
- disease
- defensin
- Prior art date
Links
- 102000044503 Antimicrobial Peptides Human genes 0.000 title claims description 401
- 108700042778 Antimicrobial Peptides Proteins 0.000 title claims description 401
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims description 274
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 220
- 201000010099 disease Diseases 0.000 title claims description 216
- 238000011282 treatment Methods 0.000 title claims description 53
- 239000003112 inhibitor Substances 0.000 title description 80
- 210000004027 cell Anatomy 0.000 claims description 287
- 210000001519 tissue Anatomy 0.000 claims description 264
- 238000000034 method Methods 0.000 claims description 228
- 150000001875 compounds Chemical class 0.000 claims description 145
- 241000282414 Homo sapiens Species 0.000 claims description 121
- 102000000541 Defensins Human genes 0.000 claims description 93
- 108010002069 Defensins Proteins 0.000 claims description 93
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 79
- 230000031018 biological processes and functions Effects 0.000 claims description 73
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 claims description 69
- 230000012010 growth Effects 0.000 claims description 65
- 230000004054 inflammatory process Effects 0.000 claims description 61
- 206010061218 Inflammation Diseases 0.000 claims description 60
- 206010028980 Neoplasm Diseases 0.000 claims description 59
- 238000012360 testing method Methods 0.000 claims description 53
- 230000004069 differentiation Effects 0.000 claims description 51
- 230000000694 effects Effects 0.000 claims description 50
- 101710125298 Beta-defensin 2 Proteins 0.000 claims description 46
- 101710176951 Beta-defensin 4A Proteins 0.000 claims description 46
- 102100038326 Beta-defensin 4A Human genes 0.000 claims description 46
- 239000008194 pharmaceutical composition Substances 0.000 claims description 46
- 230000001105 regulatory effect Effects 0.000 claims description 46
- 201000004681 Psoriasis Diseases 0.000 claims description 43
- 230000002401 inhibitory effect Effects 0.000 claims description 42
- 238000004519 manufacturing process Methods 0.000 claims description 42
- 230000033115 angiogenesis Effects 0.000 claims description 41
- 230000002496 gastric effect Effects 0.000 claims description 41
- 108020004999 messenger RNA Proteins 0.000 claims description 40
- 230000003211 malignant effect Effects 0.000 claims description 38
- 102000014509 cathelicidin Human genes 0.000 claims description 35
- 108060001132 cathelicidin Proteins 0.000 claims description 35
- 208000027418 Wounds and injury Diseases 0.000 claims description 32
- 108050002883 beta-defensin Proteins 0.000 claims description 32
- 102000012265 beta-defensin Human genes 0.000 claims description 30
- 210000002919 epithelial cell Anatomy 0.000 claims description 30
- 230000003247 decreasing effect Effects 0.000 claims description 28
- 239000004480 active ingredient Substances 0.000 claims description 27
- 206010027476 Metastases Diseases 0.000 claims description 26
- 108020004459 Small interfering RNA Proteins 0.000 claims description 26
- 230000009401 metastasis Effects 0.000 claims description 26
- 210000004927 skin cell Anatomy 0.000 claims description 25
- 125000002091 cationic group Chemical group 0.000 claims description 23
- 210000002889 endothelial cell Anatomy 0.000 claims description 23
- 210000000981 epithelium Anatomy 0.000 claims description 23
- 230000000845 anti-microbial effect Effects 0.000 claims description 22
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 21
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 21
- 230000001939 inductive effect Effects 0.000 claims description 21
- 108091034117 Oligonucleotide Proteins 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 20
- 108020004414 DNA Proteins 0.000 claims description 18
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 18
- 201000000849 skin cancer Diseases 0.000 claims description 18
- 210000004881 tumor cell Anatomy 0.000 claims description 18
- 208000023275 Autoimmune disease Diseases 0.000 claims description 17
- 230000000692 anti-sense effect Effects 0.000 claims description 17
- 201000008261 skin carcinoma Diseases 0.000 claims description 17
- 108090000994 Catalytic RNA Proteins 0.000 claims description 16
- 102000053642 Catalytic RNA Human genes 0.000 claims description 16
- 108091092562 ribozyme Proteins 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- 230000000699 topical effect Effects 0.000 claims description 16
- 101710125314 Beta-defensin 1 Proteins 0.000 claims description 14
- 102100037437 Beta-defensin 1 Human genes 0.000 claims description 14
- 230000003511 endothelial effect Effects 0.000 claims description 14
- 108091027757 Deoxyribozyme Proteins 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 13
- 230000002209 hydrophobic effect Effects 0.000 claims description 13
- 230000004913 activation Effects 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 208000017520 skin disease Diseases 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 9
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 8
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 8
- 206010029098 Neoplasm skin Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 206010072170 Skin wound Diseases 0.000 claims description 7
- 230000015556 catabolic process Effects 0.000 claims description 7
- 238000006731 degradation reaction Methods 0.000 claims description 7
- 208000010643 digestive system disease Diseases 0.000 claims description 7
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- 210000004748 cultured cell Anatomy 0.000 claims description 5
- 239000005022 packaging material Substances 0.000 claims description 5
- 208000012658 Skin autoimmune disease Diseases 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 description 46
- 210000003491 skin Anatomy 0.000 description 44
- 108090000623 proteins and genes Proteins 0.000 description 37
- 208000027866 inflammatory disease Diseases 0.000 description 36
- 210000000440 neutrophil Anatomy 0.000 description 36
- 102000004196 processed proteins & peptides Human genes 0.000 description 36
- 230000035755 proliferation Effects 0.000 description 35
- 230000014509 gene expression Effects 0.000 description 30
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 29
- 208000026935 allergic disease Diseases 0.000 description 28
- 102000049262 human DEFB4A Human genes 0.000 description 28
- 230000008506 pathogenesis Effects 0.000 description 27
- 206010020751 Hypersensitivity Diseases 0.000 description 26
- 230000004663 cell proliferation Effects 0.000 description 25
- 102000018568 alpha-Defensin Human genes 0.000 description 23
- 108050007802 alpha-defensin Proteins 0.000 description 23
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 22
- 102000019034 Chemokines Human genes 0.000 description 21
- 108010012236 Chemokines Proteins 0.000 description 21
- 206010052428 Wound Diseases 0.000 description 21
- 239000012634 fragment Substances 0.000 description 21
- 210000002510 keratinocyte Anatomy 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 201000009030 Carcinoma Diseases 0.000 description 20
- 238000013459 approach Methods 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 230000003902 lesion Effects 0.000 description 19
- 239000000203 mixture Substances 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 230000001684 chronic effect Effects 0.000 description 17
- 208000024827 Alzheimer disease Diseases 0.000 description 16
- -1 autoimmune Diseases 0.000 description 16
- 206010012601 diabetes mellitus Diseases 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 230000007815 allergy Effects 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 230000024245 cell differentiation Effects 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 210000000265 leukocyte Anatomy 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000011161 development Methods 0.000 description 14
- 230000018109 developmental process Effects 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 14
- 201000003883 Cystic fibrosis Diseases 0.000 description 13
- 208000037976 chronic inflammation Diseases 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 230000001363 autoimmune Effects 0.000 description 12
- 230000033228 biological regulation Effects 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000006020 chronic inflammation Effects 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 239000007943 implant Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 229910052742 iron Inorganic materials 0.000 description 11
- 230000001394 metastastic effect Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 230000009610 hypersensitivity Effects 0.000 description 10
- 238000010348 incorporation Methods 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 230000002018 overexpression Effects 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000003248 secreting effect Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 229940104230 thymidine Drugs 0.000 description 9
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- 208000006673 asthma Diseases 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 102000046975 human DEFB1 Human genes 0.000 description 8
- 230000007170 pathology Effects 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 230000003827 upregulation Effects 0.000 description 8
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 description 7
- 208000035473 Communicable disease Diseases 0.000 description 7
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 238000001574 biopsy Methods 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 230000008482 dysregulation Effects 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 7
- 102000055779 human DEFB103A Human genes 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 230000009885 systemic effect Effects 0.000 description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 7
- KRJOFJHOZZPBKI-KSWODRSDSA-N α-defensin-1 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@H](CSSC[C@H](NC2=O)C(O)=O)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C)C(=O)N3)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 KRJOFJHOZZPBKI-KSWODRSDSA-N 0.000 description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 208000007882 Gastritis Diseases 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 102000004890 Interleukin-8 Human genes 0.000 description 6
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 6
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000003828 downregulation Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 235000021242 lactoferrin Nutrition 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 210000003134 paneth cell Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000001185 psoriatic effect Effects 0.000 description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 5
- 101710193402 Alpha-defensin 1 Proteins 0.000 description 5
- 208000011231 Crohn disease Diseases 0.000 description 5
- 208000001840 Dandruff Diseases 0.000 description 5
- 206010012438 Dermatitis atopic Diseases 0.000 description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 5
- 101001041589 Homo sapiens Defensin-5 Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 102000016943 Muramidase Human genes 0.000 description 5
- 108010014251 Muramidase Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 5
- 108090000284 Pepsin A Proteins 0.000 description 5
- 208000024777 Prion disease Diseases 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 201000008937 atopic dermatitis Diseases 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007123 defense Effects 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 239000004325 lysozyme Substances 0.000 description 5
- 229960000274 lysozyme Drugs 0.000 description 5
- 235000010335 lysozyme Nutrition 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 201000001245 periodontitis Diseases 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 201000009890 sinusitis Diseases 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 210000001258 synovial membrane Anatomy 0.000 description 5
- 230000008467 tissue growth Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- 108010060219 Apolipoprotein E2 Proteins 0.000 description 4
- 108010025628 Apolipoproteins E Proteins 0.000 description 4
- 102000013918 Apolipoproteins E Human genes 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 102100030009 Azurocidin Human genes 0.000 description 4
- 101710154607 Azurocidin Proteins 0.000 description 4
- 102100021936 C-C motif chemokine 27 Human genes 0.000 description 4
- 102100021942 C-C motif chemokine 28 Human genes 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 101710178505 Defensin-1 Proteins 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 108010063045 Lactoferrin Proteins 0.000 description 4
- 102000010445 Lactoferrin Human genes 0.000 description 4
- 102100030417 Matrilysin Human genes 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 102100036154 Platelet basic protein Human genes 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 206010037888 Rash pustular Diseases 0.000 description 4
- 102000008847 Serpin Human genes 0.000 description 4
- 108050000761 Serpin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 101150047356 dec-1 gene Proteins 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 4
- 229940078795 lactoferrin Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 208000029561 pustule Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 239000003001 serine protease inhibitor Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002626 targeted therapy Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 3
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 3
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 3
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 3
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 3
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- 102000001902 CC Chemokines Human genes 0.000 description 3
- 108010040471 CC Chemokines Proteins 0.000 description 3
- 108050006947 CXC Chemokine Proteins 0.000 description 3
- 102000019388 CXC chemokine Human genes 0.000 description 3
- 108010083700 Chemokine CCL20 Proteins 0.000 description 3
- 108010055166 Chemokine CCL5 Proteins 0.000 description 3
- 102000009410 Chemokine receptor Human genes 0.000 description 3
- 108050000299 Chemokine receptor Proteins 0.000 description 3
- 206010008642 Cholesteatoma Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 101710178508 Defensin 3 Proteins 0.000 description 3
- 101710178510 Defensin-2 Proteins 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- 102100023795 Elafin Human genes 0.000 description 3
- 206010056274 Erythema toxicum neonatorum Diseases 0.000 description 3
- 206010016936 Folliculitis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 3
- 101000865479 Homo sapiens Defensin-6 Proteins 0.000 description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102000013519 Lipocalin-2 Human genes 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 3
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 101710117809 Phospholipase A(2) Proteins 0.000 description 3
- 102100030304 Platelet factor 4 Human genes 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 102100032446 Protein S100-A7 Human genes 0.000 description 3
- 108091030071 RNAI Proteins 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 description 3
- 108091023045 Untranslated Region Proteins 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 108010007004 cathelin Proteins 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000006727 cell loss Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010668 complexation reaction Methods 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 206010062952 diffuse panbronchiolitis Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002222 downregulating effect Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 210000000224 granular leucocyte Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 102000018511 hepcidin Human genes 0.000 description 3
- 108060003558 hepcidin Proteins 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000000329 molecular dynamics simulation Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000017066 negative regulation of growth Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 238000011369 optimal treatment Methods 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000007998 vessel formation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 102400001318 Adrenomedullin Human genes 0.000 description 2
- 101800004616 Adrenomedullin Proteins 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 2
- 101710193400 Alpha-defensin 2 Proteins 0.000 description 2
- 102000001049 Amyloid Human genes 0.000 description 2
- 108010094108 Amyloid Proteins 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100026887 Beta-defensin 103 Human genes 0.000 description 2
- 102100026886 Beta-defensin 104 Human genes 0.000 description 2
- 101710125296 Beta-defensin 3 Proteins 0.000 description 2
- 101710125300 Beta-defensin 4 Proteins 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 2
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 2
- 101710112538 C-C motif chemokine 27 Proteins 0.000 description 2
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 2
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010052495 Calgranulin B Proteins 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 206010008027 Cerebellar atrophy Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 108010082169 Chemokine CCL17 Proteins 0.000 description 2
- 102000001326 Chemokine CCL4 Human genes 0.000 description 2
- 108010055165 Chemokine CCL4 Proteins 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 102100021420 Defensin-5 Human genes 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 108010015972 Elafin Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000004878 Gelsolin Human genes 0.000 description 2
- 108090001064 Gelsolin Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 102100021186 Granulysin Human genes 0.000 description 2
- 101710168479 Granulysin Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 description 2
- 101000918983 Homo sapiens Neutrophil defensin 1 Proteins 0.000 description 2
- 101000830386 Homo sapiens Neutrophil defensin 3 Proteins 0.000 description 2
- 101000947178 Homo sapiens Platelet basic protein Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000004125 Interleukin-1alpha Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- 102100026236 Interleukin-8 Human genes 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 108010051335 Lipocalin-2 Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108090000855 Matrilysin Proteins 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 241000588655 Moraxella catarrhalis Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 101710091942 N-formyl peptide receptor 2 Proteins 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 102100029494 Neutrophil defensin 1 Human genes 0.000 description 2
- 102100024761 Neutrophil defensin 3 Human genes 0.000 description 2
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 2
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 2
- 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 2
- 101710084411 POU domain, class 2, transcription factor 2 Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- 101710195957 Platelet basic protein Proteins 0.000 description 2
- 108090000778 Platelet factor 4 Proteins 0.000 description 2
- 102100032420 Protein S100-A9 Human genes 0.000 description 2
- 206010037601 Pyelonephritis chronic Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 2
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 206010045240 Type I hypersensitivity Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 2
- 101150066984 aml gene Proteins 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 2
- 208000025255 bacterial arthritis Diseases 0.000 description 2
- 102000052586 bactericidal permeability increasing protein Human genes 0.000 description 2
- 108010032816 bactericidal permeability increasing protein Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 2
- 208000010217 blepharitis Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 201000006368 chronic pyelonephritis Diseases 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 2
- 230000008556 epithelial cell proliferation Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229940066919 hepcidin Drugs 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 208000011645 metastatic carcinoma Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 230000002956 necrotizing effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 229940030793 psoriasin Drugs 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 208000017443 reproductive system disease Diseases 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 108700022109 ropocamptide Proteins 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 108010034266 theta-defensin Proteins 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- CWLQUGTUXBXTLF-RXMQYKEDSA-N (2r)-1-methylpyrrolidine-2-carboxylic acid Chemical compound CN1CCC[C@@H]1C(O)=O CWLQUGTUXBXTLF-RXMQYKEDSA-N 0.000 description 1
- YAXAFCHJCYILRU-RXMQYKEDSA-N (2r)-2-(methylamino)-4-methylsulfanylbutanoic acid Chemical compound CN[C@@H](C(O)=O)CCSC YAXAFCHJCYILRU-RXMQYKEDSA-N 0.000 description 1
- SCIFESDRCALIIM-SECBINFHSA-N (2r)-2-(methylazaniumyl)-3-phenylpropanoate Chemical compound CN[C@@H](C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-SECBINFHSA-N 0.000 description 1
- AKCRVYNORCOYQT-RXMQYKEDSA-N (2r)-3-methyl-2-(methylazaniumyl)butanoate Chemical compound C[NH2+][C@H](C(C)C)C([O-])=O AKCRVYNORCOYQT-RXMQYKEDSA-N 0.000 description 1
- KSZFSNZOGAXEGH-SCSAIBSYSA-N (2r)-5-amino-2-(methylamino)-5-oxopentanoic acid Chemical compound CN[C@@H](C(O)=O)CCC(N)=O KSZFSNZOGAXEGH-SCSAIBSYSA-N 0.000 description 1
- OZRWQPFBXDVLAH-RXMQYKEDSA-N (2r)-5-amino-2-(methylamino)pentanoic acid Chemical compound CN[C@@H](C(O)=O)CCCN OZRWQPFBXDVLAH-RXMQYKEDSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KSPIYJQBLVDRRI-NTSWFWBYSA-N (2r,3s)-3-methyl-2-(methylazaniumyl)pentanoate Chemical compound CC[C@H](C)[C@@H](NC)C(O)=O KSPIYJQBLVDRRI-NTSWFWBYSA-N 0.000 description 1
- WTDHSXGBDZBWAW-QMMMGPOBSA-N (2s)-2-[cyclohexyl(methyl)azaniumyl]propanoate Chemical compound OC(=O)[C@H](C)N(C)C1CCCCC1 WTDHSXGBDZBWAW-QMMMGPOBSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- AXEOMQHKTSGLGS-VIFPVBQESA-N (2s)-2-amino-3-(4-hydroxy-2-methylphenyl)propanoic acid Chemical compound CC1=CC(O)=CC=C1C[C@H](N)C(O)=O AXEOMQHKTSGLGS-VIFPVBQESA-N 0.000 description 1
- UIINSJBTFLRMLY-JTQLQIEISA-N (2s)-2-amino-4-(2-methylphenyl)butanoic acid Chemical compound CC1=CC=CC=C1CC[C@H](N)C(O)=O UIINSJBTFLRMLY-JTQLQIEISA-N 0.000 description 1
- AXDLCFOOGCNDST-VIFPVBQESA-N (2s)-3-(4-hydroxyphenyl)-2-(methylamino)propanoic acid Chemical compound CN[C@H](C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-VIFPVBQESA-N 0.000 description 1
- OFMQLVRLOGHAJI-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18 Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 OFMQLVRLOGHAJI-FGHAYEPSSA-N 0.000 description 1
- JWICNZAGYSIBAR-LEEGLKINSA-N (4s)-4-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]-5-[[2-[[(2s)-3-carboxy-1-[[(2s)-1-[[1-[[(2s)-1-[[(2s)-4-carboxy-1-[[2-[[2-[[2-[[(2s)-1-[[(1s)-1-carboxy-4-(diaminomethylideneamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)N)CC1=CC=CC=C1 JWICNZAGYSIBAR-LEEGLKINSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- XCDGCRLSSSSBIA-UHFFFAOYSA-N 2-(2-methylsulfanylethylamino)acetic acid Chemical compound CSCCNCC(O)=O XCDGCRLSSSSBIA-UHFFFAOYSA-N 0.000 description 1
- IVCQRTJVLJXKKJ-UHFFFAOYSA-N 2-(butan-2-ylazaniumyl)acetate Chemical compound CCC(C)NCC(O)=O IVCQRTJVLJXKKJ-UHFFFAOYSA-N 0.000 description 1
- YDBPFLZECVWPSH-UHFFFAOYSA-N 2-[3-(diaminomethylideneamino)propylamino]acetic acid Chemical compound NC(=N)NCCCNCC(O)=O YDBPFLZECVWPSH-UHFFFAOYSA-N 0.000 description 1
- YJIYWYAMZFVECX-UHFFFAOYSA-N 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetic acid acetyloxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O YJIYWYAMZFVECX-UHFFFAOYSA-N 0.000 description 1
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 206010001324 Adrenal atrophy Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010058285 Allergy to arthropod bite Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710193394 Alpha-defensin 3 Proteins 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 208000030760 Anaemia of chronic disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 102100022987 Angiogenin Human genes 0.000 description 1
- 101710190945 Angiogenin-4 Proteins 0.000 description 1
- 108090000644 Angiozyme Proteins 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010059313 Anogenital warts Diseases 0.000 description 1
- 102100021253 Antileukoproteinase Human genes 0.000 description 1
- 101710170876 Antileukoproteinase Proteins 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 description 1
- 102100030970 Apolipoprotein C-III Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 1
- 101710115418 Apolipoprotein(a) Proteins 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 208000008037 Arthrogryposis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100033735 Bactericidal permeability-increasing protein Human genes 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 102100037841 Beta-defensin 105 Human genes 0.000 description 1
- 102100037913 Beta-defensin 106 Human genes 0.000 description 1
- 102100039817 Beta-defensin 118 Human genes 0.000 description 1
- 101710125297 Beta-defensin 5 Proteins 0.000 description 1
- 101710125302 Beta-defensin 6 Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101001047514 Bos taurus Lethal(2) giant larvae protein homolog 1 Proteins 0.000 description 1
- 241001086826 Branta bernicla Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 1
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
- 102100025250 C-X-C motif chemokine 14 Human genes 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101150102665 CCL20 gene Proteins 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101001125997 Caenorhabditis elegans Intracellular phospholipase A2 Proteins 0.000 description 1
- 102400000870 Calcitermin Human genes 0.000 description 1
- 101800005167 Calcitermin Proteins 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 108010052500 Calgranulin A Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 102100025975 Cathepsin G Human genes 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 102000004171 Cathepsin K Human genes 0.000 description 1
- 102400001321 Cathepsin L Human genes 0.000 description 1
- 108090000624 Cathepsin L Proteins 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 108010083675 Chemokine CCL27 Proteins 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 201000005019 Chlamydia pneumonia Diseases 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010008685 Chondritis Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 102000010792 Chromogranin A Human genes 0.000 description 1
- 108010038447 Chromogranin A Proteins 0.000 description 1
- 102000010791 Chromogranin B Human genes 0.000 description 1
- 108010038439 Chromogranin B Proteins 0.000 description 1
- 102000007345 Chromogranins Human genes 0.000 description 1
- 108010007718 Chromogranins Proteins 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 102100024539 Chymase Human genes 0.000 description 1
- 108090000227 Chymases Proteins 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000016917 Complement C1 Human genes 0.000 description 1
- 108010028774 Complement C1 Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102400000361 DCD-1 Human genes 0.000 description 1
- 101800003946 DCD-1 Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100029790 Defensin-6 Human genes 0.000 description 1
- 101710129420 Defensin-like peptide Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 101800002934 Enkelytin Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010039659 FALL 39 Proteins 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 101800000974 Fibrinopeptide A Proteins 0.000 description 1
- 102400000525 Fibrinopeptide A Human genes 0.000 description 1
- 101800003778 Fibrinopeptide B Proteins 0.000 description 1
- 102400001063 Fibrinopeptide B Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 108010076288 Formyl peptide receptors Proteins 0.000 description 1
- 102000011652 Formyl peptide receptors Human genes 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000023329 Gun shot wound Diseases 0.000 description 1
- 102100034445 HCLS1-associated protein X-1 Human genes 0.000 description 1
- 101710200673 HCLS1-associated protein X-1 Proteins 0.000 description 1
- 102000055206 HMGN2 Human genes 0.000 description 1
- 108700010011 HMGN2 Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010019494 Histatins Proteins 0.000 description 1
- 102000006492 Histatins Human genes 0.000 description 1
- 102000017286 Histone H2A Human genes 0.000 description 1
- 108050005231 Histone H2A Proteins 0.000 description 1
- 101000615334 Homo sapiens Antileukoproteinase Proteins 0.000 description 1
- 101000871785 Homo sapiens Bactericidal permeability-increasing protein Proteins 0.000 description 1
- 101000885708 Homo sapiens Beta-defensin 118 Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101000897486 Homo sapiens C-C motif chemokine 25 Proteins 0.000 description 1
- 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 description 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
- 101000858068 Homo sapiens C-X-C motif chemokine 14 Proteins 0.000 description 1
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 1
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 1
- 101001048718 Homo sapiens Elafin Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101001090713 Homo sapiens L-lactate dehydrogenase A chain Proteins 0.000 description 1
- 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 1
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 description 1
- 101000929203 Homo sapiens Neutrophil defensin 4 Proteins 0.000 description 1
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 description 1
- 101000973997 Homo sapiens Nucleosome assembly protein 1-like 4 Proteins 0.000 description 1
- 101000582950 Homo sapiens Platelet factor 4 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 208000024781 Immune Complex disease Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 208000026492 Isaac syndrome Diseases 0.000 description 1
- 208000000209 Isaacs syndrome Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 208000007811 Latex Hypersensitivity Diseases 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 102100035304 Lymphotactin Human genes 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010028331 Muscle rupture Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108090000973 Myeloblastin Proteins 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- VKZGJEWGVNFKPE-UHFFFAOYSA-N N-Isobutylglycine Chemical compound CC(C)CNCC(O)=O VKZGJEWGVNFKPE-UHFFFAOYSA-N 0.000 description 1
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 101800000838 Neutrophil cationic peptide 1 Proteins 0.000 description 1
- 102400001060 Neutrophil defensin 2 Human genes 0.000 description 1
- 101800000287 Neutrophil defensin 2 Proteins 0.000 description 1
- 102100036348 Neutrophil defensin 4 Human genes 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 206010030201 Oesophageal ulcer Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000004179 Oral Leukoplakia Diseases 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 101100230381 Pectobacterium carotovorum subsp. carotovorum celV gene Proteins 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 208000027086 Pemphigus foliaceus Diseases 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 229940124034 Phospholipase C inhibitor Drugs 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000034943 Primary Sjögren syndrome Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100032442 Protein S100-A8 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 101150023114 RNA1 gene Proteins 0.000 description 1
- 206010063562 Radiation skin injury Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
- 101000599054 Rattus norvegicus Interleukin-6 receptor subunit beta Proteins 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 206010039251 Rubber sensitivity Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 102000004002 Secretory Leukocyte Peptidase Inhibitor Human genes 0.000 description 1
- 108010082545 Secretory Leukocyte Peptidase Inhibitor Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 101100244894 Sus scrofa PR39 gene Proteins 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 description 1
- 102100035000 Thymosin beta-4 Human genes 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 208000025609 Urogenital disease Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000289690 Xenarthra Species 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- DLAMVQGYEVKIRE-UHFFFAOYSA-N alpha-(methylamino)isobutyric acid Chemical compound CNC(C)(C)C(O)=O DLAMVQGYEVKIRE-UHFFFAOYSA-N 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 201000002996 androgenic alopecia Diseases 0.000 description 1
- 208000022400 anemia due to chronic disease Diseases 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000665 anti-chemotactic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000469 anti-sperm effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000026764 autoimmune bullous skin disease Diseases 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000004339 autoimmune neuropathy Diseases 0.000 description 1
- 201000011385 autoimmune polyendocrine syndrome Diseases 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000015624 blood vessel development Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 201000004196 common wart Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 201000005637 crescentic glomerulonephritis Diseases 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000004920 epithelial cell of skin Anatomy 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 208000028299 esophageal disease Diseases 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 208000019064 esophageal ulcer Diseases 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 231100000562 fetal loss Toxicity 0.000 description 1
- MYRIFIVQGRMHRF-OECXYHNASA-N fibrinopeptide b Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 MYRIFIVQGRMHRF-OECXYHNASA-N 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000048466 human DEFA5 Human genes 0.000 description 1
- 102000050514 human DEFA6 Human genes 0.000 description 1
- 102000055848 human LDHA Human genes 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000036260 idiopathic disease Diseases 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000005391 latex allergy Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000001237 metamyelocyte Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000013470 microfluidic resistive pulse sensing Methods 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 206010063344 microscopic polyangiitis Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 239000002062 molecular scaffold Substances 0.000 description 1
- 229920000344 molecularly imprinted polymer Polymers 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000017445 musculoskeletal system disease Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 108700021654 myb Genes Proteins 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- XJODGRWDFZVTKW-ZCFIWIBFSA-N n-methylleucine Chemical compound CN[C@@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-ZCFIWIBFSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- GRZXCHIIZXMEPJ-HTLKCAKFSA-N neutrophil peptide-2 Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=4C=CC(O)=CC=4)NC(=O)[C@@H](N)CSSC[C@H](NC2=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](C)C(=O)N3)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N1)[C@@H](C)CC)[C@@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 GRZXCHIIZXMEPJ-HTLKCAKFSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 206010030983 oral lichen planus Diseases 0.000 description 1
- 201000008557 oral mucosa leukoplakia Diseases 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 239000003371 phospholipase C inhibitor Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 208000030773 pneumonia caused by chlamydia Diseases 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 208000025644 recurrent pneumonia Diseases 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000018277 regulation of iron ion transport Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 108010092136 ribosomal protein S30 Proteins 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 108010079996 thymosin beta(4) Proteins 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005029 transcription elongation Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 230000028063 type III hypersensitivity Effects 0.000 description 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
- 210000001692 type a synoviocyte Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 208000034280 venom allergy Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
DISEASE TREATMENT VIA ANTIMICROBIAL PEPTIDE INHIBITORS
The present invention relates to methods of treating diseases using anti- . s antimicrobial peptide (AMP) and/or anti-AMP-like molecule (AML) inhibitors, to methods of treating diseases using AMPs/AMLs, and to methods of identifying compounds capable of decreasing activities/levels of AMPs/AMLs so as to enable treatment of diseases. More particularly, the present invention relates to methods of treating diseases, including autoimmune diseases such as psoriasis and malignancies such as carcinomas, which are associated with inflammation, dysregulated cell proliferation/differentiation, angiogenesis and/or metastasis by using compounds capable of inhibiting levels/activity of cathelicidins/beta-defensins; to methods of treating diseases, such as epithelial wounds, which require therapeutic stimulation of epithelial proliferation, by using beta-defensins; and to methods of identifying compounds capable of decreasing activity/levels of AMPs so as to enable treatment of diseases including autoimmune diseases such as, psoriasis and malignant diseases such as carcinomas, which are associated with inflammation, dysregulated cell proliferation/differentiation, angiogenesis and/or metastasis.
Diseases, such as malignant, autoimmune, allergic, and wound-associated diseases, which are associated with biological processes such as inflammation, dysregulated cell proliferation/differentiation, dysregulated cell proliferation/differentiation balance, angiogenesis, and metastasis, include a vast range of highly debilitating and/or lethal pathologies, and pathologies of great economic impact, for which no satisfactory treatment methods are presently available.
For example autoimmune diseases represent diseases of major clinical and economic impact. These include major diseases such as psoriasis, rheumatoid arthritis, type I diabetes, inflammatory bowel diseases, and multiple sclerosis for . which no satisfactory treatment methods are available. Similarly, malignant diseases, such as skin carcinoma, breast carcinoma, colon carcinoma, head and neck carcinoma, . 30 hepatic carcinoma, lung carcinoma, renal cell carcinoma, urinary bladder carcinoma, and the like, represent numerous lethal diseases for which no satisfactory treatment methods are available. Diseases associated with epithelial wounds, include major diseases, such as peptic ulcers, ulcerative colitis, and wound-healing deficiencies such as diabetes related skin ulcerations, which are of great clinical and economic impact and for which no satisfactory treatment methods are available. Allergic diseases, such as allergy to seasonal pollens, ragweed, dust mites, pet fur, cosmetics, and various foods are significantly debilitating to a large proportion of the population, can be fatal, ; 5 and are of great economic significance due to the large market for allergy drugs.
There is therefore an urgent and long-felt need for optimal methods of treating such diseases which are associated with inflammation, dysregulated cell/tissue proliferation/differentiation, dysregulated cell/tissue proliferation/differentiation balance, angiogenesis metastasis, and/or epithelial wounds.
The epithelial lining of the skin, gastrointestinal tract and bronchial tree produces a number of peptides with antimicrobial activities termed antimicrobial peptides (AMPs), which appear to be involved in both innate host defense and adaptive immune responses (Yang D. et al., 2001. Cell Mol Life Sci. 58:978-89).
AMPs are cationic peptides which display antimicrobial activity at physiological concentrations under conditions prevailing in the tissues of origin. AMP synthesis and release is regulated by microbial signals, developmental and differentiation signals, cytokines and in some cases neuroendocrine signals in a tissue-specific manner. Their mode of action is unknown, however the leading theory claims that permeabilization of target membranes is the crucial step in AMP-mediated antimicrobial activity and cytotoxicity. Defensins are classified into two major groups in humans; cathelicidins and defensins. AMPs appear to have common characteristics that enable them to affect mammalian cells in a way that does not necessarily function through a ligand-receptor pathway, and that, being small, and highly ionic or hydrophobic or structurally amphiphilic, AMPs can bind mammalian cell membranes. They are able to penetrate penetrate through the cell membrane to the cytoplasm. For example, it was shown that granulysin penetrates and damages human cell membranes dependent upon negative charge (J. Immunol., 2001, 167:350— ] 356). At high concentrations they are cytotoxic to cells, they tear through the membrane causing lysis or apoptosis. Likewise they are able to change the charge . 30 density of the inner membrane by the very fact that they have charge, are small and are distributed around the cell membrane from the outer surface of the membrane.
Cathelicidins contain a conserved ‘cathelin” precursor domain. Their organization includes an N-terminal signal peptide, a highly conserved prosequence,
and a structurally variable cationic peptide at the C-terminus. The prosequence resembles cathelin, a protein originally isolated from porcine neutrophils as an } inhibitor of cathepsin L (hence, the name cathelin). The 37 amino acid-long human cathelicidin, LL-37/hCAP18 has a hydrophobic N-terminal domain in an a-helical : 5 conformation, particularly in the presence of negatively charged lipids. In a step essential for its activation, LL-37 is enzymatically cleaved from the C-terminus of hCAP18 precursor via enzymes such as neutrophil elastase and proteinase 3. LL-37 functions in synergy with other AMPs, and can directly activate host cells. The ability of cathelicidins such as LL-37 to both kill bacteria and regulate immune responses is a characteristic of numerous AMPs. The peptide can influence host immune responses via a variety of cellular interactions, for example, it has been suggest to possibly function as a chemoattractant by binding to formyl-peptide- receptor-like-1 (FPRL-1). LL-37 can recruit mast cells, then be produced by the mast cell to kill bacteria.
Defensins represent a large family of AMPs which contribute to the antimicrobial action of granulocytes, mucosal host defence in the small intestine and epithelial host defence in the skin and elsewhere (Ganz T. 2003 Nat Rev Immunol. 3:710-20). Defensins are thought to contribute to host defense by disrupting the cytoplasmic membrane of microorganisms. Defensins are produced by the epithelial cell lining of the gastrointestinal and genitourinary tracts, the tracheobronchial tree, and keratinocytes as well as by phagocytic cells and lymphocytes. Some defensins are produced constitutively, and others are produced in response to proinflammatory cytokines and microbial products. Defensins produced during innate host defence serve as signals which initiate, mobilize, and amplify adaptive immune host defenses.
These peptides are cationic and include 6-8 cysteine residues forming disulfide bridges.” Mammalian defensins can be classified into three distinct sub-families: alpha-defensins, and beta-defensins, as well as the theta-defensins which are absent in . humans.
Alpha-defensins have three disulfide bridges in a 1-6, 2-4, 3-5 alignment. : 30 Human neutrophils express four distinct alpha-defensins; alpha-defensin-1 to -4, also referred to as human neutrophil peptides (HNP-1 to -4) which are stored in azurophilic granules of neutrophils as fully processed mature peptides of about 3 kDa.
Two additional alpha-defensins, human defensin (HD)-5 and -6 are expressed in small intestinal crypt Paneth cells, and in female urogenital tract epithelial cells. Unlike neutrophils, Paneth cells store alpha-defensins as propeptides. Similarly to . cathelicidins, alpha-defensins exert action on both microbes and the host. For example, HNP 1-3 have been shown to increase the expression of tumor NEeCrosis : 5s factor (TNF)-alpha and interleukin (IL)-1 in human monocytes that have been activated by bacteria (Staphylococcus aureus), or reduce expression of the vascular : adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells activated by TNF-alpha.
The beta-defensins are characterized by having 6 cysteine motifs connected by three disulfide bridges spaced as C1-C5, C2-C4, and C3- C6. Beta-defensins have been identified numerous cell types, including epithelial cells and neutrophils. Four types are known in humans and are termed human beta-defensin-1, -2, -3 and -4.
Genomic analyses suggest that numerous beta-defensins genes remain to be discovered. Beta-defensins display broad spectrum of antimicrobial activity and additional immune cell-related functions. For example, human beta-defensin-2 has the capacity bind the chemokine receptor CCR6, to be chemotactic for dendritic cells and T-cells, and induce histamine release and prostaglandin D2 production in mast cells. Thus, it has been proposed that beta-defensins play a role in allergic reactions.
By employing chemokine receptors such as CCR6 on dendritic cells and T cells, defensins may be involved in the modulation of adaptive antimicrobial immunity (Yang D. et al, 1999. Science. 286:525-8; Yang D. et al., 2002. Trends Immunol. 23:291-6; Oppenheim et al., 2003. Ann Rheum Dis. 62 Suppl 2:ii17-21).
AMPs exert their effects either individually or as the resultant effect of multiple AMPs. For example, in the menstrual cycle there is a monthly cycle- 2s dependent expression of various AMPs (King AE. et al, 2003. J. Reprod. Immunol. 59:1-16). For example, there is higher expression during the menstrual cycle of beta- defensin-2 in the menstrual stage, beta-defensin-4 in the proliferative stage, beta-
A defensin-3 in the early secretory stage, beta-defensin-1 in the mid secretory stage, and beta-defensin-3 in the late secretory stage. It has been suggested that maintaining the : 30 balance between the AMPs is essential for normal proliferation, differentiation and in the specific example of menstrual cycle for development.
Antimicrobial peptide-like molecules (AMLs) such as chemokines, and in particular AMPs that function dually as chemokines or as cytokines, play an important role in orchestrating leukocyte recruitment during inflammation. Monoclonal antibodies and antagonists to chemokines such as for example TNF, IFN-gamma, } leukotriene receptor antagonists, IL-8, anti-IgE and anti-IL receptor antagonists are already patented and used clinically. However, these generally have major side 5 effects due to the fact that these chemokines function dually in normal growth and metabolism. Thus, inhibiting their activity also inhibits normal growth of body cells. ” However, apart from their antibacterial and anti-viral nature, AMPs play several roles that enhance the pathogenesis of disease. They act individually or in synergy as chemokines, as cytokines, proliferation and hyperproliferation biofilm inducers, bacterial-cellular binding and adhesion enhancers, inflammatory enhancers, indirectly as monocyte iron retention regulators protease inhibitors, angiogenesis enhancers, corticostatin-like molecules, enhance extracellular matrix deposition controlling its degradation, and more. Most importantly, AMPs are upregulated in several chronic diseases, as is detailed below, and play a major role in the pathogenesis of chronic inflammation and disease as well as influencing cellular differentiation and proliferation by various mechanisms.
AMPs generally work downstream (Moon, SK. er al, 2002.
Biochim. Biophys.Acta 1590:41-51; King, AE. et al., 2002. Mol. Hum.Reprod. 8:341- 349; Seo, SI. et al, 2001. J.Dermatol.Sci. 27:183-191; Tomita, T, and Nagase, T, 2001. Nippon Ronen Igakkai Zasshi 38:440-443) as well as upstream (Harder, J. et al, 2000. Am.J.Respir.Cell MolBiol. 22:714-721; Chaly, YV. et al, 2000.
Eur.Cytokine Netw. 11:257-266) to the cytokines and chemokines that are currently inhibited by the current available treatments. They are both activators of the inflammatory reaction as well as being transcribed as a response to pro-inflammatory stimuli such as interleukin 1 alpha (IL-1 alpha), tumor necrosis factor alpha (TNF- alpha) and more.
Due to the dual functionality of AMPs upstream and downstream to cytokines : such as TNF-alpha and IL-1, disease states induced by such AMPs enter a self- sustaining cycle of uncontrolled production of TNF-alpha, IL-1, resulting in : 30 deteriorating/chronic inflammation. This is especially so in situations where AMPs are overexpressed, to a larger copy number or over-activated polymorphism of genes for AMPs. Breaking of this inflammatory cycle has been achieved using TNF-alpha antagonists, IL-1 receptor antagonists, IL-10 inhibitors, and T-cell inhibitors.
However due to the need for inducing minimal of side effects, inhibiting the activity of these AMPs, and in particular, inhibiting their secondary cytokine activity, proves a preferred safer and more effective approach to treatment of inflammatory and autoimmune chronic as well as some acute conditions. : 5 Thus, numerous diseases which are associated with inflammation, dysregulated cell proliferation/differentiation, angiogenesis metastasis, and/or - epithelial wounds appear to be associated with dysregulated AMP levels in affected cells/tissues (reviewed, for example, in Gallo and Nizet, 2003. Curr. Allergy and
Asthma Reports 3:402; van Wetering et al., 1999. J Allergy Clin Immunol. 104:1131- 8).
With regards to psoriasis and other skin pathologies, it has been shown that there are increased levels of LL-37 and beta-defensin-2 in psoriasis lesions, but none to minor amounts in skin from atopic dermatitis patients, with psoriasis patients having at least 10 times as much of such AMPs in their skin as atopic dermatitis patients (Ong PY et al., 2002. N Engl J Med. 347:1151-60). Furthermore, cutaneous injury, a known psoriasis trigger, induces the release of LL-37 and beta defensin-2, and such injuries may develop into irreversible psoriatic lesions. In addition, there are other skin pathologies associated with increase in AMPs. The majority of acne biopsies display a marked upregulation of defensin-2 immunoreactivity in the lesional and perilesional epithelium - in particular in pustules - and a less marked upregulation of defensin-1 immunoreactivity (Chronnell CMT et al., 2001. J Invest Dermatol 117:1120-1125).
Psoriasis has been established as a T-cell mediated autoimmune disease with innate immunity paying a key role. Psoriasis is a result of a cutaneous defect that is triggered by an autoimmune activation (Gilhar, A. et al, 2002. J.Invest Dermatol. 119:384-391) by bacterial superantigens (Boehncke, WH. et al, 2001. J.Invest
Dermatol. 116:596-601). Histologically, psoriasis is characterized by abnormalities in } the proliferation/differentiation balance of keratinocytes and fibroblasts, with abnormal differentiation and infiltration of the epidermis and dermis by neutrophils, - 30 lymphocytes, macrophages and mast cells. Natural killer (NK) and NK-T cells have been implicated in the pathogenesis of psoriasis and are present in plaques of psoriasis (Br J Dermatol. 2003, 149:160-4). AMPs are effector molecules of human T and natural killer (NK) cells their release from NK cells plays a part in the pathogenesis of disease. The human AMPs LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations (Agerberth B. et al, 2000. Blood. 96:3086- 93).
Up to the present, suboptimal novel systemic interventions are used to treat : 5 psoriasis. These include mainly T-cell targeted therapies, monoclonal antibody against chemokine tumor necrosis factor and cytokine targeted therapies. - Treatments for psoriasis include topical application of cell proliferation/differentiation regulators such as retinoid - vitamin A — analog, which modulates or changes the cellular differentiation and proliferation of the epidermis by inducing apoptosis thereby limiting the number of proliferations (Ocker, M. et al., 2003. Int.J.Cancer 107:453-459), UV treatment which also induces cell apoptosis thereby reducing the opportunities for cells to proliferate (Mass, P. et al., 2003.
Arch.Dermatol Res. 295:71-79). Apoptosis also enables the release of anionic DNA which forms bundles in the presence of cationic AMPs thereby inhibiting antimicrobial activity and their downstream elements through the ligand-cell receptor connections, corticosteroid creams and ointment and synthetic vitamin D3. These topical treatments are aimed at regulating only the end result inflammation reactivity of the epidermis, they do not prevent the initial process from occurring.
There are many signaling pathways leading to pathogenic proliferation.
Abnormality in the proliferation/differentiation balance in psoriasis is a result of overexpression in the AMP pathway on account of other pathways such for example the TGF-beta signaling pathway which is downregulated in psoriatic skin (Doi, H. et al., 2003. J.Dermatol.Sci. 33:7-16), a functional decrease in growth regulation. In fact, it seems that AMPs such as LL-37, human beta-defensin-3, neutrophil gelatinase-associated lipocalin, and secretory leukocyte protease inhibitor act downstream to growth factors important in wound healing such as insulin-like growth factor 1 and TGF-alpha in human keratinocytes (Sorensen, OE. et al, 2003. . J.Immunol. 170:5583-5589).
Alpha-defensins have been shown to accumulate in airway secretions of : 30 patients with various chronic inflammatory lung disorders, and have been demonstrated to be cytotoxic toward airway epithelial cells and to induce pathogenic chemokine secretion in several cell types. Specifically, alpha-defensins have been shown to be increased in inflamed tissues affected by rhinitis and upper respiratory
. tract S. aureus infection. Beta-defensins are overexpressed in inflamed sinus fluid of sinusitis patients. Cathelicidin and beta-defensins have been shown to be . overexpressed in inflamed bronchi of pneumonia patients. Increased levels of AMPs have been found to correlate with levels of soluble and cellular inflammatory : 5s mediators such as IL-8 and neutrophils. Alpha- and beta-defensins have been demonstrated to be expressed at high level in the inflamed respiratory tract of patients - infected with Mycobacterium. High levels of defensins have been shown to be associated with damaged tissue in acute respiratory distress syndrome (ARDS), in idiopathic inflammatory lung diseases, such as diffuse panbronchiolitis and in idiopathic pulmonary fibrosis. It has been suggested that neutrophil defensins can induce pathogenic pulmonary epithelial-cell proliferation and incident lung remodeling. Increased levels of AMPs in respiratory tract secretions were shown to correlate with chronic inflammation in cystic fibrosis. Alpha-defensins have been shown to promote bacterial adherence to epithelial cells in vitro suggesting that these peptides play a role in the pathogenesis of diseases such as chronic obstructive pulmonary disease and cystic fibrosis. Increased numbers of neutrophils are also present in the airways of patients with asthma, suggesting that neutrophils are involved in the pathogenesis of this disease. Since defensins have the capacity to induce histamine release by mast cells and thereby increase airway hyperresponsiveness, it is possible that such molecules contribute to asthma pathogenesis. Experiments in mice support the idea that dysregulation of AMP expression may be associated with such disease pathogenesis. For example, intratracheal instillation of defensins was shown to result in acute pulmonary dysfunction, neutrophil invasion, and to bronchial release of inflammatory mediators, such as TNF-alpha and macrophage inflammatory protein (MIP)-2.
With respect to gastrointestinal pathologies, constitutive expression of beta- defensin in inflamed gastric epithelium of patients with gastritis or gastric cancers . induced by Helicobacter pylori has been reported. High levels of alpha- and beta- defensins have been observed in the inflamed colonic epithelium of patients suffering : 30 from Crohn’s disease or active ulcerative colitis.
In the case of urogenital diseases, upregulation of AMP production has been reported in inflamed tissue of urogenital tract infections. Induced expression of beta- defensin-2 has been shown to occur in inflamed tissues in tubulus epithelia with chronic pyelonephritis. Women with pelvic inflammatory diseases secondary to infection with T. vaginalis, N. gonorrhoeae, or Chlamydia trachomatis displayed high } neutrophil defensin expression levels in the vagina at levels which were strongly associated with the presence of endometritis. - 5 With respect to malignant diseases, in vitro and in vivo findings suggest that alpha-defensins are frequent peptide constituents of malignant epithelial cells in Renal cell carcinoma with a possible direct influence on tumor proliferation (Muller, CA. et al., 2002. Am.J Pathol. 160:1311-1324).
Overexpression of AMPs contributing to disease states may occur as a result of several mechanisms, including gene copy number polymorphisms (Hollox, EJ. et al., 2003. Am.J.Hum.Genet. 73:591-600), the genomic locations of their promoters, and polymorphisms in these proteins leading to their overexpression or overactivation.
Therefore, in light of the apparent roles for AMPs/AMLs in the pathogenesis of diseases which are associated with inflammation, dysregulated cell proliferation/differentiation, dysregulated cell proliferation/differentiation balance, angiogenesis metastasis, and/or epithelial wounds, the present inventors hypothesized that an optimal strategy for treating such diseases would be via methods involving decreasing the levels/activity of such AMPs/AMLs, and/or via methods involving administering such AMPs/AMLs.
The prior art approaches relating to such methods involve computationally identifying a genetic sequence encoding a novel, putative AMP-like molecule of unknown function, and of unknown relationship to a disease pathogenesis, and proposes attempting to regulate levels of such a molecule for treating a disease (U.S.
Pat. Application No. 20030044907).
The prior art approaches, however, are critically flawed. Since a role for the novel putative AMP-like molecule in pathogenesis of any disease is unknown, it cannot be reasonably be expected that regulating the levels of the putative AMP-like i molecule will have a therapeutic effect when administered to a subject having a disease. Critically, the prior art approaches have never been attempted, and as such - 30 have not demonstrated their viability for treatment of any disease. Importantly, the prior art approaches have not proposed a method of using inhibitors of AMPs such as beta-defensin-2 or LL-37 for treatment any disease.
Thus, the prior art has failed to provide an adequate solution for treating any disease by decreasing levels/activity of an AMP/AMP-like molecule.
There is thus a widely recognized need for, and it would be highly advantageous to have, a method which is devoid of the above limitation for treating diseases associated with inflammation, dysregulated cell proliferation/differentiation, . 5 angiogenesis metastasis, and/or epithelial wounds. _ SUMMARY OF THE INVENTION
According to one aspect of the present invention there is provided a method of treating a disease in a subject in need thereof, the method comprising providing to the 10 subject a therapeutically effective amount of a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the subj ect in need thereof.
According to further features in preferred embodiments of the invention described below, administering the compound to the subject is effected by exposing a location of the subject to a carrier which includes the compound at a concentration selected from a range of about 50 nanograms per milliliter to about 1 milligram per milliliter.
According to still further features in the described preferred embodiments, administering the compound to the subject is effected by administering to the subject a plurality of doses of the compound selected from a range of 2 doses to 30 doses, wherein each inter dose interval of the plurality of doses is selected from a range of about 2.4 hours to about 30 days.
According to still further features in the described preferred embodiments, administering the compound to the subject is effected via a route selected from the group consisting of the topical, intranasal, transdermal, intradermal, oral, buccal, parenteral, rectal and inhalation route.
According to still further features in the described preferred embodiments, the disease is associated with a biological process in a cell and/or tissue, wherein the biological process is selected from the group consisting of growth, differentiation, i 30 inflammation, metastasis and angiogenesis.
According to still further features in the described preferred embodiments, the subject 1s human.
According to another aspect of the present invention there is provided an article of manufacture comprising packaging material and a pharmaceutical composition, the article of manufacture being identified for treatment of a disease ] being associated with a biological process in a cell and/or tissue, the biological process being selected from the group consisting of growth, differentiation, inflammation, metastasis and angiogenesis; the pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule.
According to further features in preferred embodiments of the invention described below, the pharmaceutically acceptable carrier is selected so as to enable administration of the pharmaceutical composition via a route selected from the group consisting of the topical, intranasal, transdermal, intradermal, oral, buccal, parenteral, rectal and inhalation route.
According to still further features in the described preferred embodiments, the pharmaceutical composition is formulated as a solution, suspension, emulsion or gel.
According to still further features in the described preferred embodiments, the pharmaceutical composition is composed so as to enable exposure of a cell and/or tissue of a subject having the disease to the compound at a concentration selected from a range of about 50 nanograms per milliliter to about 1 milligram per milliliter.
According to still further features in the described preferred embodiments, the pharmaceutical composition is further identified for administration to a subject of a plurality of doses of the pharmaceutical composition selected from a range of 2 doses to 30 doses, wherein each inter dose interval of the plurality of doses is selected from a range of about 2.4 hours to about 30 days
According to still further features in the described preferred embodiments, the cell and/or tissue is selected from the group consisting of an epithelial cell and/or tissue, a skin cell and/or tissue, a keratinocytic cell and/or tissue, a gastrointestinal cell } and/or tissue and an endothelial cell and/or tissue.
According to still further features in the described preferred embodiments, the : 30 disease is selected from the group consisting of a tumor, an autoimmune disease, an epithelial disease, a skin disease, a gastrointestinal disease, an endothelial disease and a human disease.
According to still further features in the described preferred embodiments, the disease is selected from the group consisting of an epithelial tumor, an epithelial wound, a skin tumor, a skin wound, a gastrointestinal tumor, a gastrointestinal wound, an endothelial tumor, a solid tumor, a metastatic tumor, a skin autoimmune disease, and a malignant tumor.
According to still further features in the described preferred embodiments, the disease is psoriasis or skin carcinoma.
According to yet another aspect of the present invention there is provided a method of regulating a biological process in a cell and/or tissue, the method comprising exposing the cell and/or tissue to a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby regulating the biological process in the cell and/or tissue.
According to further features in preferred embodiments of the invention described below, exposing the cell and/or tissue to the compound is effected by providing the compound to a subject.
According to still further features in the described preferred embodiments, the providing to the subject the compound is effected by administering the compound to the subject and/or by expressing the compound in the subject.
According to still further features in the described preferred embodiments, the : exposing the cell and/or tissue to the compound is effected by exposing the cell and/or tissue to the compound at a concentration selected from a range of about 50 nanograms per milliliter to about one milligram per milliliter.
According to still further features in the described preferred embodiments, the cell and/or tissue is malignant and/or keratinocytic, wherein the exposing the cell and/or tissue to the compound is effected by exposing the cell and/or tissue to the compound at a concentration selected from a range of about 0.4 microgram per milliliter to about 200 micrograms per milliliter, and the AMP and/or AMP-like molecule is a cathelicidin.
According to still further features in the described preferred embodiments, the cell and/or tissue is malignant and/or keratinocytic, wherein the exposing the cell : 30 and/or tissue to the compound is effected by exposing the cell and/or tissue to the compound at a concentration selected from a range of about 0.1 microgram per milliliter to about 50 micrograms per milliliter, and the AMP and/or AMP-like molecule is a defensin.
According to still further features in the described preferred embodiments, the cell and/or tissue is a gastrointestinal and/or epithelial cell and/or tissue, wherein the ] exposing the cell and/or tissue to the compound is effected by exposing the cell and/or tissue to the compound at a concentration selected from a range of about 50 : 5 nanograms per milliliter to about 10 micrograms per milliliter, and the AMP and/or
AMP-like molecule is a defensin.
According to still further features in the described preferred embodiments, the cell and/or tissue is an endothelial cell and/or tissue, wherein the exposing the cell and/or tissue to the compound is effected by exposing the cell and/or tissue to the compound at a concentration selected from a range of about 50 nanograms per milliliter to about 10 micrograms per milliliter, and the AMP and/or AMP-like molecule is a defensin.
According to still another aspect of the present invention there is provided a method of identifying a compound being capable of regulating a biological process in a cell and/or tissue, the method comprising: (a) exposing the cell and/or tissue to a test compound which is: (i) capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule, and/or (ii) the AMP and/or
AMP-like molecule; and (b) evaluating a capacity of the test compound to regulate the biological process in the cell and/or tissue, thereby identifying the compound being capable of regulating the biological process in the cell and/or tissue.
According to still further features in the described preferred embodiments, the cell and/or tissue is a cultured cell and/or tissue.
According to still further features in the described preferred embodiments, the cell and/or tissue is derived from a human.
According to still further features in the described preferred embodiments, the exposing the cell and/or tissue to the test compound is effected by providing the test compound to a subject.
According to still further features in the described preferred embodiments, the exposing the cell and/or tissue to the test compound is effected by exposing the cell . 30 and/or tissue to a cell which produces the test compound.
According to still further features in the described preferred embodiments, the cell which produces the test compound is a B-cell hybridoma.
According to still further features in the described preferred embodiments, the providing the test compound to the subject is effected by administering the test compound to the subject and/or by expressing the test compound in the subject.
According to still further features in the described preferred embodiments, administering the test compound to the subject is effected via a route selected from : 5s the group consisting of the topical, intranasal, transdermal, intradermal, oral, buccal, parenteral, rectal and inhalation route.
According to still further features in the described preferred embodiments, the test compound is selected from the group consisting of: (a) a molecule capable of binding the AMP and/or AMP-like molecule; (b) an enzyme capable of cleaving the
AMP and/or AMP-like molecule; (c) an siRNA molecule capable of inducing degradation of an mRNA encoding the AMP and/or AMP-like molecule; (d) a
DNAzyme capable of cleaving an mRNA or DNA encoding the AMP and/or AMP- like molecule; (€) an antisense polynucleotide capable of hybridizing with an mRNA encoding the AMP and/or AMP-like molecule; (f) a ribozyme capable of cleaving an mRNA encoding the AMP and/or AMP-like molecule; (g) a non-functional analogue of at least a functional portion of the AMP and/or AMP-like molecule; (h) a molecule capable of inhibiting activation or ligand binding of the AMP and/or AMP-like molecule; and (i) a triplex-forming oligonucleotide capable of hybridizing with a
DNA encoding the AMP and/or AMP-like molecule.
According to still further features in the described preferred embodiments, the molecule capable of binding the AMP and/or AMP-like molecule is an antibody or an antibody fragment.
According to still further features in the described preferred embodiments, the antibody fragment is selected from the group consisting of a single-chain Fv, an Fab, an Fab', and an F(ab')2.
According to still further features in the described preferred embodiments, the
AMP and/or AMP-like molecule is selected from the group consisting of a defensin, a cathelicidin, a cationic peptide, a hydrophobic peptide, a human AMP and a human
AMP-like molecule.
According to still further features in the described preferred embodiments, the
AMP and/or AMP-like molecule is a beta-defensin.
According to still further features in the described preferred embodiments, the
AMP and/or AMP-like molecule is selected from the group consisting of beta-
defensin-1, beta-defensin-2 and LL-37.
According to still further features in the described preferred embodiments, the } cell and/or tissue is selected from the group consisting of an epithelial cell and/or tissue, a skin cell and/or tissue, a keratinocytic cell and/or tissue, a gastrointestinal cell : 5 and/or tissue and an endothelial cell and/or tissue.
According to still further features in the described preferred embodiments, the biological process is selected from the group consisting of growth, differentiation, inflammation, and angiogenesis.
According to a further aspect of the present invention there is provided a method of treating a disease in a subject in need thereof, the method comprising providing to the subject a therapeutically effective amount of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the subject in need thereof.
According to further features in preferred embodiments of the invention described below, administering the AMP and/or AMP-like molecule to the subject is effected by exposing a location of the subject to a carrier which includes the AMP and/or AMP-like molecule at a concentration selected from a range of about 2 nanograms per milliliter to about 10 micrograms per milliliter.
According to still further features in the described preferred embodiments, administering the AMP and/or AMP-like molecule to the subject is effected via a route selected from the group consisting of the topical, intranasal, transdermal, intradermal, oral, buccal, parenteral, rectal and inhalation route.
According to still further features in the described preferred embodiments, the subject is human.
According to yet a further aspect of the present invention there is provided an article of manufacture comprising packaging material and a pharmaceutical composition, the article of manufacture being identified for treatment of a disease being associated with a biological process in a cell and/or tissue, the biological process being selected from the group consisting of growth, differentiation, : 30 inflammation and angiogenesis; the pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, an antimicrobial peptide (AMP) and/or AMP-like molecule.
According to further features in preferred embodiments of the invention described below, the pharmaceutically acceptable carrier is selected so as to enable administration of the pharmaceutical composition via a route selected from the group } consisting of the topical, intranasal, transdermal, intradermal, oral, buccal, parenteral, rectal and inhalation route. : 5 According to still further features in the described preferred embodiments, the pharmaceutical composition is formulated as a solution, suspension, emulsion or gel.
According to still further features in the described preferred embodiments, the pharmaceutical composition is composed so as to enable exposure of a cell and/or tissue of a subject having the disease to the compound at a concentration selected from a range of about 2 nanograms per milliliter to about 10 micrograms per milliliter.
According to still further features in the described preferred embodiments, the disease is selected from the group consisting of a tumor, an epithelial disease, a skin disease, a gastrointestinal disease and an endothelial disease.
According to still further features in the described preferred embodiments, the disease is selected from the group consisting of an epithelial tumor, an epithelial wound, a skin tumor, a skin wound, a gastrointestinal tumor, a gastrointestinal wound and a malignant tumor.
According to still a further aspect of the present invention there is provided a method of regulating a biological process in a cell and/or tissue, the method comprising exposing the cell and/or tissue to an antimicrobial peptide (AMP) and/or
AMP-like molecule, thereby regulating the biological process in the cell and/or tissue.
According to further features in preferred embodiments of the invention described below, exposing the cell and/or tissue to the AMP and/or AMP-like molecule is effected by providing the AMP and/or AMP-like molecule to a subject.
According to still further features in the described preferred embodiments, the providing to the subject the AMP and/or AMP-like molecule is effected by administering the AMP and/or AMP-like molecule to the subject and/or by expressing the AMP and/or AMP-like molecule in the subject.
According to still further features in the described preferred embodiments, the : 30 exposing the cell and/or tissue to the AMP and/or AMP-like molecule is effected by exposing the cell and/or tissue to the AMP and/or AMP-like molecule at a concentration selected from a range of about 2 nanograms per milliliter to about 10 micrograms per milliliter.
According to still further features in the described preferred embodiments, the
AMP and/or AMP-like molecule is selected from the group consisting of a defensin, a } cathelicidin, a cationic peptide, a hydrophobic peptide, a human AMP and a human
AMP-like molecule.
According to still further features in the described preferred embodiments, the
AMP and/or AMP-like molecule is a beta-defensin.
According to still further features in the described preferred embodiments, the
AMP and/or AMP-like molecule is selected from the group consisting of beta- defensin-1, beta-defensin-2 and LL-37.
According to still further features in the described preferred embodiments, the cell and/or tissue is selected from the group consisting of an epithelial cell and/or tissue, a skin cell and/or tissue, a keratinocytic cell and/or tissue and a tumor cell and/or tissue.
According to still further features in the described preferred embodiments, the biological process is selected from the group consisting of growth, differentiation, inflammation and angiogenesis.
According to still further features in the described preferred embodiments, the cell and/or tissue is malignant, wherein the exposing the cell and/or tissue to the AMP and/or AMP-like molecule is effected by exposing the cell and/or tissue to the AMP and/or AMP-like molecule at a concentration selected from a range of about 0.1 microgram per milliliter to about 10 micrograms per milliliter, and the AMP and/or
AMP-like molecule is a defensin.
According to still further features in the described preferred embodiments, the cell and/or tissue is a keratinocytic cell and/or tissue, wherein the exposing the cell 2s and/or tissue to the AMP and/or AMP-like molecule is effected by exposing the cell and/or tissue to the AMP and/or AMP-like molecule at a concentration selected from a range of about 2 nanograms per milliliter to about 10 micrograms per milliliter, and the AMP and/or antimicrobial peptide-like molecule is a defensin.
According to still further features in the described preferred embodiments, the : 30 cell and/or tissue is derived from a human.
The present invention successfully addresses the shortcomings of the presently known configurations by providing: (i) a method of treating a disease which is associated with a biological process in a cell/tissue such as growth, differentiation,
inflammation, metastasis and/or angiogenesis by using a compound which is capable of decreasing levels/activity of an AMP and/or an AMP-like molecule; and/or by using an AMP and/or an AMP-like molecule; (ii) an article of manufacture including such a compound and being labeled for treatment of such a disease; and (iii) a method ofidentifying such a compound.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting. :
The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
In the drawings: . FIG. 1 is a series of photomicrographs depicting stimulation of significant proliferation of malignant keratinocytes by the AMPs human beta-defensin-1 and : 30 human beta-defensin-2. Cultured human keratinocytes (HaCaT, clone 6, A-5, 1-5, 11-4 and RT-3) were plated in 24 well dishes at 50,000 cells per plate. After attachment, human beta-defensin-1 or human beta-defensin-2 at a final concentration of 1 microgram per ml was added to the culture medium, the cells were further incubated for 48 hours, and photographs of representative fields were taken (x20).
FIG. 2 is a histogram depicting significant inhibition of growth of malignant : human keratinocytes by 1.0 microgram/ml of anti-human beta-defensin-2 antibody.
Cultured immortalized, moderately malignant or highly malignant human keratinocytes (HaCaT, A-5, and RT-3, respectively) were plated, allowed to attach, incubated in the presence of anti-human beta-defensin-2 antibody at a concentration of 1.0 microgram/ml for 48 hours, and cell proliferation was estimated via [3(H)]- thymidine incorporation assay.
FIG. 3 is a histogram depicting concentration-dependent positive and negative regulation of growth by anti-LL-37 and anti-human beta-defensin-2 antibody in primary skin keratinocytes. Cultured keratinocytes were treated for 48 hours with antibody against LL-37 (blue bars) at concentrations of 4 (“1x”) or 20 (“5x”) micrograms/ml, or with anti-human beta-defensin-2 antibody (yellow bars) at concentrations of 1 (“1x”) or 5 (“5x”) micrograms/ml. Cell proliferation was estimated by measuring [3(H)]-thymidine incorporation and expressed as percent of control untreated cells. A representative experiment is shown. Each bar represents the mean + SE of triplicates.
FIGs. 4a-c are photomicrographs depicting correction of AMP-induced dysregulation of skin differentiation by anti-AMP (human beta-defensin-2) antibody in a three-dimensional organotypic in-vitro skin model. Figure 4a depicts results obtained with an untreated control, Figure 4b depicts results following treatment with human beta-defensin-2, and Figure 4c depicts results following treatment with anti- human beta-defensin-2 antibody. Twenty-four hours following seeding of the murine epidermal compartment with non-malignant HaCaT human keratinocytes, anti-human beta-defensin-2 antibody at a concentration of 1 microgram/ml, or human beta- defensin-2 at a concentration of 20 ng/ml was added to the growth medium, as indicated. An equal volume of 0.1 % BSA were added as control. The cocultures . were treated every 2-3 days and after 2 weeks were harvested, fixed in 4 % paraformaldehyde, paraffin-embedded and sectioned (6 microns). Sections were stained with hematoxylin and eosin (H&E) following standard procedures. Shown are bright field photomicrographs of representative fields recorded using an Olympus light microscope.
FIGs. 5a-d are photographs depicting efficient treatment of psoriatic skin lesions by anti-LL-37 antibody. Figures 5a and 5b depict an untreated control lesion, and an anti-LL-37 antibody-treated lesion prior to treatment on Day 0, respectively. i Figures Sc and 5d depict untreated control lesion, and anti-LL-37 antibody-treated lesion on Day 3. Note absence of flaking in the antibody treated lesions, indicating correction of skin cell/tissue proliferation/differentiation imbalance.
FIG. 6 is a histogram depicting significant concentration-dependent negative or positive regulation of gastrointestinal epithelial cell proliferation by antibody specific for human beta-defensin-2. Cultured Caco2 human gastrointestinal epithelial cells were treated for 48 hours with anti-human beta-defensin-2 antibody at 0.5 microgram/ml (blue/pale bars) or at 1.0 microgram/ml (red/dark bars). Cell proliferation was estimated by measuring [3(H)]-thymidine incorporation and is expressed as percent of control untreated cells. A representative experiment is shown.
Each bar represents the mean + SE of triplicates.
FIG. 7 is a histogram depicting significant inhibition of primary endothelial cell proliferation by anti-human beta-defensin-2 antibody. Bovine primary endothelial cells were treated for 48 hours with anti-human beta-defensin-2 antibody : at 0.5 microgram/ml (blue/pale bars) or at 1.0 microgram/ml (red/dark bars). Cell proliferation was estimated by measuring [3(H)]-thymidine incorporation and was expressed as percent of control untreated cells. A representative experiment is shown.
Each bar represents the mean + SE of triplicates.
The present invention is of methods of using compounds capable of decreasing activities/levels of antimicrobial peptides (AMP)/antimicrobial peptide-like molecules (AMLs) and/or of using AMPs/AMLs for regulating in cells/tissues biological processes such as growth, differentiation, growth/differentiation balance, inflammation, metastasis and angiogenesis; of methods of using such molecules for treating diseases associated with such biological processes and/or which are amenable to treatment via regulation of such biological processes; of articles of manufacture ‘ 30 which include such molecules and which are labeled as being for use in treating such diseases; and of methods of identifying such compounds capable of decreasing activities/levels of AMPs/AMLs and/or of identifying such AMPS/AMLs.
Specifically, the present invention can be used to optimally treat a vast range of diseases associated with such biological processes, including inflammatory diseases/diseases associated with cellular proliferation/differentiation imbalance such . as psoriasis, diseases associated with wounds, and tumors such as metastatic/malignant carcinomas. i
The principles and operation of the present invention may be better understood with reference to the drawings and accompanying descriptions.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, itis to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.
Diseases which are associated with inflammation, dysregulated cell/tissue proliferation/differentiation, dysregulated cell/tissue proliferation/differentiation balance, angiogenesis, and/or metastasis include a multitude of diseases which are of great medical and/or economic impact and for which no satisfactory treatment methods are available. While conceiving the present invention, the present inventors have hypothesized that AMPs/AMLs are involved in the pathogenesis of such diseases, and/or and hence that methods of decreasing activities/levels and/or administering such molecules could be used for treating such diseases.
The prior art approach relating to such methods involves computationally identifying a genetic sequence encoding a novel putative AMP-like molecule of unknown function, and of unknown relationship to a disease pathogenesis, and proposes a highly speculative and theoretical method for attempting to use or regulate 2s such a molecule for treating a disease (U.S. Pat. Application No. 20030044907).
The prior art approach, however, is critically flawed. Since no function is known for the putative AMP-like molecule with respect to the pathogenesis of any : disease, it cannot be reasonably be expected that regulating the levels of the putative
AMP-like molecule will have a therapeutic effect when administered to a subject having a disease. Hence, the prior art approach is restricted to a theoretical method of using or regulating such a putative AMP-like molecule to treat a disease. The prior art approach does not provide, nor does it find any in other prior art document, any experimental support for the disease treatment method which it proposes. As such the prior art approach does not teach treatment of a specific disease, such as an inflammatory disease or a tumor, nor does it provide the ordinarily skilled artisan with } any motivation to treat diseases using a method of the present invention.
Furthermore, the prior art approach has not proposed a method of using inhibitors of classical AMPs such as beta-defensin-2 or LL-37 for treatment any disease.
Another prior art approach proposes treating a disease by using an antisense polynucleotide complementary to such a genetic sequence, and administering such antisense polynucleotides according to theoretical regimens so as to treat a disease.
The prior art approaches, however, present critical disadvantages, including: (i) use of highly speculative assignment of the role of such putative AMP-like molecules in disease pathogenesis; (ii) requirement for use of unreliable antibody generation methods; (iii) use of theoretical administration regimens for putative therapeutic agents; and (iv) never having been attempted, and hence not having demonstrated any potential for therapeutic applications.
Thus, the prior art fails to provide a viable method which comprises regulating levels/activities of an AMP/AMP-like molecule for treating a disease.
While reducing the present invention to practice it was uncovered that anti-
AMP antibodies could be used to: significantly inhibit growth and loss of substrate attachment of cultured human malignant carcinoma cells; significantly inhibit/induce growth of cultured primary human keratinocytes; efficiently correct human epithelial celltissue proliferation/differentiation imbalance in a three-dimensional organotypic cultured skin model; efficiently treat psoriasis in a human subject; significantly inhibit/induce growth of cultured human gastrointestinal epithelial cells; and efficiently inhibit growth of human endothelial cells.
While reducing the present invention to practice, it was also uncovered that
AMPs could be used to significantly upregulate or downregulate growth of cultured human epithelial cells. x Hence, in sharp contrast to prior art techniques, the method according to the present invention enables use of compounds capable of decreasing levels/activity of AMPs/AMLs, and/or the use of AMPs/AMLs for regulating biological processes such as growth, differentiation, inflammation, metastasis and angiogenesis, and treatment of numerous diseases, such as those which are associated with inflammation, dysregulated cell proliferation/differentiation, angiogenesis, and/or metastasis,
including carcinomas such as malignant metastatic skin carcinomas, wound- associated diseases such as ulcerative diseases, and autoimmune diseases/diseases associated with dysregulated cellular proliferation/differentiation such as psoriasis.
Thus, the present invention provides a method of regulating a biological process in a cell and/or tissue. The method is effected by exposing the cell and/or tissue to: a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule (AML); to an AMP; and/or to an AML.
The method can be used to regulate in a cell/tissue a biological process such as growth, differentiation, inflammation, metastasis and/or angiogenesis. By virtue of enabling regulation of such a biological process in a cell/tissue, the method can be used for treating a disease which is associated with such a biological process, and can be used for identifying the regulator, as described in further detail hereinbelow.
Diseases associated with such biological processes include, for example, autoimmune diseases, diseases associated with dysregulated cell/tissue growth/proliferation balance, wound-associated diseases, and tumors.
As used herein, the term “regulator” refers to the compound which is capable of decreasing an activity and/or level of an AMP/AML, to an AMP, and/or to an AML which is used for practicing any aspect of the present invention.
As used herein, the phrases “the compound”, “compound of the present invention”, and “AMP/AML inhibitor” interchangeably refer to the compound which is capable of decreasing an activity/level of an AMP/AML.
Any of various types of AMP/AML inhibitors may be employed according to the teachings of the present invention for regulating the biological process, depending on the application and purpose.
As used herein, the term “AMP” includes any defensin, cathelicidin, and/or thrombocidin, or variant thereof, including any naturally occurring variant of such a molecule, such as a natural mutant/polymorphic variant/allele of such a molecule, or any synthetic variant of such a molecule.
As used herein, the term “AML” includes any molecule having a biological activity which is substantially similar to that of a defensin, cathelicidin, and/or thrombocidin, includes any molecule which substantially promotes the biological activity of a defensin, cathelicidin, and/or thrombocidin, includes any molecule which is substantially structurally homologous to a defensin, cathelicidin and/or thrombocidin. i The method may be effected using a single regulator of the present invention, or using any combination of multiple regulators of the present invention. }
The AMP/AML inhibitor may be: a molecule capable of binding the
AMP/AML; an enzyme capable of cleaving the AMP/AML; an siRNA molecule capable of inducing degradation of an mRNA encoding the AMP/AML; a DNAzyme capable of cleaving an mRNA or DNA encoding the AMP/AML; an antisense polynucleotide capable of hybridizing with an mRNA encoding the AMP/AML; a ribozyme capable of cleaving an mRNA encoding the AMP/AML; a non-functional analogue of at least a functional portion of the AMP/AML; a molecule capable of inhibiting activation or ligand binding of the AMP/AML; and a triplex-forming oligonucleotide capable of hybridizing with a DNA encoding the AMP/AML.
Ample guidance for obtaining and utilizing such AMP/AML inhibitors is provided hereinbelow and in the literature of the art (for example, refer to U.S. Patent
Application No. 20030044907 which is incorporated herein by reference).
The AMP/AML inhibitor may be any small molecule, AMP/AML dominant negative, or polypeptide that competes with the AMPs for cognate cell receptors without inducing disease. For example, the AMP/AML inhibitor may be a topological analogue of an AMP/AML that has been engineered to remain anti microbial yet lose its chemoattracting ability. Engineering of disulfide bridges to dissect antimicrobial and chemotactic activities of AMPs/AMLs such as human beta- defensin-3 can be performed as previously described (Wu Z. et al., 2003. Proc. Natl.
Acad. Sci. U. S. A. 100:8880-5).
The AMP/AML inhibitor may be a synthetic antibody mimic in which multiple peptide loops are attached to a molecular scaffold (described in U.S. Patent
No. 5,770,380). } Such an AMP/AML mimic can be obtained, for example, by molecule imprinting. This technique may be performed by preparing a polymer by cross- : 30 linking a monomer around a "template molecule” (the AMP/AML). This template molecule is removed after the polymerization of the monomer and its size, shape and chemical functions are recorded in the polymer. The sites of the removed template molecule are named "imprint sites". These sites allow the recognition of the template molecule or close structural molecules. Molecularly imprinted polymers can serve as artificial binding mimics as do natural antibodies. : The molecule capable of inhibiting activation or ligand binding of the
AMP/AML may advantageously inhibit binding of a receptor expressed on cell, such : 5s as a leukocyte, which binds the AMP/AML to inhibit a biological process mediated by binding of the AMP/AML to the receptor. Examples of such AMPs/AMLs and cognate receptors thereof are shown in Table 1.
Table 1. AMPs/AMLs and cognate cell receptors, and diseases associated with interaction therebetween
AMPIAML __[Recepior__[Receplorexpressing cel
Psoriasis, rheumatoid arthritis .- (RA), atopic dermatitis, contact
Monocyte, dendritic cell, T dermatitis, chronic hepatitis, cell, neutrophils, inflammatory bowel disease
LL-37 EGFR, FPR11 eosinophils, leukocytes,
I f (IBD), allergy, B cell epithelial cell, endothelial : . malignancies, hepatocellular cells : - carcimoma, pancreatic adenocarcinoma and others beta-defensin-2 |Toll I-like receptor- 4 [Dendritic cells 1 betadefensin2 [Tolle receptor? |__
Psoriasis, RA, atopic dermatitis, contact dermatitis, chronic beta defensin-1 |CC-chemokine Hematopoietic cells, hepatitis, IBD, allergy, B cell beta defensin-2 {receptor-6 (CCR6) |dendritic cells, malignancies, hepatocellular carcinoma, pancreatic . adenocarcinoma and more
Gfmms | |oiesialmucon [Cohwsdiewe
L1 and calcitonin ._ [receptor-like receptor . cn 1 IBD, allergy, hepatocellular adrenomedullin (CRLR) gastric epithelial cells carcinoma, and more
Further examples of receptors of AMPs/AMLs such as chemokines, the cells in which such receptors are expressed, and the diseases in which the interaction between such AMPs/AMLs and such receptors are involved are provided in
D’Ambrosio et al., 2003. J. Immunol. Methods 273 3 — 13.
The activity of LL-37 (Weiner, DJ. et al., 2003. Am.J.Respir.Cell Mol.Biol. 28:738-745), defensin-3, lactoferrin and IL-8 (Perks, B. et al., 2000. Am.J.Respir.Crit
Care Med. 162:1767-1772) is inhibited by F-actin, therefore the AMP/AML inhibitor may be F-actin. F-actin forms bundles in the presence of the polycationic interleukin
IL-8, therefore F-actin is an inhibitor of downstream elements of the ligand-receptor connectivity of both LL-37 and interleukin IL-8. LL-37 and defensin-3 are inhibited by gelsolin, therefore the AMP/AML inhibitor may be gelsolin. Serpins and their : analogs or fragments are inactivators of AMP by formation of complexes with AMP (Panyutich, AV. et al., 1995. Am.J.Respir.Cell Mol.Biol. | 12:351-357; alpha-1 antichymotrypsin, the antimicrobial proteins alpha PI, SLPI and elafin are serpins that form complexes with other AMPs) thereby reducing specific types of inflammation (Hiemstra, PS, 2002. Biochem.Soc.Trans. 30:116-120), therefore the AMP/AML inhibitor may be serpins and their analogs or fragments. The AMP/AML inhibitor may be SIC, a secreted protein of streptococcus pyogenes that inactivates antibacterial peptides.
Preferably, the molecule capable of binding the AMP/AML is an antibody or an antibody fragment.
Alternately, the molecule capable of binding the AMP/AML may be any of various type of molecule, including non-immunoglobulin peptides and polypeptides,
Preferably, the antibody fragment is selected from the group consisting of a single-chain Fv, an Fab, an Fab', and an F(ab')2.
As used herein, the term “antibody” refers to a substantially intact antibody molecule.
As used herein, the phrase “antibody fragment” refers to a functional fragment of an antibody that is capable of binding to an AMP/AML.
Suitable antibody fragments for practicing the present invention include a complementarity-determining region (CDR) of an immunoglobulin light chain (referred to herein as “light chain”), a CDR of an immunoglobulin heavy chain (referred to herein as “heavy chain”), a variable region of a light chain, a variable region of a heavy chain, a light chain, a heavy chain, an Fd fragment, and antibody fragments comprising essentiglly whole variable regions of both light and heavy chains such as an Fv, a single chain Fv, an Fab, an Fab’, and an F(ab’),. . Functional antibody fragments comprising whole or essentially whole variable regions of both light and heavy chains are defined as follows: : 30 (i) Fv, defined as a genetically engineered fragment consisting of the variable region of the light chain and the variable region of the heavy chain expressed as two chains; (ii) single chain Fv (“scFv”), a genetically engineered single chain molecule including the variable region of the light chain and the variable region of the heavy chain, linked by a suitable polypeptide linker. ] (iii) Fab, a fragment of an antibody molecule containing a monovalent antigen- binding portion of an antibody molecule which can be obtained by treating whole - 5 antibody with the enzyme papain to yield the intact light chain and the Fd fragment of the heavy chain which consists of the variable and Cyl domains thereof; (iv) Fab’, a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme pepsin, followed by reduction (two Fab’ fragments are obtained per antibody molecule); and (v) F(ab’),, a fragment of an antibody molecule containing a monovalent antigen-binding portion of an antibody molecule which can be obtained by treating whole antibody with the enzyme pepsin (i.e., a dimer of Fab’ fragments held together by two disulfide bonds).
Methods of generating antibodies (i.e., monoclonal and polyclonal) are well known in the art. Antibodies may be generated via any one of several methods known in the art, which methods can employ induction of in-vivo production of antibody molecules, screening of immunoglobulin libraries (Orlandi D.R. et al, 1989. Proc.
Natl. Acad. Sci. U. S. A. 86:3833-3837; Winter G. et al., 1991. Nature 349:293-299) or generation of monoclonal antibody molecules by continuous cell lines in culture.
These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the Epstein-Barr virus (EBV)-hybridoma technique (Kohler
G. et al., 1975. Nature 256:495-497; Kozbor D. et al., 1985. J. Immunol. Methods 81:31-42; Cote RJ. et al., 1983. Proc. Natl. Acad. Sci. U. S. A. 80:2026-2030; Cole
SP. et al.,, 1984. Mol. Cell. Biol. 62:109-120).
In cases where target antigens are too small to elicit an adequate immunogenic response when generating antibodies in-vivo, such antigens (haptens) can be coupled to antigenically neutral carriers such as keyhole limpet hemocyanin (KLH) or serum albumin [e.g., bovine serum albumin (BSA)] carriers (see, for example, US. Pat. Nos. . 30 5,189,178 and 5,239,078]. Coupling a hapten to a carrier can be effected using methods well known in the art. For example, direct coupling to amino groups can be effected and optionally followed by reduction of the imino linkage formed.
Alternatively, the carrier can be coupled using condensing agents such as dicyclohexyl carbodiimide or other carbodiimide dehydrating agents. Linker compounds can also be used to effect the coupling; both homobifunctional and heterobifunctional linkers are available from Pierce Chemical Company, Rockford,
Ill. The resulting immunogenic complex can then be injected into suitable : 5 mammalian subjects such as mice, rabbits, and the like. Suitable protocols involve repeated injection of the immunogen in the presence of adjuvants according to a schedule which boosts production of antibodies in the serum. The titers of the immune serum can readily be measured using immunoassay procedures which are well known in the art.
The antisera obtained can be used directly or monoclonal antibodies may be obtained as described hereinabove.
Antibody fragments can be obtained using methods well known in the art. [(see, for example, Harlow and Lane, “Antibodies: A Laboratory Manual”, Cold
Spring Harbor Laboratory, New York, (1988)]. For example, antibody fragments according to the present invention can be prepared by proteolytic hydrolysis of the antibody or by expression in E. coli or mammalian cells (e.g., Chinese hamster ovary cell culture or other protein expression systems) of DNA encoding the fragment.
Alternatively, antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. As described hereinabove, an (Fab), antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages to produce 3.5S Fab’ monovalent fragments.
Alternatively, enzymatic cleavage using pepsin produces two monovalent Fab’ fragments and an Fc fragment directly. Ample guidance for practicing such methods is provided in the literature of the art (for example, refer to: Goldenberg, U.S. Pat.
Nos. 4,036,945 and 4,331,647; Porter, RR., 1959. Biochem. J. 73:119-126). Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other : 30 enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.
As described hereinabove, an Fv is composed of paired heavy chain variable and light chain variable domains. This association may be noncovalent (see, for example, Inbar et al., 1972. Proc. Natl. Acad. Sci. USA. 69:2659-62). Alternatively, as described hereinabove the variable domains can be linked to generate a single chain
Fv by an intermolecular disulfide bond, or alternately, such chains may be cross- linked by chemicals such as glutaraldehyde. : 5 Preferably, the Fv is a single chain Fv.
Single chain Fv’s are prepared by constructing a structural gene comprising - ee
DNA sequences encoding the heavy chain variable and light chain variable domains connected by an oligonucleotide encoding a peptide linker. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as E. coli. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two variable domains. Ample guidance for producing single chain Fv’s is provided in the literature of the art (for example, refer to: Whitlow and Filpula, 1991. Methods 2:97-105; Bird et al., 1988. Science 242:423- 426; Pack et al., 1993. Bio/Technology 11:1271-77; and Ladner et al., U.S. Pat. No. 4,946,778).
Isolated complementarity determining region peptides can be obtained by constructing genes encoding the complementarity determining region of an antibody of interest. Such genes may be prepared, for example, by RT-PCR of mRNA of an antibody-producing cell. Ample guidance for practicing such methods is provided in the literature of the art (for example, refer to Larrick and Fry, 1991. Methods 2:106- 10).
It will be appreciated that for human therapy or diagnostics, humanized antibodies are preferably used. Humanized forms of non human (e.g, murine) antibodies are genetically engineered chimeric antibodies or antibody fragments having—preferably minimal-portions derived from non human antibodies. Humanized antibodies include antibodies in which complementary determining regions of a human antibody (recipient antibody) are replaced by residues from a complementarity } determining region of a non human species (donor antibody) such as mouse, rat or rabbit having the desired functionality. In some instances, Fv framework residues of : 30 the human antibody are replaced by corresponding non human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported complementarity determining region or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the complementarity determining regions correspond to those of a non human antibody . and all, or substantially all, of the framework regions correspond to those of a relevant human consensus sequence. Humanized antibodies optimally also include at least a portion of an antibody constant region, such as an Fc region, typically derived from a human antibody (see, for example, Jones et al, 1986. Nature 321 :522-525;
Riechmann et al., 1988. Nature 332:323-329; and Presta, 1992. Curr. Op. Struct. Biol. 2:593-596).
Methods for humanizing non human antibodies are well known in the art.
Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non human. These non human amino acid residues are often referred to as imported residues which are typically taken from an imported variable domain. Humanization can be essentially performed as described (see, for example: ~ Jones et al., 1986. Nature 321:522-525; Riechmann et al., 1988. Nature 332:323-327;
Verhoeyen et al., 1988. Science 239:1534-1536; U.S. Pat. No. 4,816,567) by substituting human complementarity determining regions with corresponding rodent complementarity determining regions. Accordingly, such humanized antibodies are chimeric antibodies, wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non human species. In practice, humanized antibodies may be typically human antibodies in which some complementarity determining region residues and possibly some framework residues are substituted by residues from analogous sites in rodent antibodies.
Human antibodies can also be produced using various techniques known in the art, including phage display libraries (see, for example, Hoogenboom and Winter, 1991. J. Mol. Biol. 227:381; Marks et al., 1991. J. Mol. Biol. 222:581; Cole et al,, “Monoclonal Antibodies and Cancer Therapy”, Alan R. Liss, pp. 77 (1985); Boerner et al., 1991. J. Immunol. 147:86-95). Humanized antibodies can also be made by i introducing sequences encoding human immunoglobulin loci into transgenic animals, e.g., into mice in which the endogenous immunoglobulin genes have been partially or : 30 completely inactivated. Upon antigenic challenge, human antibody production is observed in such animals which closely resembles that seen in humans in all respects, including gene rearrangement, chain assembly, and antibody repertoire. Ample guidance for practicing such an approach is provided in the literature of the art (for example, refer to: U.S. Pat. Nos. 5,545,807, 5,545,806, 5,569,825, 5,625,126, 5,633,425, and 5,661,016; Marks et al., 1992. Bio/Technology 10:779-783; Lonberg . et al., 1994. Nature 368:856-859; Morrison, 1994. Nature 368:812-13; Fishwild et al., 1996. Nature Biotechnology 14:845-51; Neuberger, 1996. Nature Biotechnology 5s 14:826; Lonberg and Huszar, 1995. Intern. Rev. Immunol. 13:65-93; Kellermann, SA. et al., 2002. Curr. Op. Biotechnol. 13:593-597).
Once antibodies are obtained, they may be tested for activity, for example via
ELISA.
Suitable antibodies may in many cases be purchased ready for use from commercial suppliers, such as Pharmingen, Dako, Becton-Dickinson, Sigma-Aldrich, and the like. Algae can be used to industrially mass-produce antibodies (Proc Natl
Acad Sci US A. 2003, 100:438-42).
As described hereinabove, the AMP/AML inhibitor may be a small interfering
RNA (siRNA) molecule. RNA interference is a two step process. the first step, which is termed as the initiation step, input dsRNA is digested into 21-23 nucleotide (nt) small interfering RNAs (siRNA), probably by the action of Dicer, a member of the RNase III family of dsRNA-specific ribonucleases, which processes (cleaves) dsRNA (introduced directly or via a transgene or a virus) in an ATP-dependent manner. Successive cleavage events degrade the RNA to 19-21 bp duplexes (siRNA), each with 2-nucleotide 3’ overhangs [Hutvagner and Zamore Curr. Opin. Genetics and Development 12:225-232 (2002); and Bernstein Nature 409:363-366 (2001)].
In the effector step, the siRNA duplexes bind to a nuclease complex to from the RNA-induced silencing complex (RISC). An ATP-dependent unwinding of the siRNA duplex is required for activation of the RISC. The active RISC then targets the homologous transcript by base pairing interactions and cleaves the mRNA into 12 nucleotide fragments from the 3’ terminus of the siRNA [Hutvagner and Zamore
Curr. Opin. Genetics and Development 12:225-232 (2002); Hammond et al. (2001) i Nat. Rev. Gen. 2:110-119 (2001); and Sharp Genes. Dev. 15:485-90 (2001)].
Although the mechanism of cleavage is still to be elucidated, research indicates that : 30 each RISC contains a single siRNA and an RNase [Hutvagner and Zamore Curr.
Opin. Genetics and Development 12:225-232 (2002)].
Because of the remarkable potency of RNAI, an amplification step within the
RNAi pathway has been suggested. Amplification could occur by copying of the input dsRNAs which would generate more siRNAs, or by replication of the siRNAs formed. Alternatively or additionally, amplification could be effected by multiple turnover events of the RISC [Hammond et al. Nat. Rev. Gen. 2:110-119 (2001), Sharp
Genes. Dev. 15:485-90 (2001); Hutvagner and Zamore Curr. Opin. Genetics and : 5 Development 12:225-232 (2002)]. For more information on RNA1 see the following reviews Tuschl ChemBiochem. 2:239-245 (2001); Cullen Nat. Immunol. 3:597-599 (2002); and Brant] Biochem. Biophys. Act. 1575:15-25 (2002).
Synthesis of RNAi molecules suitable for use with the present invention can be effected as follows. First, the AMP/AML mRNA sequence is scanned downstream of the AUG start codon for AA dinucleotide sequences. Occurrence of each AA and the 3’ adjacent 19 nucleotides is recorded as potential siRNA target sites. Preferably, siRNA target sites are selected from the open reading frame, as untranslated regions (UTRs) are richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNA endonuclease complex [Tuschl ChemBiochem. 2:239-245]. It will be appreciated though, that siRNAs directed at untranslated regions may also be effective, as demonstrated for GAPDH wherein siRNA directed at the 5° UTR mediated about 90 % decrease in cellular GAPDH mRNA and completely abolished protein level (www.ambion.com/techlib/tn/91/912 html).
As used herein the term “about” refers to plus or minus 10 %.
Second, potential target sites are compared to an appropriate genomic database (e.g., human, mouse, rat etc.) using any sequence alignment software, such as the
BLAST software available from the NCBI server (www.ncbi.nlm.nih.gov/BLASTY).
Putative target sites which exhibit significant homology to other coding sequences are filtered out.
Qualifying target sequences are selected as template for siRNA synthesis.
Preferred sequences are those including low G/C content as these have proven to be . more effective in mediating gene silencing as compared to those with G/C content higher than 55 %. Several target sites are preferably selected along the length of the : 30 target gene for evaluation. For better evaluation of the selected siRNAs, a negative control is preferably used in conjunction. Negative control siRNA preferably include the same nucleotide composition as the siRNAs but lack significant homology to the genome. Thus, a scrambled nucleotide sequence of the siRNA is preferably used,
provided it does not display any significant homology to any other gene.
As described hereinabove, the AMP/AML inhibitor may be a DNAzyme . molecule capable of specifically cleaving an mRNA transcript or DNA sequence of the AMP/AML. DNAzymes are single-stranded polynucleotides which are capable of cleaving both single and double stranded target sequences (Breaker, R.R. and Joyce,
G. Chemistry and Biology 1995;2:655; Santoro, S.W. & Joyce, G.F. Proc. Natl, Acad.
Sci. USA 1997;943:4262). A general model (the "10-23" model) for the DNAzyme has been proposed. "10-23” DNAzymes have a catalytic domain of 15 deoxyribonucleotides, flanked by two substrate-recognition domains of seven to nine deoxyribonucleotides each. This type of DNAzyme can effectively cleave its substrate RNA at purine:pyrimidine junctions (Santoro, S.W. & Joyce, G.F. Proc.
Natl, Acad. Sci. USA 199; for rev of DNAzymes see Khachigian, LM [Curr Opin Mol
Ther 4:119-21 (2002)].
Examples of construction and amplification of synthetic, engineered
DNAzymes recognizing single and double-stranded target cleavage sites have been disclosed in U.S. Pat. No. 6,326,174 to Joyce et al.
As described hereinabove, the AMP/AML inhibitor may be an antisense polynucleotide capable of specifically hybridizing with an mRNA transcript encoding the AMP/AML.
Design of antisense molecules which can be used to efficiently decrease levels/activity of an AMP/AML must be effected while considering two aspects important to the antisense approach. The first aspect is delivery of the oligonucleotide into the cytoplasm of the appropriate cells, while the second aspect is design of an oligonucleotide which specifically binds the designated mRNA within cells in a way which inhibits translation thereof.
The prior art teaches of a number of delivery strategies which can be used to efficiently deliver oligonucleotides into a wide variety of cell types [see, for example, i Luft J Mol Med 76: 75-6 (1998); Kronenwett et al. Blood 91: 852-62 (1998); Rajur et ' al. Bioconjug Chem 8: 935-40 (1997); Lavigne et al. Biochem Biophys Res Commun : 30 237: 566-71 (1997) and Aoki et al. (1997) Biochem Biophys Res Commun 231: 540-5 (1997).
In addition, algorithms for identifying those sequences with the highest predicted binding affinity for their target mRNA based on a thermodynamic cycle that accounts for the energetics of structural alterations in both the target mRNA and the oligonucleotide are also available [see, for example, Walton et al. Biotechnol Bioeng : 65: 1-9 (1999)].
Such algorithms have been successfully used to implement an antisense 5s approach in cells. For example, the algorithm developed by Walton et al. enabled scientists to successfully design antisense oligonucleotides for rabbit beta-globin (RBG) and mouse tumor necrosis factor-alpha (TNF alpha) transcripts. The same research group has more recently reported that the antisense activity of rationally selected oligonucleotides against three model target mRNAs (human lactate dehydrogenase A and B and rat gp130) in cell culture as evaluated by a kinetic PCR technique proved effective in almost all cases, including tests against three different targets in two cell types with phosphodiester and phosphorothioate oligonucleotide chemistries.
In addition, several approaches for designing and predicting efficiency of specific oligonucleotides using an in vitro system were also published (Matveeva et al., Nature Biotechnology 16: 1374 - 1375 (1998)].
Several clinical trials have demonstrated safety, feasibility and activity of antisense oligonucleotides. For example, antisense oligonucleotides suitable for the treatment of cancer have been successfully used [Holmund et al., Curr Opin Mol Ther 1:372-85 (1999)], while treatment of hematological malignancies via antisense oligonucleotides targeting c-myb gene, p53 and Bcl-2 had entered clinical trials and had been shown to be tolerated by patients [Gerwitz Curr Opin Mol Ther 1:297-306 (1999)].
More recently, antisense-mediated suppression of human heparanase gene expression has been reported to inhibit pleural dissemination of human cancer cells in a mouse model [Uno et al., Cancer Res 61:7855-60 (2001)].
Thus, the current consensus is that recent developments in the field of : antisense technology which, as described above, have led to the generation of highly accurate antisense design algorithms and a wide variety of oligonucleotide delivery : 30 systems, enable an ordinarily skilled artisan to design and implement antisense approaches suitable for downregulating expression of known sequences without having to resort to undue trial and error experimentation.
As described hereinabove, the AMP/AML inhibitor may be a mbozyme molecule capable of specifically cleaving an mRNA transcript encoding the
AMP/AML. Ribozymes are being increasingly used for the sequence-specific . inhibition of gene expression by the cleavage of mRNAs encoding proteins of interest [Welch et al., Curr Opin Biotechnol. 9:486-96 (1998)]. The possibility of designing ribozymes to cleave any specific target RNA has rendered them valuable tools in both basic research and therapeutic applications. In the therapeutics area, ribozymes have been exploited to target viral RNAs in infectious diseases, dominant oncogenes in cancers and specific somatic mutations in genetic disorders [Welch et al., Clin Diagn
Virol. 10:163-71 (1998)]. Most notably, several ribozyme gene therapy protocols for
HIV patients are already in Phase 1 trials. More recently, ribozymes have been used for transgenic animal research, gene target validation and pathway elucidation.
Several ribozymes are in various stages of clinical trials. AN GIOZYME was the first chemically synthesized ribozyme to be studied in human clinical trials.
ANGIOZYME specifically inhibits formation of the VEGF-r (Vascular Endothelial
Growth Factor receptor), a key component in the angiogenesis pathway. Ribozyme
Pharmaceuticals, Inc., as well as other firms have demonstrated the importance of anti-angiogenesis therapeutics in animal models. HEPTAZYME, a ribozyme designed to selectively destroy Hepatitis C Virus (HCV) RNA, was found effective in decreasing Hepatitis C viral RNA in cell culture assays (Ribozyme Pharmaceuticals,
Incorporated - WEB home page).
As described hereinabove, the AMP/AML inhibitor may be a triplex forming oligonucleotides (TFOs). TFOs can be used for regulating the expression of an
AMP/AML gene in cells. Recent studies have shown that TFOs can be designed which can recognize and bind to polypurine/polypyrimidine regions in double- stranded helical DNA in a sequence-specific manner. These recognition rules are outlined by Maher III, L. J, et al, Science,1989;245:725-730; Moser, H. E., et al,
Science,1987;238:645-630; Beal, P. A, et al, Science, 1992;251:1360-1363; Cooney, - M., et al., Science,1988;241:456-459; and Hogan, M. E,, et al.,, EP Publication 375408. Modification of the oligonucleotides, such as the introduction of intercalators and backbone substitutions, and optimization of binding conditions (pH and cation concentration) have aided in overcoming inherent obstacles to TFO activity such as charge repulsion and instability, and it was recently shown that synthetic oligonucleotides can be targeted to specific sequences (for a recent review see
Seidman and Glazer, J Clin Invest 2003;112:487-94).
In general, the triplex-forming oligonucleotide has the sequence correspondence: oligo, 3'--A G G T; duplex, 5'--A G CT; and duplex, 3'--T C G A.
However, it has been shown that the A-AT and G-GC triplets have the greatest triple helical stability (Reither and Jeltsch, BMC Biochem, 2002, Sept12, Epub). The same authors have demonstrated that TFOs designed according to the A-AT and G-
GC rulé do not form non-specific triplexes, indicating that the triplex formation is indeed sequence specific.
Thus for any given sequence in the AMP/AML gene a triplex forming sequence may be devised. Triplex-forming oligonucleotides preferably are at least 15, more preferably 25, still more preferably 30 or more nucleotides in length, up to 50 or 100 bp.
Transfection of cells (for example, via cationic liposomes) with TFOs, and formation of the triple helical structure with the target DNA induces steric and functional changes, blocking transcription initiation and elongation, allowing the introduction of desired sequence changes in the endogenous DNA and resulting in the specific downregulation of gene expression. Examples of such suppression of gene expression in cells treated with TFOs include knockout of episomal supFG1 and endogenous HPRT genes in mammalian cells (Vasquez et al, Nucl Acids Res. 1999:27:1176-81, and Puri, et al, J Biol Chem, 2001;276:28991-98), and the sequence- and target specific downregulation of expression of the Ets2 transcription factor, important in prostate cancer etiology (Carbone, et al, Nucl Acid Res. 2003;31:833-43), and the pro-inflammatory ICAM-1 gene (Besch et al, J Biol Chem, 2002;277:32473-79). In addition, Vuyisich and Beal have recently shown that sequence specific TFOs can bind to dsRNA, inhibiting activity of dsRNA-dependent enzymes such as RNA-dependent kinases (Vuyisich and Beal, Nuc. Acids Res 2000;28:2369-74). : Additionally, TFOs designed according to the abovementioned principles can induce directed mutagenesis capable of effecting DNA repair, thus providing both : 30 downregulation and upregulation of expression of endogenous genes (Seidman and
Glazer, J Clin Invest 2003;112:487-94). Detailed description of the design, synthesis and administration of effective TEOs can be found in U.S. Patent Application Nos. 2003 017068 and 2003 0096980 to Froehler et al, and 2002 0128218 and 2002
0123476 to Emanuele et al, and U.S. Pat. No. 5,721,138 to Lawn.
Techniques for administering such molecules to a cell or cellular structure are : routinely practiced by the ordinarily skilled artisan, and ample guidance is provided in the literature of the art for such administration (refer, for example, to the references s relevant to such molecules cited hereinabove and to U.S. Patent Application No. 20030044907 which is incorporated herein by reference).
As described hereinabove, the method of regulating the biological process of the present invention comprises the step of exposing the cell/tissue to the regulator.
Exposing the cell/tissue to the regulator may be effected in various ways depending on the application and purpose. In cases where the cell/tissue form part of a human or an animal subject, exposing the cell/tissue to the regulator is preferably effected by providing the regulator to the subject.
Administering the regulator to a subject may be effected via any suitable route facilitating exposure of the celVtissue with the regulator, including a route selected from the group consisting of the topical, intranasal, transdermal, intradermal, oral, buccal, parenteral, rectal and inhalation route.
Preferably, subcutaneous and/or local injection of the regulator in saline solution is used for treating a disease such as arthritis.
Preferably, topical application of the regulator in lipid or saline solution, or in a cream on the skin is used for treating a cutaneous disease such as a psoriasis legion.
Preferably, for treating respiratory diseases such as cystic fibrosis and asthma, the regulator dissolved in a solution and administered using an inhaler.
Alternately, the cells may be exposed to regulator by expressing the regulator in the human or animal. In cases where the cell/tissue is a cultured cell/tissue, exposing the regulator to the cell/tissue is preferably effected by providing the regulator to the cell/tissue in-vitro using standard tissue culture methods. Preferably, providing the regulator to the cellitissue in-vitro is effected as described in the . Examples section which follows.
The regulator can be expressed in a subject by directly administering to the subject a nucleic acid construct configured so as to suitably express the regulator in- vivo. Alternatively, a nucleic acid construct for expressing the regulator may be introduced into a suitable cell ex-vivo via an appropriate gene delivery vehicle/method (transfection, transduction, homologous recombination, etc.), and using a suitable genetic expression system as needed. The modified cells may be expanded in culture and administered to the subject where they will produce the regulator in-vivo. To . enable cellular expression of the regulator, a nucleic acid construct which encodes the regulator preferably includes at least one cis acting regulatory element, most : 5 preferably a promoter which is active in the specific cell population transformed. The nucleic acid construct can further include an enhancer, which can be adjacent or distant to the promoter sequence and can function in up regulating the transcription therefrom.
Suitable in vivo nucleic acid transfer techniques include transfection with viral or non-viral constructs, such as adenovirus, lentivirus, Herpes simplex I virus, or adeno-associated virus (AAV) and lipid-based systems, polylysine based systems and dendrimers. Useful lipids for lipid-mediated transfer of the gene are, for example,
DOTMA, DOPE, and DC-Chol [Tonkinson et al., Cancer Investigation, 14(1): 54-65 (1996)]. The most preferred constructs for use in gene therapy are viruses, most preferably adenoviruses, AAV, lentiviruses, or retroviruses. A viral construct such as a retroviral construct includes at least one transcriptional promoter/enhancer or locus- defining element(s), or other elements that control gene expression by other means such as alternate splicing, nuclear RNA export, or post-translational modification of messenger. Such vector constructs also include a packaging signal, long terminal repeats (LTRs) or portions thereof, and positive and negative strand primer binding sites appropriate to the virus used, unless it is already present in the viral construct.
The construct may include a signal that directs polyadenylation, as well as one or more restriction sites and a translation termination sequence. By way of example, such a constructs will typically include a 5' LTR, a tRNA binding site, a packaging signal, an origin of second-strand DNA synthesis, and a 3' LTR or a portion thereof.
The various aspects of the present invention may be practiced by using, and/or by decreasing the activity/level, of any of various types of AMPs/AMLs, depending on the application and purpose.
Preferably, the AMP/AML is a cationic and/or hydrophobic peptide. - 30 As used herein, the term “peptide” (with the exception of the term in the context of the phrases “antimicrobial peptide” or “antimicrobial-like peptide”, refers to a polypeptide which is composed of less than 51 amino acid residue.
Preferably, the AMP/AML is a defensin or a cathelicidin.
Preferably, the defensin is a beta-defensin, most preferably beta-defensin-1 or beta-defensin-2. . Preferably, the cathelicidin 1s LL-37.
Preferably, the AMP/AML is of human origin. Alternately, it may be of non- human origin, in which case it is preferably of mammalian origin.
Numerous examples of AMPs/AMLs which may be used, and/or whose activity/levels may be decreased, for practicing the various aspects of the present invention are described in further detail hereinbelow.
The method may be practiced so as to regulate the biological process in any of various cells/tissues of the present invention.
Preferably, the method is used to regulate the biological process in an epithelial cell/tissue, an endothelial cell/tissue, a gastrointestinal tissue, and/or a tumor cell/tissue.
The cell/tissue is preferably an epithelial, skin, endothelial, gastrointestinal, and/or tumor cell/tissue.
The method may be used to regulate the biological process in any of various types of skin cells/tissues.
Preferably, the skin cell/tissue is a keratinocytic cell/tissue.
Preferably, the gastrointestinal cell/tissue is a gastrointestinal epithelial cell/tissue.
Preferably, the tumor cell/tissue is a malignant cell/tissue. Alternately, the tumor cell/tissue may be a benign tumor cell/tissue.
Preferably, the tumor cell/tissue is a metastatic tumor cell/tissue.
The method may be used to regulate the biological process in a tumor cell/tissue which is of any of various cell/tissue types.
Preferably, the malignant cell/tissue is a skin cell/tissue.
The method may be effected by exposing the cell/tissue to the regulator at any : of various concentrations, depending on the application and purpose.
Preferably, when using an AMP/AML inhibitor of the present invention for regulating the biological process, exposing the cell/tissue to the AMP/AML inhibitor is effected by exposing the cell/tissue to the AMP/AML inhibitor at a concentration selected from a range of about 50 nanograms per milliliter to about one milligram per milliliter.
Exposing the cell/tissue to the AMP/AML inhibitor may advantageously be effected, depending on the application and purpose, by exposing the cell/tissue to the : AMP/AML inhibitor at a concentration selected from a range of about 50 ng/ml to about 100 micrograms/ml, from a range of about 100 micrograms/ml to about 200 micrograms/ml, from a range of about 200 micrograms/ml to about 300 micrograms/ml, from a range of about 300 micrograms/ml to about 400 micrograms/ml, from a range of about 400 micrograms/ml to about 500 micrograms/ml, from a range of about 500 micrograms/ml to about 600 micrograms/ml, from a range of about 600 micrograms/ml to about 700 micrograms/ml, from a range of about 700 micrograms/ml to about 800 micrograms/ml, from a range of about 800 micrograms/ml to about 900 micrograms/ml, from a range of about 900 micrograms/ml to about 1 mg/ml.
Preferably, when using an AMP/AML of the present invention for regulating the biological process, exposing the cell/tissue to the AMP/AML is effected by exposing the cell/tissue to the AMP/AML at a concentration selected from a range of about 2 ng/ml to about 10 micrograms/ml.
Exposing the cell/tissue to the AMP/AML may advantageously be effected, depending on the application and purpose, by exposing the cell/tissue to the
AMP/AML inhibitor at a concentration selected from a range of about 2 ng/ml to about 1 microgram/ml, from a range of about 1 microgram/ml to about 2 micrograms/ml, from a range of about 2 micrograms/ml to about 3 micrograms/ml, from a range of about 3 micrograms/ml to about 4 micrograms/ml, from a range of about 4 micrograms/ml to about 5 micrograms/ml, from a range of about 5 micrograms/ml to about 6 micrograms/ml, from a range of about 6 micrograms/ml to about 7 micrograms/ml, from a range of about 7 micrograms/ml to about 8 micrograms/ml, from a range of about 8 micrograms/ml to about 9 micrograms/ml, from a range of about 9 micrograms/ml to about 10 micrograms/ml. : The method can be used to regulate in the cell/tissue a biological process such as growth, differentiation, inflammation, metastasis and/or angiogenesis.
For regulating growth in an epithelial, skin and/or gastrointestinal cell/tissue, the regulator may advantageously be an AMP/AML inhibitor of the present invention and/or an AMP/AML of the present invention.
For inducing growth in an epithelial, skin and/or gastrointestinal cell/tissue,
the regulator used is preferably a defensin inhibitor of the present invention and/or a cathelicidin inhibitor of the present invention. : As used herein, the phrase “defensin inhibitor” refers to a compound of the present invention which is capable of decreasing an activity and/or level of a defensin.
As used herein, the phrase “cathelicidin inhibitor” refers to a compound of the present invention which is capable of decreasing an activity and/or level of a cathelicidin.
Preferably, for inducing growth in an epithelial and/or skin cell/tissue the
AMP/AML is preferably a defensin. Preferably the defensin is used for such purpose at a concentration selected from a range of about 0.1 microgram/ml to about 10 micrograms/ml, most preferably at a concentration of about 1 microgram/ml.
As is shown in Example 1 (Figure 1) of the Examples section below, beta- defensin-1 or beta-defensin-2 at a concentration of 1 microgram/ml can be used to induce growth in a human skin cell/tissue.
Preferably, for inducing growth in an epithelial, skin and/or gastrointestinal cell/tissue a defensin inhibitor is used at a concentration selected from a range of about 50 ng/ml to about 50 micrograms/ml. Preferably the defensin inhibitor employed for such purpose is a beta-defensin-2 inhibitor of the present invention.
As used herein, the phrase “beta-defensin-2 inhibitor” refers to a compound of the present invention which is capable of decreasing an activity and/or level of beta- defensin-2.
Preferably, for inducing growth in a skin and/or keratinocytic cell/tissue, the defensin inhibitor is used at a concentration of about 0.1 microgram/ml to about 10 micrograms/ml, most preferably at a concentration of about 1 microgram/ml. As is shown in Example 2 of the Examples section (Figure 3), anti-beta-defensin-2 antibody at a concentration of 1 microgram/ml can be used to induce growth of primary human skin cells. : Preferably, for inducing growth in a skin and/or keratinocytic cell/tissue, the cathelicidin inhibitor is used at a concentration of about 0.4 microgram/ml to about 40 micrograms/ml, most preferably at a concentration of about 4 micrograms/ml. As is shown in Example 2 of the Examples section (Figure 3), anti-LL-37 antibody at a concentration of 4 micrograms/ml can be used to induce growth of primary human skin cells.
Preferably, for inducing growth in a gastrointestinal cell/tissue, the defensin inhibitor is used at a concentration selected from a range of about 50 ng/ml to about 5 micrograms/ml, most preferably at a concentration of about 0.5 microgram/ml. As is shown in Example 4 of the Examples section (Figure 6), anti-beta-defensin-2 antibody at a concentration of 0.5 microgram/ml can be used to induce growth of a human gastrointestinal epithelial cell/tissue.
For inhibiting growth in a tumor, epithelial, skin and/or gastrointestinal cell/tissue, the regulator used may advantageously be a defensin inhibitor of the present invention, and/or a cathelicidin inhibitor of the present invention. For such purpose the defensin inhibitor is preferably a beta-defensin-2 inhibitor of the present invention.
Preferably, for inhibiting growth in a tumor cell/tissue the defensin inhibitor is used at a concentration selected from a range of about 0.1 microgram/ml to about 10 micrograms/ml, more preferably at a concentration of about 1 microgram/ml. As is shown in Example 1 of the Examples section (Figure 2), anti-beta-defensin-2 antibody at a concentration of 1 microgram/ml can be used to inhibit growth of a malignant skin carcinoma cell/tissue.
Preferably, for inhibiting growth in a skin and/or keratinocytic cell/tissue, the defensin inhibitor is used at a concentration of about 50 ng/mi to about 50 micrograms/ml, most preferably at a concentration of about 5 micrograms/ml. As is shown in Example 2 of the Examples section (Figure 3), anti-beta-defensin-2 antibody at a concentration of 5 micrograms/ml can be used to inhibit growth of primary human skin cells.
Preferably, for inhibiting growth in a skin and/or keratinocytic cell/tissue, the cathelicidin inhibitor is used at a concentration of about 2 micrograms/ml to about 200 micrograms/ml, most preferably at a concentration of about 20 micrograms/ml.
As is shown in Example 2 of the Examples section (Figure 3), anti-cathelicidin antibody at a concentration of 20 micrograms/ml can be used to inhibit growth of primary human skin cells. . 30 Preferably, for inhibiting growth in a gastrointestinal cell/tissue, the defensin inhibitor is used at a concentration selected from a range of about 0.1 microgram/ml to about 10 micrograms/ml, most preferably at a concentration of about microgram/ml. As is shown in Example 4 of the Examples section (Figure 6), anti-
beta-defensin-2 antibody at a concentration of 1 microgram/ml can be used to inhibit growth of a human gastrointestinal epithelial cell/tissue. . For inhibiting angiogenesis/endothelial cell/tissue growth, the regulator used is preferably a defensin inhibitor. Preferably, for such purpose, the defensin inhibitor : s used is a beta-defensin-2 inhibitor of the present invention. Preferably, the defensin inhibitor is used at a concentration selected from a range of about 50 nanograms/ml to about 10 micrograms/ml, more preferably from a range of about 50 ng/ml to about 5 micrograms/ml and most preferably is used at a concentration of about 0.5 microgram/ml. As is shown in Example 5 of the Examples section (Figure 7), anti- beta-defensin-2 antibody at a concentration of 0.5 or 1 microgram/ml (especially 0.5 microgram/ml) can be used to inhibit angiogenesis/ human endothelial cell/tissue growth.
For inhibiting metastasis in a tumor cell/tissue, the regulator used is preferably a defensin inhibitor of the present invention. Preferably, for such purpose, the defensin inhibitor is a beta-defensin-2 inhibitor of the present invention. Preferably, the defensin inhibitor is used for such a purpose at a concentration selected from a range of about 0.1 microgram/ml to about 10 micrograms/ml, most preferably at a concentration of about 1 microgram/ml.
As is described in Example 1 of the Examples section below anti-beta- defensin-2 antibody at a concentration of 1 microgram/ml can be used to inhibit substrate detachment of human malignant skin tumor cells/tissue.
For correcting dysregulated balance of proliferation/differentiation in an epithelial and/or skin cell/tissue, the regulator is preferably a defensin inhibitor.
Preferably, the defensin inhibitor used for such a purpose is a beta-defensin-2 inhibitor of the present invention. Preferably, the beta-defensin-2 inhibitor is used for such a purpose at a concentration selected from a range of about 0.1 microgram/ml to about 1 mg/ml, most preferably at a concentration of about 1 microgram/ml or 100 . micrograms/ml.
As is shown in Example 3 (Figures 4a-c) of the Examples section below anti- beta-defensin-2 antibody at a concentration of 1 microgram/ml can be used to correct proliferation/differentiation imbalance in a highly realistic three-dimensional organotypic in-vitro human skin model. As is shown in Example 3 of the Examples section which follows (Figures 5a-d), anti-beta-defensin-2 antibody at a concentration a4 of 100 micrograms/ml can be used to inhibit flaking in a human psoriasis lesion, indicating correction of skin cell/tissue proliferation/differentiation imbalance. : For inhibiting inflammation in a cell/tissue, the regulator used is preferably a defensin inhibitor of the present invention. Preferably, for such purpose, the defensin ’ 5 inhibitor is a beta-defensin-2 inhibitor of the present invention. Preferably, the defensin inhibitor is used for such a purpose at a concentration selected from a range of about 50 ng/ml to about 1 mg/ml, most preferably at a concentration of about 0.5 microgram/ml or about 100 micrograms/ml.
As is shown in Example 3 (Figures Sa-d) of the Examples section below anti- beta-defensin-2 antibody at a concentration of 1 microgram/ml can be used to inhibit an autoimmune inflammation in a human tissue. As is further shown in Example 5 of the Examples section which follows (Figure 7), anti-beta-defensin-2 antibody at a concentration of 0.5 microgram/ml can be used to inhibit human endothelial cell/tissue growth, indicating a capacity for inhibition of angiogenesis by the regulator. It will be appreciated that by virtue of enabling inhibition of an inflammation in a human tissue, and by virtue of enabling inhibition of angiogenesis, that the presently described method enables potent inhibition of inflammation.
As described hereinabove, the present invention can be used for regulating biological processes such as growth, differentiation, inflammation, metastasis and angiogenesis. It will be appreciated that such biological processes are associated with the pathogenesis of numerous diseases, and that regulation of such biological processes according to the teachings of the present invention can be used for treating such diseases. -
Thus, according to one aspect of the present invention there is provided a method of treating a disease in a subject in need thereof. The method is effected by providing to the subject a therapeutically effective amount of a compound which is capable of decreasing an activity and/or level of an AMP and/or AMP-like molecule . (AML).
As used herein, the term “disease” refers to any medical disease, disorder, : 30 condition, or syndrome, or to any undesired and/or abnormal physiological morphological, cosmetic and/or physical state and/or condition.
Herein, the term “treating” includes abrogating, substantially inhibiting, slowing or reversing the progression of a disease, substantially ameliorating clinical symptoms of a disease or substantially preventing the appearance of clinical symptoms of a disease.
The method can be used for treating any of various diseases.
In particular, the method can be used for treating any of various diseases which are associated with: (i) a tumor; (ii) inflammation; (iii) an epithelial wound; (iv) dysregulation of growth/differentiation of a cell/tissue; (v) dysregulation of growth/differentiation balance of a cell/tissue, and (vi) diseases associated with angiogenesis.
Examples of such diseases, and others, which are amenable to treatment via the present invention are listed hereinbelow.
One of ordinary skill in the art, such as a physician, most preferably a physician specialized in the disease, will possess the necessary expertise for treating a disease according to the teachings of the present invention.
As used herein, the phrase “subject in need thereof” refers to a subject having the disease.
Preferably, the subject is a mammal, most preferably a human.
By virtue of demonstrably enabling induction of growth in an epithelial, skin and/or gastrointestinal cell/tissue, the method described above for inducing such growth is particularly suitable for treating any of various diseases in which growth of such tissue will be therapeutic. Such diseases particularly include diseases which are associated with epithelial, skin and/or gastrointestinal wounds.
By virtue of demonstrably enabling growth inhibition of a malignant, epithelial, skin and/or gastrointestinal cell/tissue, the method described above for inhibiting such growth is particularly suitable for treating any of various diseases associated with dysregulated/excessive growth, malignant, epithelial, skin and/or gastrointestinal cell/tissue. Such diseases particularly include tumors in general, gastrointestinal tumors, and malignant skin carcinomas in particular.
By virtue of demonstrably enabling growth inhibition of an endothelial cell/tissue, the method described above for inhibiting such growth is particularly suitable for treating any of various diseases associated with dysregulated/excessive growth of an endothelial cell/tissue, and hence can be used for treating any of various diseases associated with angiogenesis. Such diseases notably include solid tumors, endothelial tumors, and inflammatory diseases including autoimmune diseases such as psoriasis.
By virtue of demonstrably enabling correction of dysregulation of . growth/differentiation balance in epithelial and/or skin tissue in an in-vitro three- dimensional organotypic skin model, and in-vivo in an inflammatory lesion associated : 5s with such dysregulated balance, the method described above for correcting such balance is particularly suitable for treating any of various diseases associated with such dysregulated balance. Such diseases notably include psoriasis and dandruff.
By virtue of demonstrably enabling inhibition of an autoimmune inflammation in a human tissue, the method described above for inhibiting such inflammation is particularly suitable for treating any of various diseases associated with such inflammation. Such diseases notably include autoimmune diseases, such as psoriasis and gastrointestinal autoimmune diseases.
By virtue of demonstrably enabling inhibition of substrate detachment in a human tumor and/or skin cell/tissue, the method described above for inhibiting such detachment is particularly suitable for treating any of various diseases associated with such detachment. Such diseases notably include metastatic tumors, such as metastatic carcinomas, in particular metastatic malignant skin carcinoma.
For treating the disease, the regulator may be administered via any of various suitable regimens.
Preferably, administering the regulator to the subject is effected by administering to the subject a plurality of doses of the AMP/AML inhibitor which is selected from a range of about 2 doses to about 30 doses, wherein each inter dose interval of the plurality of doses is selected from a range of about 2.4 hours to about 30 days.
Depending on the application and purpose, the plurality of doses may advantageously be selected from a range of about 2 to about 5 doses, from a range of about 5 to about 10 doses, from a range of about 10 to about 15 doses, from a range of about 15 to about 20 doses, from a range of about 20 to about 25 doses, from a range of about 25 to about 30 doses, or from a range of about 30 to about 35 doses. . 30 Preferably, administering the regulator to the subject is effected by administering to the subject 3 doses of the AMP/AML inhibitor.
Depending on the application and purpose, €ach inter dose interval of the plurality of doses may advantageously be selected from a range of about 2.4 hours to about 3 days, from a range of about 3 days to about 6 days, from a range of about 6 days to about 9 days, from a range of about 9 days to about 12 days, from a range of . about 12 days to about 15 days, from a range of about 15 days to about 18 days, from a range of about 18 days to about 21 days, from a range of about 21 days to about 24 : 5 days, from a range of about 24 days to about 27 days, or from a range of about 27 days to about 30 days.
Preferably, the inter dose interval of the plurality of doses is about 1 day.
As is described in Example 3 of the Examples section which follows, administering 3 doses of a regulator of the present invention to the subject with an inter dose interval of about 1 day can be used for effectively treating a disease such as psoriasis in a human subject.
Disease treatment may be effected via polytherapy by administration of the regulator in conjunction with peptide inhibitors such as protease inhibitors, the serpin serine proteinase inhibitory components (alpha-1 PI) and alpha -1 antichymotrypsin (Panyutich, AV. et al., 1995. Am.J Respir.Cell Mol.Biol. 12:351-357), BAPTA-AM (an intracellular Ca(2+) chelating agent), pertussis toxin and U-73122 (a phospholipase C inhibitor; Niyonsaba, F. ef al., 2001. Eur.J.Immunol. 31:1066-1075),
T-cell targeted therapies, monoclonal antibody against chemokine tumor necrosis factor and cytokine targeted therapies, fibroblast growth factor inhibitors. For example, topical treatments may advantageously include cell proliferation regulators such as retinoid - vitamin A - analog which modulates or changes the cellular differentiation of the epidermis. Such polytherapy may be effected using anti- inflammatory drugs/treatments as a precautionary measure against relapse of psoriasis or other auto-immune disease. Such drugs/treatments include tazarotene, methotrexate, acitretin, bexarotene, ploralem, etretinate, corticosteroid creams and ointments, synthetic vitamin D3, IL-10, IL-4 and IL-1RA (receptor antagonist).
To enable treatment of the disease, the regulator is preferably included as an active ingredient in a pharmaceutical composition which includes a suitable carrier and which is suitably packaged and labeled for treatment of the disease. . 30 The regulator according to the present invention can be administered to a subject per se, or in a pharmaceutical composition where it is mixed with suitable carriers or excipients.
As used herein a "pharmaceutical composition" refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a : pharmaceutical composition is to facilitate administration of active ingredients to an organism.
Herein the term "active ingredients" refers to the regulator of the present invention accountable for the biological effect.
Hereinafter, the phrases "physiologically acceptable carrier” and "pharmaceutically acceptable carrier” which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered active ingredients. An adjuvant is included under these phrases.
Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient.
Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
Techniques for formulation and administration of drugs may be found 1n “Remington’s Pharmaceutical Sciences,” Mack Publishing Co., Easton, PA, latest edition, which is incorporated herein by reference.
Suitable routes of administration may, for example, include oral, rectal, transmucosal, transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, inrtaperitoneal, intranasal, or intraocular injections.
Alternately, one may administer the pharmaceutical composition in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a tissue region of a patient.
Pharmaceutical compositions of the present invention may be manufactured by : processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or : 30 lyophilizing processes.
Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologicaily acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically.
Proper formulation is dependent upon the route of administration chosen. : For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions, preferably in physiologically compatible buffers 5s such as Hank’s solution, Ringer’s solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
For oral administration, the pharmaceutical composition can be formulated readily by combining the active ingredients with pharmaceutically acceptable carriers well known in the art. Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurnes, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl- cellulose, sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active ingredient doses.
Pharmaceutical compositions which can be used orally, include push-fit : 30 capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, : stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.
For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
For administration by nasal inhalation, the active ingredients for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro- tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the active ingredients and a suitable powder base such as lactose or starch.
The pharmaceutical composition described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion.
Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes.
Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran.
Optionally, the suspension may also contain suitable stabilizers or agents which . 30 increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions. Cream solutions can include any lipids or organic alcohols or chemicals including for example benzyl alcohol, macrogol, hexylene glycol, carbomer, ascorbic acid, butyl hydroxyainisole, butyl hydroxytoluene, disodium edentate, water, trometamol, poxoamer.
Alternatively, the active ingredients may be in powder form for constitution : with a suitable vehicle, e.g, sterile, pyrogen-free water based solution, before use.
The pharmaceutical composition of the present invention may also be s formulated in rectal compositions such as suppositories or retention enemas, using, e.g., conventional suppository bases such as cocoa butter or other glycerides.
Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount means an amount of active ingredients (regulator of the present invention) effective to prevent, alleviate or ameliorate symptoms of a disorder (e.g. psoriasis or a carcinoma) or prolong the survival of the subject being treated.
Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.
Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human.
The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g.,
Fing), ef al., 1975, in "The Pharmacological Basis of Therapeutics”, Ch. 1 p.1).
Dosage amount and interval may be adjusted individually to provide plasma or : 30 brain levels of the active ingredients which are sufficient to achieve a desired therapeutic effect (minimal effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.
Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of : 5s the disease state is achieved.
The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
Compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredients. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as if further” detailed above.
Thus, the present invention provides an article of manufacture which comprises packaging material identified for treatment of the disease, and a pharmaceutical composition which includes a pharmaceutically acceptable carrier and, as an active ingredient, the regulator.
Preferably, the pharmaceutical composition is formulated as a solution, . suspension, emulsion or gel.
Preferably, the pharmaceutically acceptable carrier is selected so as to enable : 30 administration of the pharmaceutical composition via a route selected from the group consisting of the topical, intranasal, transdermal, intradermal, oral, buccal, parenteral, rectal and inhalation route.
Preferably, the pharmaceutical composition is composed so as to enable exposure of an affected cell/tissue of the subject having the disease, to the regulator at a suitable concentration, as described hereinabove, for treating the disease. . Preferably, the pharmaceutical composition is further identified for administration to the subject according to a suitable regimen, as described hereinabove.
Thus, the present invention provides a method of identifying a compound capable of regulating the biological process in a cell/tissue. The method is effected in a first step by exposing the cell/tissue to a test compound which is: a compound capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule (AML); and/or which is the AMP and/or AML. In a second step, the method is effected by evaluating a capacity of the test compound to regulate the biological process in the cell and/or tissue.
It will be appreciated that the method of identifying the compound can be used for screening a plurality of compounds so as to identify a compound having a desired capacity for regulating a biological process.
The method is preferably used to identify a compound capable of regulating a biological process as described hereinabove with respect to the method of the present invention of regulating a biological process.
Preferably, the test compound is a regulator as described hereinabove with respect to the method of the present invention of regulating a biological process.
The method is preferably used to identify a compound capable of regulating the biological process in the cell/tissue as described hereinabove with respect to the method of the present invention of regulating a biological process, and as described in the Examples section which follows. As is described hereinabove with respect to the method of regulating the biological process, and in the Examples section which follows, the method is preferably employed for identifying a compound which is capable of: inducing growth in an epithelial, skin, keratinocytic and/or gastrointestinal cell/tissue; inhibiting growth in a tumor, epithelial, skin, keratinocytic and/or gastrointestinal cell/tissue; inhibiting angiogenesis/endothelial cell/tissue growth; inhibiting metastasis in a tumor cell/tissue; correcting dysregulated balance of proliferation/differentiation in an epithelial, keratinocytic and/or skin cell/tissue; and/or inhibiting inflammation in an epithelial, keratinocytic an/or skin cell/tissue.
The identification method may advantageously be performed using high- throughput methodology. Ample guidance for practicing relevant high-throughput . methods is provided in the literature of the art (refer, for example, to U.S. Patent
Application No. 20030044907).
The test compound may be exposed to the cell/tissue in any of various ways.
Preferably, the test compound is exposed to the cell/tissue in-vitro as described in the : Examples section which follows. Alternately, the test compound may be exposed to the celV/tissue by exposing the test compound to a cultured cell/tissue.
Preferably, the cell which produces the test compound is a B-cell hybridoma.
Alternately, the cell which produces the test compound may be of any of various types, depending on the application and purpose.
It will be appreciated that a B-cell hybridoma is an antibody producing cell, and hence that exposing the cell/tissue to a B-cell hybridoma can be used for identifying a B-cell hybridoma which expresses an antibody which is capable of regulating the biological process.
Exposing the cell/tissue to the test compound may be effected by providing the test compound to a subject which includes the cell/tissue (in-vivo model). Preferably providing the test compound to the test subject is effected as described hereinabove with respect to providing the regulator to a subject. . 20 The identification method may be effected by exposing the test compound to: psoriasis lesions and lesions of any of various diseases associated with epithelial wounds included in the present invention; a psoriatic lesion in a psoriasis animal model; or a psoriatic lesion in a human having psoriasis; a human biopsy of a normal or pathological involved lesion maintained in an organotypic culture containing plasma and lymphocytes of patients suffering from the disease having and not having polymorphism on AMPs or their genes and promoters; and/or to a cell/tissue of a disease in which the disease inductive isoforms are ApoE4 and the non inductive isoform is ApoE3.
The identification method may be effected by exposing the test compound to a human psoriatic lesion biopsy grafted onto an animal (xenograft model), whereby the biopsy is taken with informed consent. The biopsy may be transplanted onto an immunodeficient mouse (for example, NIHS-bg-nu-xid or BNX). For establishing such a xenograft model, PBMCs may be isolated from the blood obtained from the biopsy donor and activated (for example, using a superantigen), and the animals injected with the activated PBMCs. Ample guidance for practicing the identification . method using such animal models is provided in Examples 6-8 of the Examples section below and in the literature of the art (refer, for example, to U.S. Patent ’ 5s Application No. 20030044907).
The most affected tissue in psoriasis, in addition to the activated immune system, is skin. The main cells composing skin are epidermal keratinocytes and dermal fibroblasts. Other cells include endothelial cells, melanocytes, hair follicle cells, sweat gland cells, and immune system cells. Such cells may advantageously be used to practice the identification method.
Evaluation of the regulation of the biological processes encompassed by the identification method may be effected using any of various suitable methods known to the ordinarily skilled artisan. Preferably, such evaluation is performed, where relevant, as described in the Examples section which follows.
Evaluating regulation of the biological process may be effected using quantitative evaluation of epidermal thickness when using an in-vivo model, cell count or histological evaluation.
Preferably, data obtained from the evaluation is processed using statistical analysis and ANOVA for maximum informativity.
According to one embodiment, the identification method may involve exposing the test compound to cultured microbes/bacteria and evaluating regulation of the biological process is effected by measuring survival of the microbes/bacteria.
This may be effected by a colony-forming unit assay performed with Staphylococcus aureus (isolated from clinical sample), GAS (NZ131), and enteroinvasive Escherichia coli 029 as described (Porter et al, 1997). Before analysis, the concentration of the bacteria in culture will be determined by plating different bacterial dilutions. The protocol may be performed as follows. Cells are washed twice with 10 mM sodium : ~ phosphate buffer (20 mM NaH,PO4-H;0, 20 mM Na,HPO,-7H,0) and diluted to a concentration of 2,000,000 cells per milliliter (S. aureus, GAS) or 200,000 cells per milliliter (E. coli) in phosphate buffer. S. aureus and E. coli are incubated for 4 hours at 37 degrees centigrade with various concentrations of an AMP/AML in the presence of various concentrations of the test compound to be examined, in 50 microliters of buffer in 96 well round bottom tissue culture plates (Costar 3799, Corning inc., NY).
GAS are incubated for 1 hour due to the poor ability of GAS to grow in such buffers.
After incubation, the cells are diluted from 10x to 100,000x , and each of 20 ml of . those solutions are plated in triplicate on tryptic soy broth (for S. aureus) and Todd
Hewitt broth (for GAS and E. coli), and the mean number of colonies is determined. ; 5 The number of cfu per ml is calculated, and the blocking activity of the examined test compounds to block the bactericidal activities of the AMP/AML will be calculated as follows: (cell survival after AMP/AML incubation)/(cell survival after incubation without AMP/AML)x100, which represents the percentage of cells that are alive, as compared to those which are not (cell survival after AMP/AML+est compound incubation)/(cell survival after incubation with test compound alone)x100.
All compounds identified will be screened for one or all of the following effects: their ability to inhibit the antimicrobial activity of the AMP to which they were raised against; their ability to affect the proliferation or differentiation or other cellular processes of cultured cells of the affected target tissue, originally isolated from normal or diseased individuals or models, for example HaCaT, primary human or murine keratinocytes or fibroblasts for screening for psoriasis; the effects of the inhibitors on activation of the immune system.
Identified compounds may be further screened for their effects on organotypic cocultures and animal models so as to identify inhibitors that will be able to effectively inhibit a desired biological effect or combination of biological effects.
This may include, where suitable, identifying compounds that will inhibit the effects of AMPs/AMLs on proliferation/differentiation balance but which maintain their antibacterial/antimicrobial activity.
The test compound or regulator may be any of various type of molecule, such as a small synthetic/non-polypeptidic molecule.
The test compound or regulator may advantageously be a peptide, a protein or a glycosylated protein. ] Test compounds and regulators of the present invention of any of various suitable types may be obtained from a commercial chemical library such as, for example, one held by a large chemical company such as Merck, Glaxo Welcome,
Bristol Meyers Squib, Monsanto/Searle, Eli Lilly, Novartis, Pharmacia UpJohn, and the like. Test compounds and regulators of the present invention of any of various suitable types may also be ordered via the World Wide Web (Internet) via companies such as Chemcyclopedia (http://www .mediabrains.com/client/chemcyclop/BGl1/search.asp). Alternatively, test compounds and regulators of the present invention of any of various suitable types may be synthesized de novo using standard chemical and/or biological synthesis - 5 techniques. Ample guidance for synthesis of molecules suitable for use as test compounds or regulators of the present invention of any of various suitable types is provided in the literature of the art. For biological synthesis of molecules, such as polypeptides and nucleic acids, refer, for example to: Sambrook et al., infra; and associated references in the Examples section which follows. For guidance regarding chemical synthesis of molecules, refer, for example to the extensive guidelines provided by The American Chemical Society (http://www.chemistry.org/portal/Chemistry). One of ordinary skill in the art, such as, for example, a chemist, will possess the required expertise for chemical synthesis of suitable test compounds.
In designing a small molecules capable of binding the AMP/AML, several features, such as structures of antibody, receptors, ligands, and relevant biochemical and biological data may be considered. Such features may include de novo folding design using energy minimization and molecular dynamics, and comparative modeling followed by energy minimization and molecular dynamics. These two approaches differ only in developing the trial or initial structures. The folding patterns are studied using energy minimization and molecular dynamics.
As used herein, the term "peptide" includes native peptides (either degradation products, synthetically synthesized peptides or recombinant peptides) and peptidomimetics (typically, synthetically synthesized peptides), such as peptoids and semipeptoids which are peptide analogs, which may have, for example, modifications rendering the peptides more stable while in a body or more capable of penetrating into target cells. Such modifications include, but are not limited to N terminus modification, C terminus modification, peptide bond modification, including, but not limited to, CH2-NH, CH2-S, CH2-S=0, O=C-NH, CH2-O, CH2-CH2, S=C-NH, . 30 CH=CH or CF=CH, backbone modifications, and residue modification. Methods for preparing peptidomimetic compounds are well known in the art and are specified, for example, in Quantitative Drug Design, C.A. Ramsden Gd., Chapter 17.2, F. Choplin
Pergamon Press (1992).
Peptide bonds (-CO-NH-) within the peptide may be substituted, for example, by N-methylated bonds (-N(CH3)-CO-), ester bonds (-C(R)H-C-O-O-C(R)-N-), ’ ketomethylen bonds (-CO-CH2-), c-aza bonds (-NH-N(R)-CO-), wherein R is any alkyl, e.g., methyl, carba bonds (-CH2-NH-), hydroxyethylene bonds (-CH(OH)-CH2- - 5), thioamide bonds (-CS-NH-), olefinic double bonds (-CH=CH-), retro amide bonds (-NH-CO-), peptide derivatives (-N(R)-CH2-CO-), wherein R is the "normal" side oo chain, naturally presented on the carbon atom.
These modifications can occur at any of the bonds along the peptide chain and even at several (2-3) at the same time.
Natural aromatic amino acids, Trp, Tyr and Phe, may be substituted for synthetic non-natural acid such as TIC, naphthylelanine (Nol), ring-methylated derivatives of Phe, halogenated derivatives of Phe or o-methyl-Tyr.
In addition to the above, the peptides of the present invention may also include one or more modified amino acids or one or more non-amino acid monomers (e.g. . fatty acids, complex carbohydrates etc).
As used herein in the specification and in the claims section below the term ; "amino acid” or "amino acids" is understood to include the 20 naturally occurring amino acids; those amino acids often modified post-translationally in vivo, including, for example, hydroxyproline, phosphoserine and phosphothreonine; and other unusual amino acids including, but not limited to, 2-aminoadipic acid, hydroxylysine, isodesmosine, nor-valine, nor-leucine and ornithine. Furthermore, the term "amino acid" includes both D- and L-amino acids.
Tables 2 and 3 below list naturally occurring amino acids (Table 2) and non- conventional or modified amino acids (Table 3) which can be used with the present invention.
Table 2. Naturally occurring amino acids.
TS
Apmigme Aw IN
Roparicad Jaw bp]
Guamme Jom Jo
-
Table 3. Non-conventional or modified amino acids. : bone | [L"melylspartioasid ___[Nmasp _ atooie | [Nmclylguamicaod____[Nmghi
Damme pal [LNmelyleoone [Nie
Boysime —[eys [[N-metbylnorleucine ____[Nomale [D-phenylalamne —[pphe [I N-methylvaline [Naval _
Doprofe opro [LN metbyloylghoine ___|Nmets_ © Duwi Jos |LNmelhyltbuigyoine __|Nmibug_
ETS CLS CERT Lau bo netics [DN ino mere
ET TE
L--methylhistidine L-0t-methylhomo phenylalanine
L-t-methylisoleucine Mile IN-(2-methylthioethylglycine
D-N-methylglutamine Damgin ~~ |N-(3-guanidinopropyl)glycine - D-N-methylglutamate N-(1-hydroxyethyl)glycine
D-N-methylhistidine N-(hydroxyethyl)glycine
D-N-methylisoleucine Dnmile [N-(imidazolylethylglycine ) D-N-methylleucine N-(3-indolylyethyl)glycine
N-methylcyclohexylalanine D-N-methylmethionine
D-N-methylornithine Dnmorn [N-methylcyclopentylalanine
N-methylglycine D-N-methylphenylalanine
N-methylaminoisobutyrate D-N-methylproline
N-(1-methylpropyl)glycine D-N-methylserine
N-(2-methylpropyl)glycine D-N-methylthreonine
D-N-methyltryptophan N-(1-methylethyl)glycine
D-N-methyltyrosine N-methyla-napthylalanine
D-N-methylvaline Dnmval [N-methylpenicillamine
L-t-butylglycine [Tous ~ |N-(thiomethyl)glycine
Lthylglycine Fg lpocilomine [Pen
L-ot-methylarginine L-o-methylasparagine
L-o-methylaspartate L-o-methyl-t-butylglycine )
L-o-methylglutamine L-0-methylglutamate
L-o-methylhistidine L-o-methylhomophenylalanine Mhphe
L-0t-methylisoleucine N-(2-methylthioethyl)glycine
L-0l-methylleucine Mew [1-amethyllysine
L-o-methylmethionine L-a-methylnorieucine [Mole {L-o-methylnorvaline L-o-methylormnithine
L- ai-methylphenylalanine L-o-methylproline
L-a-methylserine L-c-methylthreonine
L-o-methylvaline L-o-methyltyrosine
L-ot-methylleucine Mval Nnbhm |L-N-methylhomophenylalanine |Nmhphe
N-(N-(2,2-diphenylethyl) | [N-N-(3,3-diphenylpropyl) ] carbamylmethyl-glycine carbamylmethyl(1)glycine 1-carboxy-1-(2,2-diphenyl Nmbc . ethylamino)cyclopropane
The peptides of the present invention can be utilized in a linear or cyclic form.
A peptide can be either synthesized in a cyclic form, or configured so as to 5s assume a cyclic structure under suitable conditions.
For example, a peptide according to the teachings of the present invention can include at least two cysteine residues flanking the core peptide sequence. In this case, . cyclization can be generated via formation of S-S bonds between the two Cys residues. Side-chain to side chain cyclization can also be generated via formation of . s an interaction bond of the formula -(-CH2-)n-S-CH-2-C-, wherein n = 1 or 2, which is possible, for example, through incorporation of Cys or homoCys and reaction of its free SH group with, e.g., bromoacetylated Lys, Om, Dab or Dap. Furthermore, cyclization can be obtained, for example, through amide bond formation, €.g., by incorporating Glu, Asp, Lys, Om, di-amino butyric (Dab) acid, di-aminopropionic (Dap) acid at various positions in the chain (-CO-NH or -NH-CO bonds). Backbone to backbone cyclization can also be obtained through incorporation of modified amino acids of the formulas H-N((CH2)n-COOH)-C(R)H-COOH or H-N((CH2)n-COOH)-
C(R)H-NH2, wherein n = 1-4, and further wherein R is any natural or non-natural side chain of an amino acid.
Depending on the application and purpose, any of various AMPs/AMLs may be employed and/or regulated so as to practice the various embodiments of the present . invention. Numerous examples of AMPs/AMLs suitable for use in the present invention are listed on the Internet/World ~~ Wide Web at http://www bbem. units. it/~tossi/pagl.htm, and are described hereinbelow.
Examples of AMPs/AMLs include defensins, cathelicidins, and thrombocidins (alternately termed “platelet microbicidal proteins [PMPs]”).
Examples of defensins include alpha-defensins, beta-defensins, and neutrophil defensins. :
Examples of alpha-defensins include alpha-defensin-1 to -6 (Mol Immunol. 2003 Nov;40(7):463-7; J Clin Invest. 1985 Oct; 76(4):1427-35).
Examples of beta-defensins include beta-defensin-1 (Genomics. 1997 Aug 1;43(3):316-20; Biochem Biophys Res Commun. 2002 Feb 15;291(1):17-22; FEBS . Lett. 1995 Jul 17;368(2):331-5; Paulsen F ef al., J Pathol. 2002 Nov;198(3):369-77), beta-defensin-2 (Biochemistry. 2001 Apr 3;40(13):3810-6; Gene. 1998 Nov : 30 19;222(2):237-44; Paulsen F ef al., J Pathol. 2002 Nov;198(3):369-77), beta-defensin- 3 (Cell Tissue Res. 2001 Nov;306(2):257-64; J Biol Chem. 2002 Mar 8:277(10):8279-89. Epub 2001 Dec 11; J Biol Chem. 2001 Feb 23,276(8):5707-13;
Paulsen F et al, J Pathol. 2002 Nov;198(3):369-77), beta-defensin-4 (J Immunol.
2002 Sep 1;169(5):2516-23), beta-defensin-5 (Am J Pathol. 1998 May;152(5):1247- 58; J Biol Chem. 1992 Nov 15;267(32):23216-25), and beta-defensin-6 (FEBS Lett. ] 1993 Jan 4;315(2):187-92; Crit Care Med. 2002 Feb;30(2):428-34).
Beta-defensins include those encoded by five conserved beta-defensin gene . s clusters identified using a computational search strategy (Schutte BC. et al., 2002.
Proc Natl Acad Sci U S A. Feb 19;99(4):2129-33).
Examples of neutrophil defensins include neutrophil alpha-defensins and neutrophil beta-defensins.
Examples of neutrophil alpha-defensins include neutrophil alpha-defensin- 1//human neutrophil peptide (HNP)-1 (J Clin Invest. 1985 Oct; 76(4):1436-9; Paulsen
F et al, J Pathol. 2002 Nov;198(3):369-77), neutrophil alpha-defensin-2/HNP-2 (J
Clin Invest. 1985 Oct; 76(4):1436-9; Paulsen F et al., J Pathol. 2002 Nov;198(3):369- 77), neutrophil alpha-defensin-3/HNP-3 (J Clin Invest. 1985 Oct;76(4):1436-9;
Paulsen F et al, J Pathol. 2002 Nov;198(3):369-77), neutrophil alpha-defensin- 1s 4/HNP-4 (Mol Immunol. 2003 Nov;40(7):463-7), human defensin-5 (HD-5; D.E. ’
Jones and C.L. Bevins, J. Biol. Chem. 267 (1992), pp- 23216-23225; J Biol Chem. . 1992 Nov 15:267(32):23216-25; Mol Immunol. 2003 Nov;40(7):469-75; Quayle AJ et al., Am. J. Pathol. 1998, 152:1247-1258; FEBS Lett. 1993 Jan 4;315(2):187-92;
D.E. Jones and C.L. Bevins, FEBS Lett. 315 (1993); Paulsen F et al., J Pathol. 2002
Nov;198(3):369-77), and human defensin-6 (HD-6; Mol Immunol. 2003
Nov;40(7):463-7), human defensin-5 (HD-5; D.E. Jones and C.L. Bevins, J. Biol.
Chem. 267 (1992), pp. 23216-23225; J Biol Chem. 1992 Nov 15;267(32):23216-25;
Mol Immunol. 2003 Nov;40(7):469-75; Quayle AJ et al, Am. J. Pathol. 1998, 152:1247-1258; FEBS Lett. 1993 Jan 4;315(2):187-92; D.E. Jones and C.L. Bevins,
FEBS Lett. 315 (1993); Paulsen F et al., J Pathol. 2002 Nov;198(3):369-77).
Examples of cathelicidins include LL-37/hCAP18 (LL-37) in humans (Curr
Drug Targets Inflamm Allergy. 2003 Sep;2(3):224-31; Eur J Biochem. 1996 Jun ; 1;238(2):325-32; Paulsen F et al., J Pathol. 2002 Nov;198(3):369-77). LL-37 is a 37 amino acid residue peptide corresponding to amino acid residue coordinates 134-170 . 30 of its precursor hCAP18/human cathelicidin antimicrobial peptide protein (GenBank:
ACCESSION NP 004336; VERSION NP_004336.2 G1L:39753970; REFSEQ: accession NM_004345.3). The proliferation and angiogenesis pathway of LL-37 can be inhibited using pertussis toxin, an inhibitor of G-protein coupled receptors
(Koczulla, R. et al., 2003. J.Clin.Invest 111:1665-1672). Similar AMPs/AMLs are listed in the following patent applications: US 2003120037, US 200309626, . US20020141620, US20020507, CA 2383172, US 20020072495 and are incorporated by reference herein. The human antibacterial cathelicidin precursor hCAP-18, is . 5 synthesized in myelocytes and metamyelocytes and localizes to specific granules in neutrophils (Blood. 1997 Oct 1;90(7):2796-803).
Examples of AMP-like molecules include chemokines or fragments thereof.
Examples of such chemokines include CC chemokines and CXC chemokines.
Considerable overlap of chemokine and AMP functions has been demonstrated (Cole et al, 2001. J. Immunol. 167:623), and certain chemokines and defensins have actually been shown to bind to the same chemokine receptor, CCR6. Defensins and certain chemokines strikingly share similar characteristics, including size, disulfide bonding, interferon (IFN) inducibility, cationic charge, and more. Relevant similarities between chemokines and AMPs are described in the literature (refer, for example, to Durr and Peschel, 2002. Infection and Immunity 70:6515). As such various chemokines and antibodies specific for such chemokines may be employed in various applications of the present invention.
Examples of such CC chemokines include CCL1, CCL5/RANTES (Infect
Immun. 2002 Dec;70(12):6524-33; Eur J Biochem 1996 Apr 1;237(1):86-92), CCLS,
CCL11, CCL17, CCL1S, CCL19, CCL20/activation-regulated chemokine (LARC)/macrophage inflammatory protein-3alpha (MIP-3alpha)/Exodus-1/Scya20 (Yang D et al., Journal of Leukocyte Biology Volume 74, September 2003;74(3):448- 55), CCL21, CCL22, CCL25, CCL27/CTACK, and CCL28 (J Biol Chem. 2000 Jul 21;275(29):22313-23; J Immunol. 2003 Feb 1;170(3):1452-61). CCL chemokines are described in Yang D et al, Journal of Leukocyte Biology Volume 74, September 2003;74(3):448-55.
Examples of such CXC chemokines include CXCLI, CXCL2, CXCL3, } CXCL4 (PF-4), CXCL7/NAP-2, CXCL8/IL-8, CXCL9 (MIG; Yang D et al., Journal of Leukocyte Biology Volume 74, September 2003;74(3):448-55), CXCL10/IP-10 : 30 (The Jounal of Immunology, 2001, 167: 623-627), CXCL11l/ IP-9/I-TAC (The
Journal of Immunology, 2001, 167: 623-627), CXCL12/SDF-1 (Yang D et al,
Journal of Leukocyte Biology Volume 74, September 2003;74(3):448-55), CXCL13,
CXCL14, connective tissue activating peptide 3 (CTAP-3; Infect Immun. 2002
Dec;70(12):6524-33; Eur J Biochem 1996 Apr 1;237(1):86-92), and CTAP-3 precursor platelet basic protein. CXC chemokines are described in Yang D ef al,
Journal of Leukocyte Biology Volume 74, September 2003;74(3):448-55.
Examples of fibrinopeptides include fibrinopeptide-A (Infect Immun. 2002 : 5 Dec;70(12):6524-33; Eur J Biochem 1996 Apr 1;237(1):86-92), fibrinopeptide-B (Infect Immun. 2002 Dec;70(12):6524-33; Eur J Biochem 1996 Apr 1;237(1):86-92).
Examples of AMPs/AMLs further include XCL1 (Yang D et al., Journal of
Leukocyte Biology Volume 74, September 2003;74(3):448-55), MIP-1beta (Yang D et al., Journal of Leukocyte Biology Volume 74, September 2003;74(3):448-55).
Further examples of AMPs/AMLs include adrenomedullin (Regul Pept. 2003
Apr 15;112(1-3):147-52; J Biol Chem 1998 Jul 3;273(27):16730-8), alpha-melanocyte stimulating hormone (Cutuli M et al, J Leukoc Biol. 2000 Feb;67(2):233-9;
Neuroimmunomodulation-2002-2003;10(4):208-16), an angiogenin (Nature
Immunology, March 2003), angiogenin-4 (Nature Immunology, March 2003), antibacterial peptides B/enkelytin (Neuroimmunol 2000 Sep 22:;109(2):228-35), antileukoprotease (ALP; Biochem Biophys Res Commun. 1998 Jul 30;248(3):904-9;
Am J Respir Crit Care Med 1999 Jul;160(1):283-90), a lymphokine-activated killer cell-derived antimicrobial peptide, a platelet-derived antimicrobial peptide, antimicrobial peptide PR39, an apolipoprotein, an apolipoprotein-C, apolipoprotein-
C2 (Hypertens Pregnancy 2002;21(3):199-204; Peptides. 2000 Mar;21(3):327-30), apolipoprotein-C3 (Hypertens Pregnancy 2002;21(3):199-204; Peptides. 2000
Mar:21(3):327-30), an apolipoprotein-E (Hypertens Pregnancy 2002;21(3):199-204;
Peptides. 2000 Mar;21(3):327-30), apolipoprotein-E2 (Brain Res 1997 Feb 21;749(1):135-8; Biochemistry 2002 Oct 1;41(39):11820-3; Eur J Clin Chem Clin
Biochem 1997 Aug;35(8):581-9), a bactericidal/permeability-increasing protein (Paulsen F et al, J Pathol. 2002 Nov;198(3):369-77; Mol Microbiol 1995 Aug 17:523-31; J Biol Chem 1987 Nov 5;262(31):14891-4), a bone morphogenetic protein . (BMP), BMP-2/4, BMP-5, buforin, calcitermin (FEBS Lett. 2001 Aug 24;504(1-2):5- 10), a cathepsin, cathepsin B, cathepsin G, cathepsin K, a lysosomal cathepsin, a : 30 chromogranin (Blood 2002 Jul 15;100(2):553-9), chromogranin A (Blood 2002 Jul 15;100(2):553-9), chromogranin B (Blood 2002 Jul 15;100(2):553-9), chymase (Immunology 2002 Apr;105(4):375-90), connective tissue activating peptide-3, cystatin (APMIS. 2003 Nov;111(11):1004-1010; Biol Chem Hoppe Seyler 1988
May;369 Suppl:191-7), DCD-1 (J Immunol Methods. 2002 Dec 1;270(1):53-62), dermicidin (Nat ~~ Immunol. 2001 Dec;2(12):1133-7), elastase-specific ] inhibitor/SKALP (skin-derived antileucoproteinase)/elafin (Biochem Soc Trans. 2002
Apr;30(2):111-5; J Invest Dermatol 2002 Jul;119(1):50-5), eNAP-1, eosinophil : 5 cationic protein (Peptides. 2003 Apr;24(4):523-30; J Immunol 2002 Mar 168:2356- 64; Eur J Biochem 1996 Apr 1;237(1):86-92; Peptides. 2003 Apr;24(4):523-30; J Exp
Med 1989 Jul 1;170(1):163-76), ESC42, ESkine, FALL-39 (Proc Natl Acad Sci U S
A. 1995 Jan 3;92(1):195-9), Fas ligand (FasL; Berthou C ef al, J Immunol. 1997 Dec 1;159(11):5293-300), fractalkine, a glycosaminoglycan, granulysin (Reprod Biol
Endocrinol. 2003 Nov 28; J Immunol. 2003 Mar 15;170(6):3154-61; Cancer Immunol
Immunother. 2002 Jan;50(11):604-14. Epub 2001 Nov; Expert Opin Investig Drugs. 2001 Feb;10(2):321-9), granzyme B (Berthou C et al, J Immunol. 1997 Dec 1;159(11):5293-300), HAX-1, heparin binding protein/CAP37 (Paulsen F et al., J
Pathol. 2002 Nov;198(3):369-77; J Clin Invest 1990 May;85(5):1468-76), a hepcidin (J Biol Chem. 2001 Mar 16;276(11):7806-10. Epub 2000 Dec 11; Eur J Biochem 2002 Apr 269:2232-7), an HE2, HE2alpha (Biol Reprod. 2002 Sep;67(3):804-13), an
HE2alpha C-terminal fragment (Biol Reprod. 2002 Sep;67(3):804-13), HE2betal (Biol Reprod. 2002 Sep;67(3):804-13), an HE2-gene derived transcript, histatin (Antimicrob Agents Chemother 2001 Dec 45:3437-44; Biochem Cell Biol. 1998;76(2-3):247-56), a histone, histone H2A, histone H-2b (Peptides. 2003
Apr;24(4):523-30; J Immunol 2002 Mar 168:2356-64; Eur J Biochem 1996 Apr 1;237(1):86-92), HMG-17, HtpG, an HtpG homolog, HSI binding protein, interleukin-8, lactoferrin (Eur J Nucl Med. 2000 Mar;27(3):292-301; Paulsen F ef al,
J Pathol. 2002 Nov;198(3):369-77; J Mammary Gland Biol Neoplasia 1996
Jul;1(3):285-95), a lymphokine-activated killer (LAK) cell AMP (Hua Xi Yi Ke Da
Xue Xue Bao 2002 Jan;33(1):87-90), lysozyme (Paulsen F et al, J Pathol. 2002
Nov;198(3):369-77; Anat Embryol (Berl) 2002 Jul;205(4):315-23), a macrophage . inflammatory protein (MIP), MIP-1alpha, MIP-1beta, MIP-3alpha, a mast cell granule serine proteinase (Immunology 2002 Apr;105(4):375-90), a matrix metalloproteinase : 30 (MMP), MMP-2, MMP-7 (Paulsen F er al, J Pathol. 2002 Nov;198(3):369-77), migration inhibitory factor (J Immunol. 1998 Sep 1;161(5):2383-90; Scand J Infect
Dis. 2003;35(9):573-6), MMP-9, MRPS (Behring Inst Mitt. 1992 Apr;(91):126-37),
MRP14 (Behring Inst Mitt. 1992 Apr;(91):126-37), neutrophil gelatinase-associated lipocalin (NGAL; Exp Dermatol. 2002 Dec;11(6):584-91; Mol Cell. 2002
Nov;10(5):1033-43), neutrophil lysozyme (Int J Antimicrob Agents. 1999 . Sep;13(1):47-51), an opioid peptide, perforin (Berthou C er al., J Immunol. 1997 Dec 1;159(11):5293-300), phospholipase A(2) (PLA(2); Peptides. 2003 Apr;24(4):523-30; : 5s J Exp Med 1989 Jul 1;170(1):163-76), platelet basic protein (Infect Immun. 2002
Dec;70(12):6524-33; Eur J Biochem 1996 Apr 1;237(1):86-92), platelet factor-4, psoriasin (J Histochem Cytochem. 2003 May;51(5):675-85; Glaser R ef al, J Invest
Dermatol 117: 768(abstr 015)), retrocyclin (Proc Natl Acad Sci U S A 2002 Feb 19;99(4):1813-8), secretory leukocyte proteinase inhibitor (SLPI; Shugars DC et al,
Gerontology. 2001 Sep-Oct;47(5):246-53; Biochem Soc Trans. 2002 Apr;30(2):111- 5; J Invest Dermatol 2002 Jul;119(1):50-5), secretory phospholipase A(2) (Peptides. 2003 Apr;24(4):523-30; J Immunol 2002 Mar 168:2356-64; Eur J Biochem 1996 Apr 1;237(1):86-92; Paulsen F et al, J Pathol. 2002 Nov;198(3):369-77), substance P, an
S100 calcium-binding protein, S100A7, S100A8, S100A9, a thymosin, thymosin beta-4 (Infect Immun. 2002 Dec;70(12):6524-33; Eur J Biochem 1996 Apr 1;237(1):86-92; Infect Immun. 2002 Dec;70(12):6524-33; Eur J Biochem 1996 Apr 1:237(1):86-92), thymus and activation-regulated chemokine (TARC), TL1A, tryptase (Immunology 2002 Apr;105(4):375-90), ubiquicidin (Eur J Nucl Med. 2000
Mar;27(3):292-301; Hiemstra PS, van den Barselaar MT et al., J Leukocyte Biol 1999; 66: 423-428; J Nucl Med 2001 May 42:788-94), and urokinase-type plasminogen activator.
The AMP/AML may any one of 28 potential candidates for defensin like peptides which were computationally discovered. (Am J Respir Cell Mol Biol. 2003
Jul;29(1):71-80).
As described hereinabove, the present invention can be used to treat any of various diseases which are associated with: (i) a tumor; (ii) inflammation; (iit) an epithelial wound; (iv) dysregulation of growth/differentiation of a cell/tissue; (v) dysregulation of growth/differentiation balance of a cell/tissue; and/or (vi) angiogenesis. : 30 Examples of diseases which can be treated according to the present invention are listed in U.S. Patent Application No. @@@.
Examples of diseases which can be treated according to the present invention are also as follows.
Examples of tumors include a skin tumor, a keratinocytic tumor, a gastrointestinal tumor, a carcinoma, a melanoma, a squamous cell tumor, oral } squamous cell carcinoma, lymphoma, a malignant tumor, a benign tumor, a solid tumor, a metastatic tumor and a non-solid tumor. : 5 The concentration of human beta-defensin-2 in oral squamous cell carcinoma is much higher than in normal oral epithelium (Sawaki, K. et al., 2002. Anticancer
Res. 22:2103-2107). There is a genetic link between proliferation of cells and cancer.
Impairment of regulation of proliferation and differentiation lead to cancer development. A developing tumor needs help from neighboring cells in order to become cancerous. Overexpression or overactivity of cytokines is involved in orchestrating these processes. Continuous assault by chronic inflammation contributes to the transformation of cells as well. Angiogenesis is an important process for cancer development. AMPs are inductors of angiogenesis (Koczulla, R. ef al, 2003. I.Clin.Invest 111:1665-1672). Therefore inhibiting differentiation and proliferation as well as angiogenesis by antagonists to AMPs and cytokines can be used to treat cancer. Urokinase-type plasminogen activator (uPA), has antimicrobial properties (Gyetko, MR. et al., 2002. J.Immunol. 168:801-809) and is involved in metastatic spreading of malignant cells. The in vitro and in vivo findings suggest that alpha-defensins are frequent peptide constituents of malignant epithelial cells in renal cell carcinoma with a possible direct influence on tumor proliferation (Muller, CA. et al, 2002. Am.J.Pathol. 160:1311-1324). Certain anti-angiogenic compounds were found to have potent anticancer property in vivo experimental studies. Therefore inhibition of angiogenic AMPs such as LL-37 is one form of treatment for cancer.
Matrix metalloproteinases (MMPs) are known to play an important role in extracellular matrix remodeling during the process of tumor invasion and metastasis.
Overexpression of MMP-2 and MMP-9 proteins was observed in a large percentage of ESCC tumors, respectively localized in tumor cell cytoplasm and stromal elements : (J Cancer Res Clin Oncol. 2003 Oct 16).
BMP-2/4 and BMP-5 but not BMPR-IA might be involved in the metastasis of : 30 oral carcinoma cells (Overexpression of BMP-2/4, -5 and BMPR-IA associated with malignancy of oral epithelium Oral Oncol. 2001, 37:225-33.)
Examples of diseases associated with an epithelial wound include a healing deficiency, an ulcer, a skin ulcer, a bed sore, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, and a diabetes related healing deficiency.
Examples of diseases include an idiopathic/inflammatory disease, a chronic/inflammatory disease, an acute/inflammatory disease, an : 5 inflammatory/cutaneous disease, an inflammatory/gastrointestinal disease, a tumor associated with inflammation, an allergic disease, an autoimmune disease, an infectious disease, a malignant disease, a transplantation related disease, an inflammatory/degenerative disease, an injury associated with inflammation, a disease associated with a hypersensitivity, an inflammatory/cardiovascular disease, an inflammatory/glandular ~~ disease, an inflammatory/hepatic disease, an inflammatory/neurological disease, an inflammatory/musculo-skeletal disease, an inflammatory/renal ~~ disease, an inflammatory/reproductive disease, an inflammatory/systemic disease, an inflammatory/connective tissue disease, an inflammatory/neurodegenerative disease, necrosis, an inflammatory disease associated with an implant, an inflammatory/hematological disease, an inflammatory/eye disease, an inflammatory/respiratory disease.
Examples of cutaneous/inflammatory diseases include psoriasis, dandruff, pemphigus vulgaris, lichen planus, atopic dermatitis, scleroderma, dermatomyositis, alopecia, blepharitis, skin carcinoma, melanoma, squamous cell carcinoma, acne vulgaris, erythema toxicum neonatorum, folliculitis, skin wrinkles, autoimmune bullous skin disease, bullous pemphigoid, pemphigus foliaceus, dermatitis, and drug eruption. , Dandruff can be classed as an inflammatory, abnormal proliferative or abnormal differentiation disease whereby flaky skin on the scalp protrudes, as with psoriasis, due to abnormalities in proliferation/differentiation balance caused by over reactivity of AMPs such as LL-37 and the defensins. Statistical surveys in Swedish population showed a correlation between dandruff and psoriasis. People with a genetic (in-the-family) risk of developing psoriasis have a significantly higher proportional rate of dandruff sufferers. Therefore the psoriasis treatment method : 30 described by the present invention is applicable to treatment of psoriasis.
Examples of gastrointestinal/inflammatory diseases include Crohn’s disease, chronic autoimmune gastritis, autoimmune atrophic gastritis, primary sclerosing cholangitis, autoimmune achlorhydra, colitis, ileitis, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, an eating disorder, gallstones and a gastrointestinal ulcer. } Crohn’s disease is an inflammatory bowel disease. Since the bowel is exposed to the outer environment, the importance of AMPs as part of its defense and normal : 5 cellular regulation is important, as in skin, and the activity of the AMPs plays an important role in the normal physiology as well as pathological conditions in these tissues. Abnormalities in the expression and/or activity of the AMPs will contribute to pathologies in these tissues. Paneth cells (a specific type of cell in the intestine) are required to help promote normal vessel formation in cooperation with bacteria — mice absent Paneth cells were incapable of appropriate blood vessel formation. Of note, colonization by one particular type of bacteria commonly found in normal mouse and human intestine, called Bacteroides thetaiotaomicron, or B. thetaiotaomicron, stimulated blood vessel development as efficiently as implantation of a whole microbial society. The conclusion, B. thetaiotaomicron and Paneth cells work together to stimulate postnatal blood vessel formation. The ability of AMPs to act as chemoattractants for cells of the innate- and adaptive-immune system plays an important role in perpetuating chronic inflammation in the gastrointestinal tract (Cunliffe, RN, Mahida, YR., 2003. J Leukoc Biol. Oct 2 [Epub ahead of print]). The
AMP LL-37, beta-defensins, human alpha-defensins, beta-defensins (including HDS),
HN-6, lysozyme and secretory PLA2, TL1A, are expressed in Paneth cells and intestine, secretory epithelial cells in the small intestine (Ghosh, D. et al., 2002.
Nat.Immunol. 3:583-590; Fellermann, K. et al., 2003. Eur. J. Gastroenterol. Hepatol. 15:627-634). Where alpha-defensins are overexpressed, they are chemoattract naive
T and immature dendritic cells and dendritic cells and monocytes (Yang, D. et al, 2000. J. Leukoc. Biol. 68:9-14; Risso, A., 2000. J. Leukoc. Biol. 68:785-792; Territo,
MC. et al, 1989. J.Clin.Invest 84:2017-2020). Human alpha-defensins as well as other AMPs contribute to local intestinal host defense as part of innate immunity and ) may be of major relevance in microbial infection and chronic inflammatory bowel disease (Wehkamp, J. et al., 2002. Dig. Dis. Sci. 47:1349-1355). The alpha-defensins convert an acute inflammation to a chronic inflammation by downregulating human polymorphonuclear leukocyte chemotaxis, for example, alpha-defensin-1/human neutrophil protein-1, acts as an antichemotactic agent for human polymorphonuclear leukocytes). It is known that chronic inflammation is commonly characterized by the presence of increased cell proliferation and connective tissue than exudate with the presence of lymphocytes and plasma cells rather than polymorphonuclear leukocytes. ] Thus, suitable regulation of such AMPs/AMLs can be used to treat diseases such as inflammatory bowel disease, Crohn’s disease and ulcerative colitis. : 5 Gastritis is an inflammatory condition of the stomach. There are two main forms of gastritis, A and B. Gastritis type A is considered to develop in an autoimmune process. In both types there is a role for infectious agents such as
Helicobacter pylori. AMPs are involved in both processes. Defensins are involved in pathogenesis of gastritis (Bajaj-Elliott, M. er al., 2002. Gut 51:356-361). Thus, suitable regulation of such AMPs/AMLs can be used to treat diseases such as gastritis.
Examples of allergic/inflammatory diseases include asthma, hives, urticaria, a pollen allergy, a dust mite allergy, a venom allergy, a cosmetics allergy, a latex allergy, a chemical allergy, a drug allergy, an insect bite allergy, an animal dander allergy, a stinging plant allergy, a poison ivy allergy, anaphylactic shock, anaphylaxis, atopic allergy and a food allergy.
Examples of hypersensitivity include Type I hypersensitivity, Type 11 hypersensitivity, Type III hypersensitivity, Type IV hypersensitivity, immediate hypersensitivity, antibody mediated hypersensitivity, immune complex mediated hypersensitivity, T lymphocyte mediated hypersensitivity, delayed type hypersensitivity, helper T lymphocyte mediated hypersensitivity, cytotoxic T lymphocyte mediated hypersensitivity, TH1 lymphocyte mediated hypersensitivity, and TH2 lymphocyte mediated hypersensitivity.
Examples of cardiovascular/inflammatory and/or inflammatory/hematological diseases include atherosclerosis, Takayasu’s arteritis, polyarteritis nodosa, Raynaud’s phenomenon, temporal arteritis, inflammatory anemia, inflammatory lymphopenia, pernicious anemia, occlusive disease, myocardial infarction, thrombosis, Wegener’s granulomatosis, lymphoma, leukemia, Kawasaki syndrome, anti-factor VIII ] autoimmune disease, necrotizing small vessel vasculitis, microscopic polyangiitis,
Churg and Strauss syndrome, pauci-immune focal necrotizing glomerulonephritis, : 30 crescentic glomerulonephritis, antiphospholipid syndrome, antibody induced heart failure, thrombocytopenic purpura, autoimmune hemolytic anemia, cardiac autoimmunity, Chagas’ disease, iron-deficiency anemia, and anti-helper T lymphocyte autoimmunity.
Inflammation is part of the pathological process leading to the development of atherosclerosis. Chlamydia pneumonia as well as other various Microorganisms serve . as potential etiological factors, linking inflammation and atherosclerosis.
Inflammation is a predisposing factor as well as a consequence of several CNS ‘ 5 pathologies. Inflammation is part of the pathophysiologic processes occurring after the onset of cerebral ischemia in ischemic stroke, as well as other CNS pathologies such as head injury and subarachnoid hemorrhage. In addition, inflammation in the
CNS or in the periphery by itself is considered as a risk factor for the triggering the development of cerebral ischemia. Endothelial cells express and secrete AMPs.
Cationic antimicrobial protein of 37 kDa (CAP37) also termed heparin binding protein, originally isolated from human neutrophils, is an important multifunctional inflammatory mediator is expressed within the vascular endothelium associated with atherosclerotic plaques (Lee, TD. et al., 2002. Am.J.Pathol. 160:841-848). Human beta-defensin-2 is expressed by astrocytes and its expression is increased in response to cytokines and LPS (Hao, HN. er al, 2001 J Neurochem. 77:1027-1035).
Therefore, AMP inhibition can be used for treatment or prevention of these conditions.
Anemia associated with inflammatory/chronic diseases is one of the body’s methods of fighting pathogens by reducing available inter cellular iron uptake of pathogens. Iron is absorbed by neutrophils. Sometimes chronic inflammation can occur without the presence of pathogens. Under chronic inflammatory conditions, cytokines induce a diversion of iron traffic leading to hypoferremia. Such as in chronic bacterial endocarditis, osteomyelitis, juvenile rheumatoid arthritis, rheumatic fever, Crohn's disease, and ulcerative colitis and Chronic renal failure. Transferrin bound iron transports to monocytes causing anemia. This “transport” is thought to be related to AMP activity. Cytokines IL-1, IL-6 and TNF-beta initiate defensin production and defensin initiate the cytokine production, the result being iron over : absorption by monocytes. The regulation of iron transport by cytokines is a key mechanism in the pathogenesis of anemia of chronic disease (Ludwiczek, S. et al, } 30 2003. Blood 101:4148-4154). Therefore, regulation of AMPs can be used to regulate iron level homeostasis. Hepcidin AMP is known to regulate iron uptake, therefore inhibiting hepcidin can be used to increase iron absorption (Nicolas, G. et al., 2002.
Blood Cells Mol.Dis. 29:327-335). However, there are other AMPs indirectly involved in iron regulation such as defensin and LL-37. Since HNP-1 is a non- specific defensive peptide present in neutrophils, it plays an important role in the protection against diseases such as oral lichen planus, leukoplakia, and glossitis associated with iron deficiency (Mizukawa, N. et al, 1999. Oral Dis. 5:139-142). : s Likewise all cationic neutrophil derived AMPs would induce iron hypoferremia when over expressed. Therefore inhibition of these AMPs can be used to treat such : diseases.
Leukocyte SLPI (secretory leukocyte proteinase inhibitor (SLPI)) expression seems to be up-regulated in active Wegner’s granulomatosis, therefore inhibiting its activity can be used to treat diseases such as Wegener's granulomatosis and other types of vasculitis
Examples of glandular/inflammatory diseases include type I diabetes, type II diabetes, type B insulin resistance, Schmidt's syndrome, Cushing’s syndrome, thyrotoxicosis, benign prostatic hyperplasia, pancreatic disease, Hashimoto’s thyroiditis, idiopathic adrenal atrophy, Graves’ disease, androgenic alopecia, thyroid disease, thyroiditis, spontaneous autoimmune thyroiditis, idiopathic myxedema, ovarian autoimmunity, autoimmune anti-sperm infertility, autoimmune prostatitis,
Addison's disease, and Type I autoimmune polyglandular syndrome.
Diabetes mellitus is a systemic disease with several major complications affecting both the quality and length of life. One of these complications is periodontal disease (periodontitis). Periodontitis is much more than a localized oral infection. (Tacopino, AM., 2001. Ann.Periodontol. 6:125-137). When diabetes mellitus is under therapeutic control, periapical and other lesions heal as readily as in nondiabetics (Bender, 1B, Bender, AB. et al, 2003. J.Endod. 29:383-389). Recent studies on diseases which involve insulin insensitivity (e.g. obesity, type 2 diabetes and atherosclerosis) also show increased cytokine production and markers of inflammation. Evidence at present favors chronic inflammation as a trigger for chronic insulin insensitivity, rather than the reverse situation. (Grimble, RF., 2002.
Curr.Opin.Clin. Nutr. Metab Care 5:551-559). Recent human studies have established : 30 a relationship between high serum lipid levels and periodontitis. Possible causes are a high glucose levels (such as hyperglycemia of diabetics) with added LDL levels such as in high diabetic patients are prone to elevated low density lipoprotein cholesterol and triglycerides (LDL/TRG) even when blood glucose levels are well controlled,
lead to LPS-like bondings that induce AMP overexpression. Thus, the present invention can be used to treat diabetes and diabetes related diseases such as . periodontitis and diabetes associated healing deficiencies.
Proliferative retinopathy is one of the chronic complications of diabetes. The : 5 process includes the development of abnormal blood vessels that might lead to retinal detachment and blindness. LL37 and other AMPs are involved in angiogenesis (Koczulla, R. et al, 2003. J.Clin.Invest 111:1665-1672), therefore antibodies and antagonists to LL-37 can be used to prevent the development of newly formed blood vessels and therefore for preventing diabetes related eye diseases.
Examples of hepatic/inflammatory diseases include primary biliary cirrhosis, active chronic hepatitis, lupoid hepatitis, autoimmune hepatitis, and hepatic cirrhosis.
Examples of neurological/inflammatory diseases include neurodegenerative disease, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, myasthenia gravis, motor neuropathy, Guillain-Barre syndrome, autoimmune neuropathy,
Lambert-Eaton myasthenic syndrome, paraneoplastic neurological disease, paraneoplastic cerebellar atrophy, non-paraneoplastic stiff man syndrome, progressive cerebellar atrophy, Rasmussen’s encephalitis, amyotrophic lateral sclerosis, Sydeham chorea, Gilles de la Tourette syndrome, autoimmune polyendocrinopathy, dysimmune neuropathy, acquired neuromyotonia, arthrogryposis multiplex, optic neuritis, spongiform encephalopathy, migraine, headache, cluster headache, and stiff-man syndrome.
With respect to multiple sclerosis (MS), defensins and lactoferrins exist in cerebrospinal fluid (CSF). These peptides have antimicrobial expression in some diseases like pneumonia and meningitis, which may trigger a pathway. It seems that pathways to MS are similar to rheumatoid arthritis where AMPs reside in the synovial fluid surrounding the joint. Peptides involved are amongst others: IP-10, defensins and lactoferrins, CAP37.
There is a relationship between polymorphism at the apolipoprotein E2 Apo(a) locus relation to Alzheimer's disease (AD; Barbier, A. et al, 1997. : 30 Fur.J.Clin.Chem.Clin.Biochem. 35:581-589; Compton, D. ef al., 2002. Neurosci.Lett. 331:60-62). ApoE has antimicrobial properties and therefore regulating this molecule can be use to treat Alzheimer’s disease. Essentially, all polymorphisms of this peptide are somehow involved in the pathogenesis of the disease however the e4 isoform is more active. People with the e4/e4 genotype have the highest risk, but people with the e2/e4 or e3/e4 genotypes are also likely to develop the disease. While the APOE . e4 allele defines a greater risk, the presence of e4 cannot alone predict the disorder prior to the onset of symptoms — only 40 percent of all Alzheimer's patients have the 5s e4 allele. The ed allele is also associated with higher cholesterol absorption which leads to higher cholesterol levels in the blood. The e4/e4 genotype is found in only 1- 3 percent of the Westernized population. However, the probability that a Westernized individual with the e4/e4 genotype will develop Alzheimer's disease is 60 percent, with women at greater risk than men. For individuals who consume high-cholesterol diets, having the e4 allele may also increase the risk of coronary artery disease.
Complex formation with ApoE enhances internalization of soluble Abeta uptake into terminals. LPS-induced astrogliosis in ApoE transgenic mice is regulated isoform- specifically by ApoE3 and not by ApoE4 and suggest that similar mechanisms may mediate the phenotypic expression of the ApoE4 genotype in AD and in other neurodegenerative diseases. Therefore inhibitors of the present invention specific for this protein polymorphism can prevent or delay the onset of Alzheimer disease (Rebeck, GW. et al., 2002. J. Alzheimers. Dis. 4:145-154). The beneficial non-rejected
ApoE2 and E3 is introduced as a replacement (via injection or otherwise) in conjunction with the monoclonal antibody/antagonist to the “bad” isomer/isozyme/polymorphic protein at its specific site (the analogue) responsible for the onset of Alzheimer’s disease (Baum, L. et al., 2000. Microsc.Res. Tech. 50:278- 281). In AD but not in controls, the cerebral microcirculation expresses the inflammatory mediator AMP CAP37, the heparin binding protein (Grammas, P., 2000. Neurobiol. Aging 21:199-205). Antibody and antagonists to CAP37 can therefore also be used for treating Alzheimer’s disease (Pereira, HA. er al., 1996.
Neurobiol. Aging 17:753-759; Neurobiol Aging, 2002, 23:531-6). FPRL1, an LL-37 receptor therefore constitutes a molecular target for the development of therapeutic
X agents for Alzheimer Disease (Cui, Y. ef al, 2002. J .Leukoc.Biol. 72:628-635). LL- 37 acts in parallel with A(beta) peptides in activating the same G-protein-coupled ) 30 chemoattractant receptor, FPR-Like-1 (Le, Y. et al., 2001. J Neurosci. 21:RC123).
Examples of connective tissue/inflammatory diseases include arthritis, rheumatoid arthritis, pyogenic arthritis, mixed connective tissue disease, cholesteatoma, relapsing polychondritis, autoimmune myositis, primary Sjogren’s syndrome, smooth muscle autoimmune disease, myositis, tendinitis, a ligament inflammation, chondritis, a joint inflammation, a synovial inflammation, carpal tunnel } syndrome, osteoarthritis, ankylosing spondylitis, a skeletal inflammation, an autoimmune ear disease, osteoporosis, fibromyalgia, periodontitis, and an : 5 autoimmune disease of the inner ear.
With respect to diseases such as arthritis, AMPs are expressed and produced in healthy and inflamed human synovial membranes. Deposition of the AMPs lysozyme, lactoferrin, secretory phospholipase A(2) (sPA(2)), matrilysin (MMP7), human neutrophil alpha-defensin-1, -2, and -3, human beta-defensi-1, and human beta-defensin-2 was determined by immunohistochemistry. Expression of mRNA. for the AMPs bactericidal permeability-increasing protein (BPI), heparin binding protein,
LL37, human alpha-defensin-5, human alpha-defensin-6, and human beta-defensin-1, 2, and -3 was analyzed by reverse transcription-polymerase chain reaction (RT-
PCR). RT-PCR revealed CAP37 and human beta-defensin-1 mRNA in samples of healthy synovial membrane. Additionally, human beta-defensin-3 and/or LL37 mRNA was detected in synovial membrane samples from patients with pyogenic arthritis ~~ (PA), osteoarthritis (OA) or rheumatoid arthritis (RA).
Immunochistochemistry has identified lysozyme, lactoferrin, sPA(2), and MMP7 in type A synoviocytes of all samples. Human beta-defensin-1 was only present in type
B synoviocytes of some of the samples. Immunoreactive human beta-defensin-2 peptide was only visible in some inflamed samples. HNP1-3 was detected in both healthy and inflamed synovial membranes. The data suggest that human synovial membranes produce a broad spectrum of AMPs. Under inflammatory conditions, the expression pattern changes, with induction of human beta-defensin-3 in PA (LL37 in
RA; human beta-defensin-3 and LL37 in OA) as well as down-regulation of human beta-defensin-1 (Paulsen, F. et al, 2002. J.Pathol. 198:369-377; Cunliffe, RN,
Mahida, YR., 2003. J Leukoc Biol. Oct 2 [Epub ahead of print]). Thus blocking one or more of these proteins or their activity will inhibit the pathological process in a disease such as arthritis. : 30 Microbial mixed keratin-biofilms in cholesteatomas are caused by AMPs which are overexpressed (Jung, HH. et al, 2003. Laryngoscope 113:432-435; Chole,
RA, Faddis, BT., 2002 Arch.Otolaryngol. Head Neck Surg. 128:1129-1133), AMPs such as LL-37 or other defensins or other AMPs are involved. Therefore, suitable regulation of such AMPs can be used for treating diseases such as cholesteatomas.
Examples of inflammatory/renal diseases include diabetic nephropathy.
High glucose levels (such as hyperglycemia of diabetics) with added LDL levels such as in high diabetic patients are prone to elevated low density lipoprotein : 5s cholesterol and triglycerides (LDL/TRG) even when blood glucose levels are well controlled, and lead to LPS-like bondings that induce AMP overexpression.
Overexpression of beta-defensin-1 mRNA plays a role in diabetic nephropathy (Page,
RA, Malik, AN. et al., 2003. Biochem.Biophys.Res.Commun. 310:513-521). The cytotoxic activity of defensins can be correlated to the location of the inflammation in the kidney where defensins play a role in the pathogenesis of chronic glomerulonephritis and pyelonephritis (Rebenok, AZ. et al, 1999. Ter. Arkh. 71:62- 67). Therefore inhibiting such AMPs can be used to treat diabetic nephropathy.
Examples of inflammatory/reproductive diseases include repeated fetal loss, ovarian cyst, or a menstruation associated disease.
Examples of inflammatory/systemic diseases include systemic lupus erythematosus, systemic sclerosis, septic shock, toxic shock syndrome, Reiter’s syndrome, and cachexia.
Examples of inflammatory/infectious diseases include candidiasis, a fungal infection, mycosis fungoides, a chronic infectious disease, a subacute infectious disease, an acute infectious disease, a viral disease, a bacterial disease, a protozoan disease, a parasitic disease, a mycoplasma disease, gangrene, sepsis, a prion disease, influenza, tuberculosis, bacterial pneumonia, malaria, acquired immunodeficiency syndrome, chronic fatigue syndrome, and severe acute respiratory syndrome.
LL-37 binds to surface proteins of fungi and bacterial LPS. LL-37 is not hostile to fungi in saline solution (Turner, J. et al, 1998. Antimicrob.Agents
Chemother. 42:2206-2214). Likewise, not all AMPs are hostile to Candida.
Therefore inhibiting LL-37 and to other AMPs that are not hostile to fungi can be used to prevent the adhesion of fungi to cells, and hence to treat fungal diseases.
Examples of transplantation related/inflammatory diseases include graft : 30 rejection, chronic graft rejection, subacute graft rejection, acute graft rejection hyperacute graft rejection, rejection of an implant and graft versus host disease.
Examples of implants include a prosthetic implant, a breast implant, a silicone implant, a dental implant, a penile implant, a cardiac implant, an artificial joint, a bone fracture repair device, a bone replacement implant, a drug delivery implant, a catheter, a pacemaker, an artificial heart, an artificial heart valve, a drug release implant, an electrode, and a respirator tube.
Examples of injury/inflammation include a skin wound, an abrasion, a bruise, : 5 a cut, a puncture wound, a laceration, an impact wound, a concussion, a contusion, a thermal burn, frostbite, a chemical burn, a sunburn, a desiccation, a radiation burn, a radioactivity burn, a smoke inhalation, a torn muscle, a pulled muscle, a torn tendon, a pulled tendon, a pulled ligament, a torn ligament, a hyperextension, a torn cartilage, a bone fracture, a pinched nerve and a gunshot wound.
Examples of inflammatory/respiratory diseases include asthma, allergic asthma, diffuse panbronchiolitis, emphysema, idiopathic pulmonary fibrosis, cystic fibrosis, influenza, sinusitis, sinusitis and chronic obstructive pulmonary disease.
The literature provides evidence that the present invention can be used to treat diseases such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, and sinusitis. Inflammation is stimulated by AMPs (respiratory epithelial, endothelial, bronchus, larynx, kidney, fibroblast, and other endothelial cells). Furthermore, adherence of Haemophilus influenzae to bronchial epithelial cells is enhanced by neutrophil defensins, which are released from activated neutrophils during inflammation (Gorter, AD. et al., 1998. J.Infect.Dis. 178:1067-1074). Adherence of
H. influenzae to various epithelial, fibroblast-like and endothelial cell types was significantly enhanced by defensins. Defensins stimulated also the adherence of
Moraxella catarrhalis, Neisseria meningitidis and nonencapsulated Streptococcus pneumoniae (Gorter, AD. ef al., 2000. FEMS Immunol. Med. Microbiol. 28:105-111),
H. influenzae, M. catarrhalis, N. meningitidis and nonencapsulated , S. pneumoniae.
The chronic inflammation of cystic fibrosis (CF) is associated with increased levels of
AMPs in respiratory tract secretions. However, the CF airway surface fluid - is diminished in its ability to kill bacteria. This defect is reflected in chronic, high-level . bacterial colonization and recurrent pneumonia with organisms such as P. aeruginosa.
The bacteria-killing ability of CF airway fluid is restored when its salt concentration is : 30 lowered to normal levels, suggesting that the abnormally high salt concentrations produced by the defective CF transmembrane conductance regulator might be responsible. The bacterial killing ability of epithelial-derived AMPs such as the human beta-defensins and cathelicidin are inactivated by high salt concentrations,
suggesting a defect in this component of innate immune defense might be responsible for the chronic pulmonary infections seen in CF patients. As with Candidiasis, AMPs . in high saline solutions encourage pathogenic activity by enabling pathogens to cling on to cell surface membranes. High concentrations of defensins have been found in : 5 purulent airway secretions from patients with chromic obstructive pulmonary disease, cystic fibrosis, diffuse panbronchiolitis, increasing infection and disease progression.
Antibodies to defensins 1-6 can therefore reduce infection and inflammation. M. pneumoniae infection contributes to the pathogenesis of chronic asthma at different levels of the airways by inducing the chemokine RANTES in small airways.
Inhibition of RANTES is necessary. Thus, blocking the expression of these and other
AMPs will be advantageous to halting the progression of the disease and to treatment.
Intratracheal instillation of defensins causes acute lung inflammation and dysfunction, suggesting that high concentrations of defensins in the airways may play an important role in the pathogenesis of inflammatory lung diseases (Zhang, H. et al., 2001.
Am.J.Physiol Lung Cell Mol.Physiol 280:L947-L954). They are overexpressed in cystic fibrosis, diffuse panbroncheolitis, idiopathic pulmonary fibrosis and acute respiratory distress syndrome, and in infectious diseases (Aarbiou, J. et al, 2002.
Ann.Med. 34:96-101). In addition to their antimicrobial role, human neutrophil defensins also contribute to adaptive immunity by mobilizing T cells and dendritic cells (Yang, D. et al., 2000. J.Leukoc.Biol. 63:9-14).
Human beta-defensin-2 is expressed in nasal mucosa and is upregulated in a condition of chronic inflammation of the sinus (Chen, PH, Fang, SY., 2003.
Eur.Arch. Otorhinolaryngol. Sep 18 [Epub ahead of print]). Therefore downregulation of human beta-defensin-2 can be used to treat diseases such as sinusitis.
Examples of inflammatory/eye diseases include dry-eye disease, phacogenic uveitis, blepharitis and sympathetic ophthalmia.
Dry eye disease is a chronic inflammatory eye disease. Is particularly an issue for post-menopausal women, the elderly, and patients with systemic diseases such as
Sjogren’s syndrome, rheumatoid arthritis, lupus and diabetes (37% of people with : 30 diabetes suffer from the disease and 28% of adults having the disease). Defensins act as chemokines to T-cells (Stern, ME, et al, 2002. Invest Ophthalmol.Vis.Sci. 43:2609-2614). Upregulation of AMP including human beta-defensin-2 is a feature of dry eye disease. Human beta-defensin-2 was expressed in conjunctival epithelium of patients with moderate dry eye (Narayanan, S. ef al., 2003. Invest
Ophthalmol. Vis.Sci. 44:3795-3801). Therefore inhibiting AMP/AML (especially } human beta-defensin-2) production and activity can be used to treat diseases such as dry-eye disease.
Erythema toxicum neonatorum is a common, inflammatory skin reaction in healthy newborn infants characterized by an accumulation of activated immune cells in the lesions. Its etiology and physiologic significance are still unclear. Recently strong staining for psoriasin was seen in the entire epidermal layer (Marchini, G. et al., 2003. Pediatric Dermatology 20:377-384). Thus, blocking this protein may be beneficial for treating the condition.
The majority of acne biopsies display a marked upregulation of defensin-2 immunoreactivity in the lesional and perilesional epithelium - in particular in pustules - and a less marked upregulation of defensin-1 immunoreactivity (Chronnell, CMT. et al., 2001. Journal of Investigative Dermatology 117:1120-1125).
Folliculitis is a common skin disease with inflammation of the hair follicle, clinically manifested as papules and pustules. It was recently shown by immunohistochemistry that human neutrophil peptide (HNPs) and human beta- defensin-2 are abundantly present in the lesions of superficial folliculitis.
Immunoreactivity for HNPs was observed in infiltrating PMN leukocytes and pustules in the interfollicular spaces. In contrast, immunoreactivity for human beta-defensin-2 was observed in the perilesional and lesional epidermis of the affected hair follicle.
The distribution pattern of human beta-defensin-2 was similar to that in acne vulgaris lesions (Oono, T. et al., 2003. British Journal of Dermatology 148:188-191)
Increased levels of AMP expression appear also appear to be correlated with pathogenesis of diseases such as lichen planus which is associated with elevated levels of beta-defensin, and sarcoidosis which is associated with elevated levels of
LL-37. Cathelicidin levels were found to be increased in inflammatory skin lesions of . erythema toxicum neonatorum, and to apparently correlate with inflammatory/activated neutrophils, eosinophils, and dendritic cells. High levels of : 30 LL-37 have also been demonstrated in epidermis during pathogenesis of verruca vulgaris or condyloma accuminata.
Examples of the disease include aging and aging-related diseases. In the
Examples section, below, it is shown that the keratinocyte proliferation/differentiation balance is affected by the concentration of antimicrobial peptides. Over expressing human beta-defensin-2 on 3-D organotypic skin co-culture models caused the unorganized proliferation of keratinocytes and fibroblasts. Aging of skin and other body tissue has many causes. One major contributor to wrinkles and aging in skin is the buildup of discrepancies and disorganization in collagen proteins. Fibroblasts are cells that produces the collagen matrix surrounding cells therefore increasing the density of fibroblasts implies increasing collagen output thereby rejuvenating skin.
As described in the Examples section below, antibody to human beta-defensin-2 on 3-
D organotypic skin co-culture models showed increased differentiation on account of proliferation of keratinocytes as well as increased proliferation of fibroblasts. This led to more dense fibroblast regions and a better organized skin than the untreated control (normal skin). Both keratinocytes and fibroblasts were organized better than the control untreated skin and there appeared a significant enlargement of normalized epidermal thickness. The result data below shows that AMPs regulate the differentiation/proliferation balance and in so doing their level of concentration in skin determines how well the cells are organized. This demonstrated the importance of AMPs and inhibitors to AMPs for fibroblasts, and therefore collagen as well, as for keratinocyte organization and for anti aging and anti wrinkle therapies for skin. This anti aging therapy should holds true for many body tissues where AMPs can be found.
Complexation or cross linking of fibrils and protofibrils with amps is involved in pathogenesis of age related diseases. As in other chronic inflammatory diseases
AMP inhibitors can prevent inflammation and tissue morphological changes leading to diabetes, Alzheimer’s disease, Parkinson’s disease, and spongiform encephalopathies. The first stages of diabetes commence with high insulin levels leading to overexpression of AMPs which in turn results in morphological changes in pancreatic tissue. This results in systemic underexpression of insulin. In addition, protofibril complexation with AMPs is implicated in diseases such as age-related ] diseases like type II diabetes, Alzheimer's disease, Parkinson's disease, spongiform encephalopathies and other prion diseases, and type II diabetes. Clumps of misfolded : 30 proteins known as amyloid fibrils are involved in killing cells in such diseases.
Smaller structures (protofibrils) formed prior to the mature fibrils, are more likely to get through the cell membrane, and may therefore be the more toxic than fibrils,
Therapeutic efforts have focused on breaking up these deposits. In Alzheimer's disease they are called amyloid plaques; in Parkinson's disease they are called Lewy bodies; in type II diabetes they are called islet amyloid deposits and occur in the vislets of Langerhans, " the area of the pancreas where insulin is produced and regulated. Type II diabetes is one of the most common amyloid-related diseases. : 5 Inhibiting the earlier stage of protofibril formation is essential to preventing age related diseases. It has been shown that chronic inflammatory diseases, like : Alzheimer’s disease for example, involve colocalization of AMPs with amyloid plaques (Pereira, HA. et al., 1996. Neurobiol. Aging 17:753-759). It is postulated that
AMPs form complexes with the protofibrils. Complex formation is controlled by a finely balanced interplay of hydrophobic and electrostatic interactions with none of these two interactions alone being strong enough to ensure complexation under these polar conditions. Evidence for this has been demonstrated where the highly cationic small protein defensin was isolated along with the amyloid A protein from the fibrils (Liepnieks, JJ. et al., 1995. Biochim.Biophys.Acta 1270:81-86). Likewise the antimicrobial protein ApoE4 isoform has an associated higher risk for Alzheimer and is also the most cationic of all the differing isoforms of ApoE differing from ApoE3 by one charge unit and from ApoE2 by two (Mahley, RW, Rall, SC, Jr., 2000.
Annu.Rev.Genomics Hum.Genet. 1:507-537; Castano, EM. et al, 1995.1] .Biol.Chem. 270:17610-17615). The present inventors hypothesize that AMPs (being amongst other things highly cationic and small peptides) act as catalysts or as cross linking initiators with amyloid protein, in light of the close ultrastructural, relationship between sulfated proteoglycans and AA amyloid fibrils (Snow AD. et al., 1987. Lab
Invest. 57:687-98). The present inventors further hypothesize that the complex bonds initiators directly or indirectly through the inflammatory process to form the protofibril, and that AMPs assist protofibrils to adhere to cell membranes. Likewise small anionic molecules would also stimulate fibril development. For example, heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in-vitro (Cohlberg JA. et al., 2002. Biochemistry 41:1502-11) in the same way as do small cationic peptides. Therefore down regulating AMPs can be : 30 used for preventing age related diseases. Defensins are overexpressed in Alzheimer’s disease due to inflammation (Hsiao-Nan ef al., Journal of Eurochemistry, 2001, 77, 1027-1035). In high concentrations, defensins, especially alpha-defensins can be \ cytotoxic to human cells leading to cell death found in Alzheimer’s disease, multiple sclerosis and diabetes. Microglia are also activated in Alzheimer’s disease, releasing
AMPs such as CAP37. The protein Secreted Protein of Streptococcus pyogenes That
Inactivates Antibacterial Peptides (SIC; Inga-Maria Frick ef al., 2003. J. Biol. Chem. 278:16561-16566) inactivates AMPs and hence can be used as a treatment for : s Alzheimer’s disease and other inflammatory diseases. Defensins attach to complement (especially C1 complement). This complement-AMP attachment is found in Alzheimer’s plaques (McGeer, EG. et al., 1994. FEBS Lett. 356:1 69-73).
As described above, preventing binding of AMPs/AMLSs to cognate receptors may be used to inhibit a biological process mediated by binding of the AMP/AML to the receptor. Over 50 AMPs/AMLs and over 20 receptors thereof are involved disease pathogenesis, therefore inhibiting correct target combinations of ligand and receptors is essential for treatment of such diseases. Examples of such AMPs/AMLs and cognate receptors thereof, and the types of diseases which can be treated using this approach are shown in Table 1.
Ample guidance for practicing methods and techniques of the present invention, and for obtaining and utilizing materials employed for practicing the present jrevention is provided in the literature of the art (refer, for example, to U.S.
Patent Application No. 20030044907)
Thus, the present invention enables for the first time relative to the prior art, treatment of any of various diseases, such as psoriasis and tumors, which are associated with biological processes in cells/tissues such as dysregulated growth/differentiation, dysregulated growth/differentiation balance, inflammation, metastasis and angiogenesis using AMPs/AMLs, and/or inhibitors thereof. The present invention also enables for the first time relative to the prior art identification of such AMPs/AMLs, and of such inhibitors.
It is expected that during the life of this patent many relevant drug screening techniques will be developed and the scope of the phrase “method of identifying a compound” is intended to include all such new technologies a priori. : 30 Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.
: 5 Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non limiting fashion.
Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, “Molecular Cloning: A laboratory Manual” Sambrook ef al., (1989); “Current Protocols in Molecular Biology” Volumes I-III Ausubel, R. M., ed. (1994); Ausubel et al., “Current Protocols in Molecular Biology”, John Wiley and
Sons, Baltimore, Maryland (1989); Perbal, “A Practical Guide to Molecular Cloning”,
John Wiley & Sons, New York (1988); Watson et al, “Recombinant DNA”,
Scientific American Books, New York; Birren ef al. (eds) “Genome Analysis: A
Laboratory Manual Series”, Vols. 1-4, Cold Spring Harbor Laboratory Press, New
York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; “Cell Biology: A Laboratory Handbook”,
Volumes I-III Cellis, J. E., ed. (1994); “Current Protocols in Immunology” Volumes
I-III Coligan J. E., ed. (1994); Stites et al. (eds), “Basic and Clinical Immunology” (8th Edition), Appleton & Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), “Selected Methods in Cellular Immunology”, W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; “Oligonucleotide Synthesis” Gait, M. J., ed. (1984); “Nucleic Acid Hybridization”
Hames, B. D., and Higgins S. J., eds. (1985); “Transcription and Translation” Hames,
B. D., and Higgins S. J., eds. (1984); “Animal Cell Culture” Freshney, R. I, ed. . 30 (1986); “Immobilized Cells and Enzymes” IRL Press, (1986); “A Practical Guide to
Molecular Cloning” Perbal, B., (1984) and “Methods in Enzymology” Vol. 1-317,
Academic Press; “PCR Protocols: A Guide To Methods And Applications”,
Academic Press, San Diego, CA (1990); Marshak er al., “Strategies for Protein
Purification and Characterization — A Laboratory Course Manual” CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the : 5 reader.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below.
EXAMPLE 1
Use of anti-AMP antibodies for inhibition of carcinoma cell proliferation and loss of substrate-attachment:
Optimal treatment method for carcinomas such as metastatic malignant skin carcinoma
Background: No optimal therapy exists for treatment of metastatic malignant carcinomas, such as metastatic malignant skin carcinoma. An optimal strategy for treating such diseases would be to identify factors involved in inducing carcinoma cell growth and loss of substrate attachment and identifying compounds capable of inhibiting such factors so as to inhibit such growth and loss of substrate attachment.
While reducing the present invention to practice, a significant role for AMPs in driving carcinoma proliferation and loss of substrate attachment was identified, and the capacity of anti-AMP antibodies to inhibit such growth and loss of substrate attachment so as to enable optimal treatment of carcinoma, including malignant metastatic skin carcinoma was demonstrated, as described below, thereby overcoming the limitations of the prior art. . Materials and Methods:
Antimicrobial peptides (AMPs): The antimicrobial peptides human beta- : 30 defensin-1 and human beta-defensin-2 were obtained from Sigma (Catalogue numbers: D9565 and D9690, respectively).
Antibodies: The anti-human beta-defensin-2 antibody used was polyclonal goat anti-human beta-defensin-2 antibody obtained by immunization with greater than
98 % pure recombinant human beta-defensin-2 (GenBank: ACCESSION AAC33549;
VERSION AAC33549.1 GI:3510600; DBSOURCE: accession AF040153.1), and affinity chromatography purification of antiserum using an immobilized human beta- defensin-2 matrix. . 5 Thymidine incorporation cell proliferation assay: Cell proliferation was evaluated by measuring [3(H)]-thymidine incorporation into DNA. Cells were pulsed with [3(H)]-thymidine (1 microcurie/mL, ICN, Irvine, CA) for 1 hour, at 37 degrees centigrade. After incubation, cells were washed 3 times with PBS, incubated for 15 minutes at room temperature in 5 % trichloroacetic acid and solubilized in 1 % triton
X-100. The radioactivity incorporated into the cells was counted in the [3(H)]- window of a Tricarb liquid scintillation counter. Mean values were determined from measurements of triplicate samples under each experimental condition for each experiment. Thymidine incorporation was determined as number of disintegrations per minute (DPM) per mg of protein.
Experimental Results:
Skin carcinoma cells are significantly stimulated to proliferate by AMPs: In order to investigate the effects of AMPs on malignant keratinocyte growth, epidermal human keratinocyte cell lines were chronically treated with AMPs, and their proliferation was monitored. These cells lines include immortalized (cell lines HaCaT and clone 6), weakly malignant cells (cell lines A-5 and I-5) and highly malignant cells (cell lines II-4 and RT-3). As can be seen in Figure 1, in all skin epithelial cells exposure to AMPs led to a marked increase in cell proliferation, and to a marked decrease in cell attachment. This data clearly demonstrates that AMPs may be involved in the pathogenesis of carcinomas such as skin carcinoma, both with respect to cellular hyperproliferation as well as with respect to metastasis.
Inhibition of skin carcinoma cell growth and loss of substrate attachment by anti-AMP antibody: Cultured immortalized, moderately malignant or highly malignant human keratinocytes (HaCaT, A-5, and RT-3, respectively) were plated, allowed to attach, incubated in the presence of anti-human beta-defensin-2 antibody at : 30 a concentration of 1.0 microgram/ml for 48 hours, and cell proliferation was estimated via [3(H)]-thymidine incorporation assay. As can be seen in Figure 2, significant inhibition of growth of the malignant keratinocytes was induced by 1.0 microgram/ml of anti-human beta-defensin-2 antibody. The antibody treatment was also observed to result in significantly enhanced substrate-attachment of the cells. These results thereby demonstrate that such anti-AMP antibody treatment can be used to treat carcinomas such as malignant metastatic skin carcinoma.
Conclusion: The above-described results clearly demonstrate that AMPs, such : 5s as human beta-defensin-1 and human beta-defensin-2, are involved in driving pathogenic proliferation of carcinoma cells, such as metastatic malignant carcinoma cells, and demonstrate for the first time that compounds capable of inhibiting the activity of AMPs, such as anti-AMP antibodies, can be used for optimal treatment of carcinomas, such as malignant metastatic skin carcinomas.
EXAMPLE 2
Use of anti-AMP antibodies for regulation of skin cell proliferation:
Optimal treatment method for diseases requiring therapeutic regulation of skin growth, such as skin wounds, burns, and skin tumors
Background: No optimal therapy exists for treatment of various diseases, such as skin wounds and bums, requiring therapeutic regulation of skin growth. An optimal strategy for treating such diseases would be to inhibit the activity of factors involved in preventing skin growth. While reducing the present invention to practice, the capacity of specific concentrations of anti-AMP antibodies to upregulate or downregulate skin growth so as to enable optimal treatment of diseases, such as skin wounds and burns, was demonstrated, as described below, thereby overcoming the limitations of the prior art.
Materials and Methods:
Antibodies: The anti-human beta-defensin-2 antibody used was polyclonal goat anti-human beta-defensin-2 antibody obtained by immunization with greater than 98 % pure recombinant human beta-defensin-2 (GenBank: ACCESSION AAC33549;
VERSION AAC33549.1 GIL:3510600; DBSOURCE: accession AF040153.1), and } affinity chromatography purification of antiserum using an immobilized human beta- defensin-2 matrix. The anti-LL-37 antibody used was protein A-purified polyclonal - 30 rabbit anti-human LL-37 antibody raised by immunization with the 37 amino acid residue-long LL-37 peptide [amino acid residue coordinates 134-170 of hCAP18/Mhuman cathelicidin antimicrobial peptide precursor protein (GenBank:
ACCESSION NP 004336; VERSION NP_004336.2 GI:39753970; REFSEQ:
accession NM_004345.3)].
Thymidine incorporation cell proliferation assay: Cell proliferation was evaluated by measuring [3(H)]-thymidine incorporation into DNA. Cells were pulsed with [3(H)]-thymidine (1 microcurie/mL, ICN, Irvine, CA) for 1 hour, at 37 degrees : 5 centigrade. After incubation, cells were washed 3 times with PBS, incubated for 15 minutes at room temperature in 5 % trichloroacetic acid and solubilized in 1 % triton
X-100. The radioactivity incorporated into the cells was counted in the [3(H)]- window of a Tricarb liquid scintillation counter. Mean values were determined from measurements of triplicate samples under each experimental condition for each 10 experiment. Thymidine incorporation was determined as number of disintegrations per minute (DPM) per mg of protein.
Experimental Results:
Concentration-dependent upregulation or downregulation of primary keratinocyte growth by anti-AMP antibodies: To investigate the effects of anti-AMP 15 antibodies on skin growth, cultured primary keratinocytes were treated for 48 hours with antibody against LL-37 (blue bars) at concentrations of 4 (“1x”) or 20 (“5x”) micrograms/ml, or with anti-human beta-defensin-2 antibody (yellow bars) at concentrations of 1 (“1x”) or 5 (“5x”) micrograms/ml, and cell proliferation was measured. As shown in Figure 3, treatment with 4 or 1 micrograms/ml of anti-LL-37 20 or human beta-defensin-2 antibody, respectively, resulted in significant induction of keratinocyte proliferation, whereas treatment with 5-fold higher concentrations, 20 or micrograms/ml, respectively, of such antibodies unexpectedly resulted in significant growth inhibition of the keratinocytes.
Conclusion: The above-described results clearly demonstrate for the first time relative to the prior art that antibodies specific for AMPs such as human beta- defensin-2 and LL-37 can be used for positively and negatively regulating skin growth, and hence can be used for optimal treatment of diseases such as those requiring therapeutic skin growth which include, for example, skin wounds and bums.
EXAMPLE 3
Use of anti-AMP antibodies for optimal treatment of diseases, such as psoriasis, which are associated with inflammation, autoimmunity and/or skin cell/tissue proliferation/differentiation imbalance : 5 Background: Diseases associated with inflammation, autoimmunity and/or skin cell/tissue proliferation/differentiation imbalance include numerous diseases, such as psoriasis and dandruff, for which no optimal therapy exists. Angiogenesis and epithelialization common in psoriatic skin is enhanced by AMPs such as LL-37 (Koczulla, R. et al., 2003. J.Clin.Invest 111:1665-1672; Heilborn, JD. et al., 2003. J
Invest Dermatol 120:379-389). An optimal strategy for treating such diseases would be to identify factors involved in dysregulation of skin cell/tissue proliferation/differentiation, and to use compounds capable of inhibiting the activity of such factors to treat such diseases. Such compounds, however, have not been identified. AMPs/AMLs involved in psoriasis include psoriasin, defensins, LL-37,
CTACK/CCL27, CCL28, fractalkine, neutrophil gelatinase-associated lipocalin (NGAL) ( Exp Dermatol. 2002, 11:584-91). Therefore the present inventors have hypothesized that inhibiting regulating such AMPs/AMLs may be used for treating psoriasis. While reducing the present invention to practice, a method of using anti-
AMP antibodies for optimal treatment in a human of a disease associated with inflammation, autoimmunity and/or skin cell/tissue proliferation/differentiation imbalance, such as psoriasis, was demonstrated for the first time, as described below, thereby overcoming the limitations of the prior art.
Materials and Methods:
Antimicrobial peptides (AMPs): The antimicrobial peptide human beta- defensin-2 was employed (Sigma Cat. No. D9690).
Antibodies: The anti-human beta-defensin-2 antibody used was polyclonal goat anti-human beta-defensin-2 obtained by immunization with greater than 98 % . pure recombinant human beta-defensin-2 (GenBank: ACCESSION AAC33549;
VERSION AAC33549.1 GI:3510600; DBSOURCE: accession AF040153.1), and : 30 affinity chromatography purification of antiserum using an immobilized human beta- defensin-2 matrix. The anti-LL-37 antibody used was protein A-purified polyclonal rabbit anti-human LL-37 antibody raised by immunization with the 37 amino acid residue-long LL-37 peptide [amino acid residue coordinates 134-170 of .
hCAP18/human cathelicidin antimicrobial peptide precursor protein (GenBank:
ACCESSION NP 004336; VERSION NP_004336.2 GI:39753970; REFSEQ: accession NM_004345.3)].
Three-dimensional organotypic in-vitro skin cultures: Dermal equivalents for : 5 organotypic cocultures were prepared with native type I collagen extracted from rat "tail tendons with 0.1% acetic acid. The lyophilized collagen was redissolved with 0.1 % acetic acid to a final concentration of 4 mg per ml. Eight volumes of ice-cold collagen solution were mixed with 1 volume of 10x Hank’s buffered saline followed by neutralization with 2 molar NaOH. One volume of fetal calf serum (FCS) was added together with suspended murine fibroblasts (passages 5-8) and mixed thoroughly resulting in a final concentration of 3.2 mg collagen per ml and 100,000 cells per ml. From this mixture, 2.5 ml aliquots are poured into polycarbonate membrane filter inserts (Falcon no. 3501, Becton Dickinson, Heidelberg, Germany), placed in special deep six well trays (Becton Dickinson) and allowed to solidify at 37 degrees centigrade. Glass rings (24 mm outer, 20 mm inner diameter) were placed onto the gels, to compress them and to provide a flat central area for keratinocyte seeding. The gels were equilibrated with DMEM (Biological Industries, Israel) supplemented with 10 % FCS and 50 mg L-ascorbic acid (Sigma) per ml. The next day, 1,000,000 HaCaT human cultured non-malignant keratinocytes (2.5-3.5 x 10° per square centimeter) were seeded in DMEM supplemented with 10 % FCS and 50 mg L-ascorbic acid (Sigma) per ml on the collagen matrix. After submersion in medium and overnight incubation, the cultures were raised to the air-medium interface by lowering the medium level. The cultures were further incubated with ] medium changes every 2-3 d.
Human in-vivo psoriatic lesion treatment: Anti-LL-37 antibody (100 micrograms/ml) diluted in PBS containing 0.1% BSA, or negative control antibody- free buffer carrier was applied to lesions in a human subject in a blind trial.
Experimental Results:
Correction of skin proliferation/differentiation imbalance by anti-AMP - 30 (human beta-defensin-2) antibody: A unique model of 3D organotypic skin co- culture was established in order to investigate the effects of AMPs on proliferation- differentiation imbalance of skin cells/skin, and to investigate the possibility that
AMP activity inhibition will correct such imbalance. Primary human keratinocytes were seeded on a mouse fibroblast-containing collagen gel dermal layer equivalent.
Within a few weeks, under the growth conditions described above, the 3D- organotypic coculture became organized, mimicking the histological structure of the skin tissue in vivo, including the skin epidermal layers as well as keratin formation. : 5s Appropriate proliferation-differentiation of keratinocytes and fibroblasts is a prerequisite for full organization of the organotypic skin co-culture. Any imbalance will lead to inability of the epidermal cells to form a mature fully developed skin equivalent.
In order to examine the effects of AMPs on the growth/differentiation balance of skin cells/skin, the cultured skin was exposed to 20 ng/ml of human beta-defensin- 2. As can be seen in Figure 4b, such exposure to human beta-defensin-2 led to decreased ability of the keratinocytes to form a normal epidermal layer in comparison to the untreated control (Figure 4a). However, treatment with 1 microgram/m} of anti- human beta-defensin-2 antibody unexpectedly led to significant restoration of the proliferation/differentiation imbalance, as evidenced by the normal histological differentiation of the cultured skin (Figure 4c).
These results strongly suggested, therefore that treatment with anti-AMP antibody could be used to treat diseases, such as psoriasis and dandruff, which are associated with an imbalance in skin cell/tissue proliferation/differentiation.
While conceiving the present invention, the present invention theorized that cancer is a permanent imbalance between the proliferation/differentiation pathways caused by an imbalance in the proportion of outer membrane defensin-1 (downregulated) and defensin-2 (upregulated), and hence that the presently described method can be used for treating cancer. " Efficient treatment of in-vivo human psoriatic skin lesions by anti-AMP (LL-37) antibody: In order to investigate the possibility of using anti-AMP antibodies for treating diseases, such as psoriasis, which are associated with inflammation, autoimmunity and/or an imbalance in skin cell/tissue proliferation/differentiation, in- vivo human psoriatic lesions were treated with anti-AMP (LL-37) antibody. The : 30 treatment was performed using a blind trial by topical application on psoriatic lesions daily for 3 days of anti-LL-37 antibody at a concentration of 100 micrograms/ml, and by monitoring the appearance of the lesions after 10 hours and subsequently for a duration 14 days. As control, a non specific antibody was applied on an adjacent lesion in the same subject. The treatment solutions applied in a blind trial were identified 10 hours following treatment (data not shown). Treatment with the } antibody unexpectedly specifically resulted in significant healing of the treated lesions after only 10 hours. As can be seen in Figures 5a-d, healing of the lesions in response : 5s to anti-AMP antibody treatment resulted in a significant decrease in inflammation and scaling three days following treatment. The effects of the treatment lasted for at least two weeks following treatment (data not shown). The experiment was repeated 4 times on different lesions giving the same results each time. Conclusion: The above-described results clearly demonstrate for the first time relative to the prior art, treatment of a disease using an anti-AMP antibody. Specifically, the above described results clearly demonstrate for the first time relative to the prior art optimal in-vivo treatment in a human subject of a disease, such as psoriasis, which is associated with inflammation and/or skin cell/tissue proliferation/differentiation imbalance, using anti-AMP antibody.
EXAMPLE 4
Regulation of gastrointestinal epithelial cell proliferation using anti-AMP antibody:
Optimal treatment method for diseases associated with gastrointestinal cell hyperproliferation such as inflammatory bowel diseases, Helicobacter-associated gastrointestinal diseases, and gastrointestinal carcinomas
Background: No optimal therapy exists for treatment of diseases associated with dysregulated gastrointestinal epithelial cell proliferation such as inflammatory bowel diseases, Helicobacter-associated gastrointestinal diseases, and gastrointestinal carcinomas. While reducing the present invention to practice, the capacity of anti-
AMP antibodies to regulate growth of gastrointestinal epithelial cells so as to enable optimal treatment of diseases associated with dysregulated gastrointestinal cell proliferation, such as inflammatory bowel diseases, Helicobacter-associated } gastrointestinal diseases, and gastrointestinal carcinomas, was demonstrated, as described below, thereby overcoming the limitations of the prior art. : 30 Materials and Methods:
Antibodies: The anti-human beta-defensin-2 antibody used was polyclonal goat anti-human beta-defensin-2 antibody obtained by immunization with greater than 98 % pure recombinant human beta-defensin-2 (GenBank: ACCESSION AAC33549;
VERSION AAC33549.1 GI:3510600; DBSOURCE: accession AF040153.1), and affinity chromatography purification of antiserum using an immobilized human beta- } defensin-2 matrix.
Thymidine incorporation cell proliferation assay: Cell proliferation was : 5 evaluated by measuring [3(H)]-thymidine incorporation into DNA. Cells were pulsed with [3(H)]-thymidine (1 microcurie/mL, ICN, Irvine, CA) for 1 hour, at 37 degrees centigrade. After incubation, cells were washed 3 times with PBS, incubated for 15 minutes at room temperature in 5 % trichloroacetic acid and solubilized in 1 % triton
X-100. The radioactivity incorporated into the cells was counted in the [3(H)]- window of a Tricarb liquid scintillation counter. Mean values were determined from measurements of triplicate samples under each experimental condition for each experiment. Thymidine incorporation was determined as number of disintegrations per minute (DPM) per mg of protein.
Experimental Results:
Significant concentration-dependent negative or positive regulation of gastrointestinal epithelial cell proliferation by anti-AMP (human beta-defensin-2) antibody: In order to investigate the effects of anti-AMP antibodies on proliferation of gastrointestinal epithelial cells/epithelium, cultured Caco2 human gastrointestinal epithelial cells were treated for 48 hours with anti-human beta-defensin-2 antibody at 0.5 or at 1.0 microgram/ml concentration, and cell proliferation was measured via [3(H)]-thymidine incorporation assay. The antibody was unexpectedly uncovered to have significant concentration-dependent regulatory effect on the growth of the cells.
As can be seen in Figure 6, at 1 microgram/ml concentrations of the antibody there was in inhibitory effect on the growth of the gastrointestinal epithelial cells, whereas at the lower concentration of 0.5 microgram/ml, the antibody stimulated increased cell proliferation.
Conclusion: The above-described results clearly demonstrate for the first time ] relative to the prior art that anti-AMP antibodies can be used for upregulation and downregulation of gastrointestinal epithelial cells. As such, the above described : 30 results provide an optimal method for treating gastrointestinal diseases associated with dysregulated growth of gastrointestinal epithelial cells, such as inflammatory bowel diseases, Helicobacter infection-associated diseases, and gastrointestinal carcinomas.
EXAMPLE 5
Inhibition of endothelial cell proliferation using anti-AMP antibody:
Optimal treatment method for diseases associated with endothelial hyperproliferation/angiogenesis and/or inflammation, such as solid malignancies, . 5 psoriasis, autoimmune diseases and endothelial tumors
Background: No optimal therapy exists for treatment of diseases associated with endothelial hyperproliferation/angiogenesis and/or inflammation, such as solid malignancies, endothelial tumors, autoimmune diseases and psoriasis. While reducing the present invention to practice, the capacity of anti-AMP antibodies to inhibit growth of endothelial cells/angiogenesis so as to enable optimal treatment of diseases associated with endothelial hyperproliferation/angiogenesis and/or inflammation, such as solid malignancies, psoriasis, autoimmune diseases and endothelial tumors was demonstrated, as described below, thereby overcoming the limitations of the prior art.
Materials and Methods:
Antibodies: The anti-human beta-defensin-2 antibody used was polyclonal goat anti-human beta-defensin-2 antibody obtained by immunization with greater than 98 % pure recombinant human beta-defensin-2 (GenBank: ACCESSION AAC33549;
VERSION AAC33549.1 GI:3510600; DBSOURCE: accession AF040153.1), and affinity chromatography purification of antiserum using an immobilized human beta- defensin-2 matrix.
Thymidine incorporation cell proliferation assay: Cell proliferation was evaluated by measuring [3(H)]-thymidine incorporation into DNA. Cells were pulsed with [3(H)]-thymidine (1 microcurie/mL, ICN, Irvine, CA) for 1 hour, at 37 degrees centigrade. After incubation, cells were washed 3 times with PBS, incubated for 15 minutes at room temperature in 5 % trichloroacetic acid and solubilized in 1 % triton
X-100. The radioactivity incorporated into the cells was counted in the [3(H)]- } window of a Tricarb liquid scintillation counter. Mean values were determined from measurements of triplicate samples under each experimental condition for each . 30 experiment. Thymidine incorporation was determined as number of disintegrations per minute (DPM) per mg of protein.
Experimental Results:
Significant inhibition of endothelial cell proliferation by anti-AMP (human beta-defensin-2) antibody: In order to investigate the effects of anti-AMP antibodies on endothelial cell proliferation, bovine primary endothelial cells were treated for 48 s hours with anti-human beta-defensin-2 antibody at 0.5 or at 1.0 microgram/ml concentration, and proliferation was assessed via [3(H)]-thymidine incorporation assay. Antibody treatment was found to have a significant inhibitory effect on endothelial cell proliferation, particularly at a concentration of 0.5 micrograms/ml, as can be seen in Figure 7.
Conclusion: The above-described results clearly demonstrate for the first time relative to the prior art that anti-AMP antibodies, such anti-human beta-defensin-2 antibodies, can be used for significantly inhibiting endothelial proliferation/angiogenesis and/or inflammation, and hence can be used for optimal treatment of diseases associated with endothelial hyperproliferation/angiogenesis and/or inflammation, such as solid malignancies, endothelial tumors, autoimmune diseases and psoriasis.
EXAMPLE 6
Cell Culture and protein lysate preparation
Cell Culture and protein lysate preparation: Primary human and murine keratinocytes or cell lines and human and murine fibroblasts are prepared and maintained as described previously (Wertheimer, E. ef al., 1993. Nat.Genet. 5:71-73;
Spravchikov, N. et al., 2001. Diabetes 50:1627-1 635)
Keratinocytes: Briefly, freshly isolated keratinocytes were cultured in Eagle’s medium (Biological Industries, Beit Haemek, Israel) with 10% chelexed fetal calf serum (Biological Industries, Beit Haemek, Israel), 1% antibiotics and Ca2+ concentration adjusted to 0.05mM. After 5 days in culture, in order to induce differentiation, the growth medium was switched to medium containing Ca2+ at defined concentrations ([Ca2+] of 0.05mM for proliferating phase; 0.12 mM for : 30 induction of differentiation; 1.0 mM for terminal differentiation) for 48 hours. After 48 hours, unless indicated otherwise, cells were harvested by scraping into lysis buffer [Phosphate-buffered saline (PBS) containing Triton X-100, 1%; EDTA, 1mM; sodium fluoride, 10 mM; sodium 200 micromolar orthovanadate; and a protease inhibitor cocktail]. The lysate was microcentrifuged at maximum speed and the
Triton-soluble supernatant was further analyzed by SDS-PAGE and immunoblotting.
The Triton-insoluble pellet was kept for analysis of cytoskeletal proteins, as described below. Protein concentrations were measured using a modified Lowry assay (Bio- : 5 Rad DC Protein Assay Kit).
Preparation of cytoskeletal protein samples for analysis of keratin expression: The Triton-insoluble fraction (pellet) obtained as described above was incubated for 30 minutes in a special lysis buffer containing beta-mercaptoethanol (20%) and SDS (5%). The samples were spun for 30 minutes at maximal speed na microcentrifuge, and the lysate was further analyzed by SDS-PAGE and Western blot analysis following standard procedures.
EXAMPLE 7
Chemotaxis assays.
Chemotaxis assays. Cells (e.g. neutrophils, monocytes, T cells, HEK293; 25 microliters at a density of 1.0-3.0 x 10° cells/ml) in RPMI medium (Beit Haemek) containing 0.5% BSA (Sigma-Aldrich) are placed on the top of a 96-well ChemoTx disposable chemotaxis apparatus with a 5 micron pore size (Neuroprobe). Tenfold serial dilutions of the tested reagent in RPMI medium with or without 0.5% BSA are placed in the bottom wells of the chamber. The apparatus is incubated for 60-600 min at 37 °C in an atmosphere of 5% carbon dioxide, and the cells migrating at each concentration of chemoattractant is counted with the use of an inverted microscope.
Cells (1x10"/mL) are suspended in a buffer containing 0.25% BSA, 145 mM
NaCl, 5 mM KCl, 10 mM Na/MOPS, 1 mM CaCl,, | mM MgCl,, 10 mM glucose, 10 mM HEPES (all from Sigma-Aldrich), pH 7.4, and incubated with 2 micromolar
Fura-2-AM (Molecular Probes, Eugene, OR), for 40 min at room temperature. The cells are washed once, resuspended in the buffer containing 0.25% BSA, and are kept at room temperature. Just before use, aliquots of the cells 4x10”) are washed and resuspended in 2 ml buffer containing 0.05% BSA in a stirred cuvette at 37°C. . 30 Measurement of intracellular Ca2+ concentration and chemotaxis assays are performed as previously described (Maghazachi, AA. et al., 1997. FASEB J. 11:765-
EXAMPLE 8
Psoriasis animal models
Human Psoriatic Skin-SCID Mouse Transplant Model: Transplantation of human skin onto immunocompromised mice (either congenitally athymic [nude] mice : 5 or severe combined immunodeficiency [SCID] mice) provides one of the an approach to the study of psoriasis.
SCID mice (CB-17 strain; Taconic Farms Inc., Germantown, New York) will be used as tissue recipients. Keratomed tissue samples as well as 20ml blood will be obtained from normal or psoriatic volunteer and cut into 1 x 1 cm sections. Main blood components involved are Natural Killer cells. Two to four mice will be transplanted bilaterally with each human skin sample, depending on tissue availability. After mice will be anesthetized (sodium pentobarbital; 1.8 mg per 25 gm body weight, i.p.), the dorsal region of each mouse will be shaved bilaterally. Mouse skin will be surgically removed to size, and replaced with the human tissue. The transplanted tissue will be secured to the back of the mouse with absorbable sutures (4-0 Dexon "S"; Davis-Geck, Manati, Puerto Rico). The transplants will be further bandaged with Xeroform petrolatum dressing for 5 days. The animals will be maintained in a pathogen-free environment throughout the preparation and treatment phases. PBMC is isolated from the blood obtained. In some animals Psonasis is enhanced or maintained by injection of the donors activated PBMC (super antigen) into xenograft. (Smith, T, Nickoloff, BJ., 1996. J.Clin.Invest 98:1878-1 887).
Antibody screening will be initiated 3 to 5 weeks after transplantation.
Flaky skin (fsn) mouse model: Another model that will be tested is a murine model that express a psoriasiform phenotype i.e., the flaky skin (fsn) mutation.
Breeding pairs of CBy.A fsn/J mice (The Jackson Laboratory, Bar Harbor, ME) will be obtained. As the genetic defect resulting in the flaky skin phenotype is unknown and as homozygous mutant mice are not fertile, the offspring of CBY(FSN/fsn) mice will be used for all experiments. In the CBy.A background, erythrosquamous skin lesions are readily seen at the age of 5-6 weeks, allowing the separation of fsn/fsn mice from their wild-type or heterozygous littermates. For antibody treatment studies, mice will be used between 12 and 16 weeks of age (littermates in most cases), after it ~ has been established that the phenotype remained stable within this time frame.
Animal treatment protocols: Animals will be divided into treatment groups
(vehicle plus test reagents) or a control group (vehicle alone). The monoclonal antibodies or inhibitory agents will be delivered topically, intradermal or intraperitoneally in 100 microliters of PBS (6 mg/kg of body weight as an initial concentration used. This will be adjusted according to results. The control mice were 5s treated with PBS alone. Treatment was continued daily for 14 days.
Quantitative Evaluation of Epidermal Thickness: After the treatment phase, mice will be killed and the transplanted human tissue surgically removed and fixed in 3% formalin. After paraffin embedding, one to three S-micron-thick sections will be cut from each tissue piece, mounted onto microscope slides, and stained with hematoxylin and eosin. The epidermal area will be measured as a function of changes in epidermal thickness per unit length using NIH Image software (N ational Institutes of Health, Bethesda, Maryland). Specifically, randomly chosen tissue section fields will be visualized by light microscopy at x10 magnification. At this level of magnification, the entire epidermal area of each tissue section is "captured" in equal segments (three to four segments across a typical tissue section), and the area of each segment can be quantified using the NIH Image analysis program. Multiple areas from bilateral transplants on two to four mice per treatment group for each donor will be quantified in this way, to provide 100 or more measurements. The mean epidermal area will be determined from these values. For the Human Psoriatic Skin—SCID
Mouse Transplant Model an additional control value will be set; Before transplantation, a small piece of tissue from each donor will be fixed in 3% buffered formalin and used for zero-time assessment of epidermal thickness.
Histology and Immunohistochemical Assessment: Several other histologic characteristics of psoriasis will be followed to evaluate the effectiveness of treatment.
This including epidermal hyperplasia, and dermal and/or intra-epidermal infiltration with lymphocytes and neutrophils. For this purpose 5-microm-thick sections will be obtained from each tissue piece, stained with hematoxylin and eosin, and evaluated } microscopically.
Statistical Analysis: Statistical significance will be assessed by the paired two- - 30 tailed Student's t-test, and P < 0.05 will be considered significant. In addition, measurements of epidermal thickness for each group will be analyzed by ANOVA and comparisons between paired groups. The analysis accounts for the correlation between pre-treatment values and post-treatment values for each individual tissue,
using a mixed model approach. ] Tt is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in : s combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents, and patent applications and sequences identified by their accession numbers mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent, or patent application or sequence identified by its accession number was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. ;
Claims (99)
- WHAT IS CLAIMED IS:} 1. A method of treating a disease in a subject in need thereof, the method comprising providing to the subject a therapeutically effective amount of a compound : being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the subject in need thereof.
- 2. The method of claim 1, wherein said providing to the subject said compound is effected by administering said compound to the subject and/or by expressing said compound in the subject.
- 3. The method of claim 1, wherein said compound is selected from the group consisting of: (a) a molecule capable of binding said AMP and/or AMP-like molecule; (b) an enzyme capable of cleaving said AMP and/or AMP-like molecule; (©) an siRNA molecule capable of inducing degradation of an mRNA encoding said AMP and/or AMP-like molecule; (d) a DNAzyme capable of cleaving an mRNA or DNA encoding said AMP and/or AMP-like molecule; (e) an antisense polynucleotide capable of hybridizing with an mRNA encoding said AMP and/or AMP-like molecule; ® a ribozyme capable of cleaving an mRNA encoding said AMP and/or AMP-like molecule; (2) a non-functional analogue of at least a functional portion of said AMP and/or AMP-like molecule; (h) a molecule capable of inhibiting activation or ligand binding of said AMP and/or AMP-like molecule; and (1) a triplex-forming oligonucleotide capable of hybridizing with a DNA : encoding said AMP and/or AMP-like molecule.
- 4. The method of claim 3, wherein said molecule capable of binding said AMP and/or AMP-like molecule is an antibody or an antibody fragment.
- 5. The method of claim 4, wherein said antibody fragment is selected” from the group consisting of a single-chain Fv, an Fab, an Fab’, and an F(ab')2.
- 6. The method of claim 2, wherein said administering said compound to the subject is effected by exposing a location of the subject to a carrier which includes said compound at a concentration selected from a range of about 50 nanograms per milliliter to about 1 milligram per milliliter.
- 7. The method of claim 2, wherein said administering said compound to the subject is effected by administering to the subject a plurality of doses of said compound selected from a range of 2 doses to 30 doses, wherein each inter dose interval of said plurality of doses is selected from a range of about 2.4 hours to about days.
- 8. The method of claim 2, wherein said administering said compound to the subject is effected via a route selected from the group consisting of the topical, intranasal, transdermal, intradermal, oral, buccal, parenteral, rectal and inhalation route.
- 0. The method of claim 1, wherein said AMP and/or AMP-like molecule is selected from the group consisting of a defensin, a cathelicidin, a cationic peptide, a hydrophobic peptide, a human AMP and a human AMP-like molecule.
- 10. The method of claim 1, wherein said AMP and/or AMP-like molecule is a beta-defensin.
- 11. The method of claim 1, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1 beta-defensin-2 and LL-37. :
- 12. The method of claim 1, wherein the disease is associated with a biological process in a cell and/or tissue, wherein the biological process is selected from the group consisting of growth, differentiation, inflammation, metastasis and angiogenesis.
- 13. The method of claim 12, wherein said cell and/or tissue is selected from the group consisting of an epithelial cell and/or tissue, a skin cell and/or tissue, a } keratinocytic cell and/or tissue, a gastrointestinal cell and/or tissue and an endothelial cell and/or tissue.
- 14. The method of claim 1, wherein the subject is human.
- 15. The method of claim 1, wherein the disease is selected from the group consisting of a tumor, an autoimmune disease, an epithelial disease, a skin disease, a gastrointestinal disease, and an endothelial disease.
- 16. The method of claim 1, wherein the disease is selected from the group consisting of an epithelial tumor, an epithelial wound, a skin tumor, a skin wound, a gastrointestinal tumor, a gastrointestinal wound, an endothelial tumor, a solid tumor, a metastatic tumor, a skin autoimmune disease, and a malignant tumor.
- 17. The method of claim 1, wherein the disease is psoriasis or skin carcinoma.
- 18. An article of manufacture comprising packaging material and a pharmaceutical composition, the article of manufacture being identified for treatment of a disease being associated with a biological process in a cell and/or tissue, the biological process being selected from the group consisting of growth, differentiation, inflammation, metastasis and angiogenesis; the pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule.
- 19. The article of manufacture of claim 18, wherein said compound is : selected from the group consisting of: (a) a molecule capable of binding said AMP and/or AMP-like molecule; (b) an enzyme capable of cleaving said AMP and/or AMP-like molecule; (©) an siRNA molecule capable of inducing degradation of an mRNA encoding said AMP and/or AMP-like molecule; (d) a DNAzyme capable of cleaving an mRNA or DNA encoding said . AMP and/or AMP-like molecule; (e) an antisense polynucleotide capable of hybridizing with an mRNA encoding said AMP and/or AMP-like molecule; ® a ribozyme capable of cleaving an mRNA encoding said AMP and/or ’ AMP-like molecule; (2) a non-functional analogue of at least a functional portion of said AMP and/or AMP-like molecule; and (h) a molecule capable of inhibiting activation or ligand binding of said AMP and/or AMP-like molecule; and (1) a triplex-forming oligonucleotide capable of hybridizing with a DNA encoding said AMP and/or AMP-like molecule.
- 20. The article of manufacture of claim 19, wherein said molecule capable of binding said AMP is an antibody or an antibody fragment. :
- 21. The article of manufacture of claim 20, wherein said antibody fragment is selected from the group consisting of a single-chain Fv, an Fab, an Fab’, and an F(ab")2.
- 22. The article of manufacture of claim 18, wherein said pharmaceutically acceptable carrier is selected so as to enable administration of the pharmaceutical composition via a route selected from the group consisting of the topical, intranasal, transdermal, intradermal, oral, buccal, parenteral, rectal and inhalation route.
- 23. The article of manufacture of claim 18, wherein said pharmaceutical composition is formulated as a solution, suspension, emulsion or gel.
- 24. The article of manufacture of claim 18, wherein said pharmaceutical composition is composed so as to enable exposure of a cell and/or tissue of a subject having the disease to said compound at a concentration selected from a range of about 50 nanograms per milliliter to about 1 milligram per milliliter.
- 25. The article of manufacture of claim 18, wherein said pharmaceutical composition is further identified for administration to a subject of a plurality of doses : of said pharmaceutical composition selected from a range of 2 doses to 30 doses, wherein each inter dose interval of said plurality of doses is selected from a range of } about 2.4 hours to about 30 days
- 26. The article of manufacture of claim 18, wherein said AMP and/or AMP-like molecule is selected from the group consisting of a defensin, a cathelicidin, a cationic peptide, a hydrophobic peptide, a human AMP and a human AMP-like molecule.
- 27. The article of manufacture of claim 18, wherein said AMP and/or AMP-like molecule is a beta-defensin.
- 28. The article of manufacture of claim 18, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1 beta- defensin-2 and LL-37.
- 29. The article of manufacture of claim 18, wherein said cell and/or tissue is selected from the group consisting of an epithelial cell and/or tissue, a skin cell and/or tissue, a keratinocytic cell and/or tissue, a gastrointestinal cell and/or tissue and an endothelial cell and/or tissue.
- 30. The article of manufacture of claim 18, wherein said disease 1s selected from the group consisting of a tumor, an autoimmune disease, an epithelial disease, a skin disease, a gastrointestinal disease, an endothelial disease and a human disease. }
- 31. The article of manufacture of claim 18, wherein said disease is selected from the group consisting of an epithelial tumor, an epithelial wound, a skin tumor, a : skin wound, a gastrointestinal tumor, a gastrointestinal wound, an endothelial tumor, a solid tumor, a metastatic tumor, a skin autoimmune disease, and a malignant tumor.
- 32. The article of manufacture of claim 18, wherein said disease is psoriasis or skin carcinoma.
- 33. A method of regulating a biological process in a cell and/or tissue, the method comprising exposing the cell and/or tissue to a compound being capable of : decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP- like molecule, thereby regulating the biological process in the cell and/or tissue. oo
- 34. The method of claim 33, wherein said exposing the cell and/or tissue to said compound is effected by providing said compound to a subject.
- 35. The method of claim 34, wherein said providing to the subject said compound is effected by administering said compound to said subject and/or by expressing said compound in said subject.
- 36. The method of claim 33, wherein said compound is selected from the group consisting of: (a) a molecule capable of binding said AMP and/or AMP-like molecule; (b) an enzyme capable of cleaving said AMP and/or AMP-like molecule; (c) an siRNA molecule capable of inducing degradation of an mRNA encoding said AMP and/or AMP-like molecule; (d) a DNAzyme capable of cleaving an mRNA or DNA encoding said AMP and/or AMP-like molecule; (e) an antisense polynucleotide capable of hybridizing with an mRNA encoding said AMP and/or AMP-like molecule; (f) a ribozyme capable of cleaving an mRNA encoding said AMP and/or AMP-like molecule; (2) a non-functional analogue of at least a functional portion of said AMP and/or AMP-like molecule; and (h) a molecule capable of inhibiting activation or ligand binding of said : AMP and/or AMP-like molecule; and @) a triplex-forming oligonucleotide capable of hybridizing with a DNA encoding said AMP and/or AMP-like molecule.
- 37. The method of claim 36, wherein said molecule capable of binding said AMP and/or AMP-like molecule is an antibody or an antibody fragment.
- 38. The method of claim 37, wherein said antibody fragment is selected : from the group consisting of a single-chain Fv, an Fab, an Fab’, and an F(ab')2.
- 39. The method of claim 33, wherein said exposing the cell and/or tissue to said compound is effected by exposing the cell and/or tissue to said compound at a concentration selected from a range of about 50 nanograms per milliliter to about one milligram per milliliter.
- 40. The method of claim 33, wherein said AMP and/or AMP-like molecule is selected from the group consisting of a defensin, a cathelicidin, a cationic peptide, a hydrophobic peptide, a human AMP and a human AMP-like molecule.
- 41. The method of claim 33, wherein said AMP and/or AMP-like molecule is a beta-defensin.
- 42. The method of claim 33, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1 beta-defensin-2 and LL-37.
- 43. The method of claim 33, wherein the biological process is selected from the group consisting of growth, differentiation, inflammation, metastasis and angiogenesis.
- 44. The method of claim 33, wherein the cell and/or tissue is selected from the group consisting of an epithelial cell and/or tissue, a skin cell and/or tissue, a keratinocytic cell and/or tissue, a gastrointestinal cell and/or tissue and an endothelial cell and/or tissue.
- 45. The method of claim 33, wherein the cell and/or tissue 1s malignant and/or keratinocytic, wherein said exposing the cell and/or tissue to said compound is effected by exposing the cell and/or tissue to said compound at a concentration selected from a range of about 0.4 microgram per milliliter to about 200 micrograms per milliliter, and whereas said AMP and/or AMP-like molecule is a cathelicidin.
- 46. The method of claim 33, wherein the cell and/or tissue is malignant : and/or keratinocytic, wherein said exposing the cell and/or tissue to said compound 1s effected by exposing the cell and/or tissue to said compound at a concentration selected from a range of about 0.1 microgram per milliliter to about 50 micrograms per milliliter, and whereas said AMP and/or AMP-like molecule is a defensin.
- 47. The method of claim 33, wherein the cell and/or tissue is a gastrointestinal and/or epithelial cell and/or tissue, wherein said exposing the cell and/or tissue to said compound is effected by exposing the cell and/or tissue to said compound at a concentration selected from a range of about 50 nanograms per milliliter to about 10 micrograms per milliliter, and whereas said AMP and/or AMP- like molecule is a defensin.
- 48. The method of claim 33, wherein the cell and/or tissue is an endothelial cell and/or tissue, wherein said exposing the cell and/or tissue to said compound is effected by exposing the cell and/or tissue to said compound at a concentration selected from a range of about 50 nanograms per milliliter to about 10 micrograms per milliliter, and whereas said AMP and/or AMP-like molecule is a defensin.
- 49. The method of claim 33, wherein the cell and/or tissue is derived from a human.
- 50. A method of identifying a compound being capable of regulating a biological process in a cell and/or tissue, the method comprising: (a) exposing the cell and/or tissue to a test compound which is: (1) a compound being capable of decreasing an activity and/or level of an i antimicrobial peptide (AMP) and/or AMP-like molecule; and/or (ii) said AMP and/or AMP-like molecule; and (b) evaluating a capacity of said test compound to regulate the biological process in the cell and/or tissue, thereby identifying the compound being capable of regulating the biological process in the cell and/or tissue.
- SI. The method of claim 50, wherein the cell and/or tissue is a cultured cell and/or tissue.
- 52. The method of claim 50, wherein the cell and/or tissue is derived from a human.
- 53. The method of claim 50, wherein said exposing the cell and/or tissue to said test compound is effected by providing said test compound to a subject.
- 54. The method of claim 50, wherein said exposing the cell and/or tissue to said test compound is effected by exposing the cell and/or tissue to a cell which produces said test compound.
- 55. The method of claim 50, wherein said cell which produces said test compound is a B-cell hybridoma.
- 56. The method of claim 53, wherein said providing said test compound to said subject is effected by administering said test compound to said subject and/or by expressing said test compound in said subject.
- 57. The method of claim 56, wherein said administering said test compound to said subject is effected via a route selected from the group consisting of the topical, intranasal, transdermal, intradermal, oral, buccal, parenteral, rectal and inhalation route.
- 58. The method of claim 50, wherein said test compound is selected from : the group consisting of: (a) a molecule capable of binding said AMP and/or AMP-like molecule; (b) an enzyme capable of cleaving said AMP and/or AMP-like molecule; (©) an siRNA molecule capable of inducing degradation of an mRNA encoding said AMP and/or AMP-like molecule; (d) a DNAzyme capable of cleaving an mRNA or DNA encoding said AMP and/or AMP-like molecule; (e) an antisense polynucleotide capable of hybridizing with an mRNA encoding said AMP and/or AMP-like molecule; ® a ribozyme capable of cleaving an mRNA encoding said AMP and/or AMP-like molecule; (2) a non-functional analogue of at least a functional portion of said AMP and/or AMP-like molecule; and (h) a molecule capable of inhibiting activation or ligand binding of said AMP and/or AMP-like molecule; and (1) a triplex-forming oligonucleotide capable of hybridizing with a DNA encoding said AMP and/or AMP-like molecule.
- 59. The method of claim 58, wherein said molecule capable of binding said AMP and/or AMP-like molecule is an antibody or an antibody fragment.
- 60. The method of claim 59, wherein said antibody fragment is selected from the group consisting of a single-chain Fv, an Fab, an Fab', and an F(ab")2.
- 61. The method of claim 50, wherein said AMP and/or AMP-like molecule is selected from the group consisting of a defensin, a cathelicidin, a cationic peptide, a hydrophobic peptide, a human AMP and a human AMP-like molecule.
- 62. The method of claim 50, wherein said AMP and/or AMP-like molecule 1s a beta-defensin.
- 63. The method of claim 50, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1, beta-defensin-2 and LL-37.
- 64. The method of claim 50, wherein the cell and/or tissue is selected from the group consisting of an epithelial cell and/or tissue, a skin cell and/or tissue, a keratinocytic cell and/or tissue, a gastrointestinal cell and/or tissue and an endothelial cell and/or tissue. .
- 65. The method of claim 50, wherein the biological process is selected from the group consisting of growth, differentiation, inflammation, and angiogenesis.
- 66. © A method of treating a disease in a subject in need thereof, the method comprising providing to the subject a therapeutically effective amount of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the subject in need thereof.
- 67. The method of claim 66, wherein said providing to the subject said AMP and/or AMP-like molecule is effected by administering said AMP and/or AMP- like molecule to the subject and/or by expressing said AMP and/or AMP-like molecule in the subject.
- 68. The method of claim 67, wherein said administering said AMP and/or AMP-like molecule to the subject is effected by exposing a location of the subject to a carrier which includes said AMP and/or AMP-like molecule at a concentration selected from a range of about 2 nanograms per milliliter to about 10 micrograms per milliliter.
- 69. The method of claim 67, wherein said administering said AMP and/or AMP-like molecule to the subject is effected via a route selected from the group consisting of the topical, intranasal, transdermal, intradermal, oral, buccal, parenteral, rectal and inhalation route.
- 70. The method of claim 66, wherein said AMP and/or AMP-like molecule is selected from the group consisting of a defensin, a cathelicidin, a cationic peptide, a hydrophobic peptide, a human AMP and a human AMP-like molecule.
- 71. The method of claim 66, wherein said AMP and/or AMP-like molecule is a beta-defensin.
- 72. The method of claim 66, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1, beta-defensin-2 and LL-37.
- 73. The method of claim 66, wherein the subject is human.
- 74. The method of claim 66, wherein the disease is associated with a biological process in a cell and/or tissue, wherein said biological process is selected from the group consisting of growth, differentiation, inflammation and angiogenesis.
- 75. The method of claim 74, wherein said cell and/or tissue is selected from the group consisting of an epithelial cell and/or tissue, a skin cell and/or tissue, a keratinocytic cell and/or tissue and a tumor cell and/or tissue.
- 76. The method of claim 66, wherein the disease is selected from the group consisting of a tumor, an epithelial disease, a skin disease, a gastrointestinal disease and an endothelial disease.
- 77. The method of claim 66, wherein the disease is selected from the group consisting of an epithelial tumor, an epithelial wound, a skin tumor, a skin wound, a gastrointestinal tumor, a gastrointestinal wound and a malignant tumor.
- 78. An article of manufacture comprising packaging material and a pharmaceutical composition, the article of manufacture being identified for treatment » of a disease being associated with a biological process in a cell and/or tissue, said biological process being selected from the group consisting of growth, differentiation, inflammation and angiogenesis; the pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, an antimicrobial peptide (AMP) and/or AMP-like molecule.
- . 79. The article of manufacture of claim 78, wherein said pharmaceutically acceptable carrier is selected so as to enable administration of the pharmaceutical composition via a toute selected from the group consisting of the topical, intranasal, transdermal, intradermal, oral, buccal, parenteral, rectal and inhalation route.
- 80. The article of manufacture of claim 78, wherein said pharmaceutical composition is formulated as a solution, suspension, emulsion or gel.
- 81. The article of manufacture of claim 78, wherein said pharmaceutical composition is composed so as to enable exposure of a cell and/or tissue of a subject having the disease to said compound at a concentration selected from a range of about 2 nanograms per milliliter to about 10 micrograms per milliliter.
- 82. The article of manufacture of claim 78, wherein said AMP and/or AMP-like molecule is selected from the group consisting of a defensin, a cathelicidin, a cationic peptide, a hydrophobic peptide, a human AMP and a human AMP-like molecule.
- 83. The article of manufacture of claim 78, wherein said AMP and/or AMP-like molecule is a beta-defensin.
- 84. The article of manufacture of claim 78, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1 beta- defensin-2 and LL-37.
- 85. The article of manufacture of claim 78, wherein said cell and/or tissue is selected from the group consisting of an epithelial cell and/or tissue, a skin cell and/or tissue, a keratinocytic cell and/or tissue and a tumor cell and/or tissue.
- 86. The article of manufacture of claim 78, wherein said disease is selected from the group consisting of a tumor, an epithelial disease, a skin disease, a gastrointestinal disease and an endothelial disease.
- 87. The article of manufacture of claim 78, wherein said disease is selected from the group consisting of an epithelial tumor, an epithelial wound, a skin tumor, a skin wound, a gastrointestinal tumor, a gastrointestinal wound and a malignant tumor.
- 88. A method of regulating a biological process in a cell and/or tissue, the method comprising exposing the cell and/or tissue to an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby regulating the biological process in the cell and/or tissue.
- . 89. The method of claim 88, wherein said exposing the cell and/or tissue to said AMP and/or AMP-like molecule is effected by providing said AMP and/or AMP- -- like molecule to a subject.
- 90. The method of claim 89, wherein said providing to the subject said AMP and/or AMP-like molecule is effected by administering said AMP and/or AMP- like molecule to said subject and/or by expressing said AMP and/or AMP-like molecule in said subject.
- 91. The method of claim 88, wherein said exposing the cell and/or tissue to said AMP and/or AMP-like molecule is effected by exposing the cell and/or tissue to said AMP and/or AMP-like molecule at a concentration selected from a range of about 2 nanograms per milliliter to about 10 micrograms per milliliter.
- 92. The method of claim 88, wherein said AMP and/or AMP-like molecule is selected from the group consisting of a defensin, a cathelicidin, a cationic peptide, a hydrophobic peptide, a human AMP and a human AMP-like molecule.
- 93. The method of claim 88, wherein said AMP and/or AMP-like molecule is a beta-defensin.
- 94, The method of claim 88, wherein said AMP and/or AMP-like molecule is selected from the group consisting of beta-defensin-1, beta-defensin-2 and LL-37.
- 95. The method of claim 88, wherein the cell and/or tissue is selected from. the group consisting of an epithelial cell and/or tissue, a skin cell and/or tissue, a keratinocytic cell and/or tissue and a tumor cell and/or tissue.
- 96. The method of claim 88, wherein the biological process is selected from the group consisting of growth, differentiation, inflammation and angiogenesis.
- 97. The method of claim 88, wherein the cell and/or tissue is malignant, wherein said exposing the cell and/or tissue to said AMP and/or AMP-like molecule is effected by exposing the cell and/or tissue to said AMP and/or AMP-like molecule at a concentration selected from a range of about 0.1 microgram per milliliter to about micrograms per milliliter, and whereas said AMP and/or AMP-like molecule 1s a defensin.
- 98. The method of claim 88, wherein the cell and/or tissue is a keratinocytic cell and/or tissue, wherein said exposing the cell and/or tissue to said AMP and/or AMP-like molecule is effected by exposing the cell and/or tissue to said AMP and/or AMP-like molecule at a concentration selected from a range of about 2 nanograms per milliliter to about 10 micrograms per milliliter, and whereas said AMP and/or antimicrobial peptide-like molecule is a defensin.
- 99. The method of claim 88, wherein the cell and/or tissue is derived from a human.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL15355702A IL153557A0 (en) | 2002-12-19 | 2002-12-19 | Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200504523B true ZA200504523B (en) | 2006-02-22 |
Family
ID=29798384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200504523A ZA200504523B (en) | 2002-12-19 | 2005-06-02 | Disease treatment via antimicrobial peptide inhibitors. |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1729014A (en) |
IL (1) | IL153557A0 (en) |
ZA (1) | ZA200504523B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101722038B1 (en) * | 2007-07-26 | 2017-04-03 | 레반스 테라퓨틱스, 아이엔씨. | Antimicrobial peptide, compositions, and methods of use |
CN102552306B (en) * | 2010-12-13 | 2015-04-08 | 马鞍山国声生物技术有限公司 | Small molecule interference RNA for reducing antibacterial peptide yield of neutrophils |
WO2014144289A2 (en) * | 2013-03-15 | 2014-09-18 | The Procter & Gamble Company | A noninvasive method for measuring antimicrobial peptides from skin as an objective measurement of natural protection from microbes |
CN103611181B (en) * | 2013-10-25 | 2015-06-17 | 无锡灵锡医疗器械科技有限公司 | Antibacterial peptide hydrogel and preparation method thereof |
WO2016143904A1 (en) * | 2015-03-12 | 2016-09-15 | 三井化学株式会社 | Method for disrupting exosomes, exosome disruption kit, and method for separating exosomes derived from normal cells |
CN106620694B (en) * | 2016-12-30 | 2019-12-27 | 西安交通大学 | Application of Cornulin as target in preparation of medicine for preventing and treating psoriasis |
CN106943594A (en) * | 2017-03-29 | 2017-07-14 | 西安交通大学 | Psoriasin antibody and the antibody of LL 37 are preparing the application in preventing and treating the medicine of psoriasis |
CN110101841B (en) * | 2019-06-28 | 2020-11-03 | 福州大学 | Application of antibacterial peptide Lchamp2-3 in anti-tumor cell metastasis drugs |
CN110749582B (en) * | 2019-10-25 | 2021-09-07 | 中南大学 | Preparation method and application of silicon carbide @ BSA-antibacterial peptide nanoprobe |
CN113577243B (en) * | 2021-07-14 | 2022-07-12 | 润辉生物技术(威海)有限公司 | Active polypeptide-PDRN composition and application thereof in preparation of nursing products |
CN114277087A (en) * | 2021-12-22 | 2022-04-05 | 清远一生自然生物研究院有限公司 | Application method of antibacterial peptide in-vitro inhibition of escherichia coli |
-
2002
- 2002-12-19 IL IL15355702A patent/IL153557A0/en unknown
-
2003
- 2003-12-21 CN CN 200380105021 patent/CN1729014A/en active Pending
-
2005
- 2005-06-02 ZA ZA200504523A patent/ZA200504523B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL153557A0 (en) | 2003-07-06 |
CN1729014A (en) | 2006-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8202835B2 (en) | Disease treatment via antimicrobial peptides or their inhibitors | |
EP1572101A2 (en) | Disease treatment via antimicrobial peptide inhibitors | |
AU2008277257B2 (en) | Disease treatment via antimicrobial peptides or their inhibitors | |
ZA200504523B (en) | Disease treatment via antimicrobial peptide inhibitors. | |
US20150258172A1 (en) | Disease treatment via antimicrobial peptides or their inhibitors | |
EP1628530B1 (en) | Methods and compositions for the prevention and treatment of sepsis | |
EP3901175A1 (en) | Anti-cd73 monoclonal antibody and application thereof | |
US10066014B2 (en) | Anti CD84 antibodies, compositions comprising same and uses thereof | |
WO2002051438A2 (en) | Use of repulsive guidance molecule (rgm) and its modulators | |
US7741275B2 (en) | Agents and use thereof | |
US11725056B2 (en) | Methods for targeting the immune checkpoint PD1 pathway for treating pulmonary fibrosis | |
US20140235544A1 (en) | Disease treatment via antimicrobial peptides or their inhibitors | |
EP1899376A2 (en) | Antibodies against hmgb1 and fragments thereof | |
US8309091B2 (en) | CEACAM8-related method for treating autoimmune diseases | |
US20110091485A1 (en) | Modulation of cell junctions | |
US8501192B2 (en) | Use of soluble CEACAM8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis | |
Gentile | THE PROTECTIVE ROLE OF PTX3 IN MOUSE SKIN CARCINOGENESIS | |
Engel | Caveolin‐1 and CD40L‐CD40‐TRAF interactions in vascular and metabolic disease |